Human	B-protein
neutrophil	I-protein
elastase	I-protein
proteolytically	O
activates	O
the	O
platelet	B-protein
integrin	I-protein
alphaIIbbeta3	B-protein
through	O
cleavage	O
of	O
the	O
carboxyl	B-protein
terminus	I-protein
of	O
the	O
alphaIIb	B-protein
subunit	I-protein
heavy	I-protein
chain	I-protein
.	O

Involvement	O
in	O
the	O
potentiation	O
of	O
platelet	O
aggregation	O
.	O

Neutrophil	B-protein
elastase	I-protein
(	O
NE	B-protein
)	O
and	O
cathepsin	B-protein
G	I-protein
are	O
two	O
serine	B-protein
proteinases	I-protein
released	O
concomitantly	O
by	O
stimulated	O
polymorphonuclear	B-cell_type
neutrophils	I-cell_type
.	O

We	O
previously	O
demonstrated	O
that	O
while	O
NE	B-protein
by	O
itself	O
does	O
not	O
activate	O
human	B-cell_type
platelets	I-cell_type
,	O
it	O
strongly	O
enhances	O
the	O
weak	O
aggregation	O
induced	O
by	O
a	O
threshold	O
concentration	O
of	O
cathepsin	B-protein
G	I-protein
(	O
threshold	O
of	O
cathepsin	B-protein
G	I-protein
)	O
(	O
Renesto	O
,	O
P.	O
,	O
and	O
Chignard	O
,	O
M.	O
(	O
1993	O
)	O
Blood	O
82	O
,	O
139-144	O
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
delineate	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
this	O
potentiation	O
process	O
.	O

Two	O
main	O
pieces	O
of	O
data	O
prompted	O
us	O
to	O
focus	O
on	O
the	O
activation	O
of	O
the	O
platelet	B-protein
fibrinogen	I-protein
receptor	I-protein
,	O
the	O
alphaIIbbeta3	B-protein
integrin	I-protein
.	O

First	O
,	O
previous	O
studies	O
have	O
shown	O
this	O
integrin	B-protein
to	O
be	O
particularly	O
prone	O
to	O
proteolytic	O
regulation	O
of	O
its	O
function	O
.	O

Second	O
,	O
we	O
found	O
that	O
the	O
potentiating	O
activity	O
of	O
NE	B-protein
on	O
the	O
threshold	O
of	O
cathepsin	B-protein
G	I-protein
-induced	O
platelet	O
aggregation	O
was	O
strictly	O
dependent	O
on	O
the	O
presence	O
of	O
exogenous	B-protein
fibrinogen	I-protein
.	O

Using	O
flow	O
cytometry	O
analysis	O
,	O
NE	B-protein
was	O
shown	O
to	O
trigger	O
a	O
time-dependent	O
binding	O
of	O
PAC-1	B-protein
and	O
AP-5	B-protein
,	O
two	O
monoclonal	B-protein
antibodies	I-protein
specific	O
for	O
the	O
activated	O
and	O
ligand-occupied	O
conformers	O
of	O
alphaIIbbeta3	B-protein
.	O

Furthermore	O
,	O
the	O
potentiated	O
aggregation	O
was	O
shown	O
to	O
result	O
from	O
an	O
increased	O
capacity	O
of	O
platelets	O
to	O
bind	O
fibrinogen	O
.	O

Indeed	O
,	O
the	O
combination	O
of	O
NE	B-protein
and	O
threshold	O
of	O
cathepsin	B-protein
G	I-protein
increased	O
the	O
binding	O
of	O
PAC-1	B-protein
approximately	O
5.5-fold	O
over	O
basal	O
values	O
measured	O
on	O
nontreated	B-cell_type
platelets	I-cell_type
,	O
whereas	O
this	O
binding	O
raised	O
only	O
by	O
approximately	O
3-fold	O
in	O
threshold	O
of	O
cathepsin	B-cell_type
G-stimulated	I-cell_type
platelets	I-cell_type
(	O
p	O
<	O
0.05	O
)	O
.	O

By	O
contrast	O
,	O
phosphatidic	O
acid	O
accumulation	O
,	O
pleckstrin	O
phosphorylation	O
,	O
and	O
calcium	O
mobilization	O
produced	O
by	O
the	O
combination	O
of	O
NE	B-protein
and	O
threshold	O
of	O
cathepsin	B-protein
G	I-protein
were	O
not	O
significantly	O
different	O
from	O
those	O
measured	O
with	O
threshold	O
of	O
cathepsin	B-protein
G	I-protein
alone	O
(	O
p	O
>	O
0.05	O
)	O
,	O
indicating	O
that	O
the	O
phospholipase	B-protein
C	I-protein
/protein	B-protein
kinase	I-protein
C	I-protein
pathway	O
is	O
not	O
involved	O
in	O
the	O
potentiation	O
of	O
aggregation	O
.	O

The	O
foregoing	O
data	O
,	O
as	O
well	O
as	O
the	O
requirement	O
of	O
catalytically	O
active	O
NE	B-protein
to	O
trigger	O
alphaIIbbeta3	B-protein
activation	O
and	O
potentiate	O
threshold	O
of	O
cathepsin	B-protein
G	I-protein
-initiated	O
platelet	O
aggregation	O
,	O
led	O
us	O
to	O
examine	O
whether	O
the	O
structure	O
of	O
this	O
integrin	B-protein
was	O
affected	O
by	O
NE	B-protein
.	O

Immunoblot	O
and	O
flow	O
cytometry	O
analysis	O
revealed	O
a	O
limited	O
proteolysis	O
of	O
the	O
carboxyl	B-protein
terminus	I-protein
of	O
the	O
alphaIIb	B-protein
subunit	I-protein
heavy	I-protein
chain	I-protein
(	O
alphaIIbH	B-protein
)	O
,	O
as	O
judged	O
by	O
the	O
disappearance	O
of	O
the	O
epitope	O
for	O
the	O
monoclonal	B-protein
antibody	I-protein
PMI-1	I-protein
.	O

Mass	O
spectrometry	O
studies	O
performed	O
on	O
a	O
synthetic	O
peptide	O
mapping	O
over	O
the	O
cleavage	B-protein
domain	I-protein
of	O
alphaIIbH	B-protein
predicted	O
the	O
site	O
of	O
proteolysis	O
as	O
located	O
between	O
Val837	O
and	O
Asp838	O
.	O

Treatment	O
by	O
NE	B-protein
of	O
ATP-depleted	B-cell_type
platelets	I-cell_type
or	O
Chinese	B-cell_line
hamster	I-cell_line
ovary	I-cell_line
cells	I-cell_line
expressing	O
human	B-protein
recombinant	I-protein
alphaIIbbeta3	I-protein
clearly	O
established	O
that	O
activation	O
of	O
the	O
integrin	B-protein
was	O
independent	O
of	O
signal	O
transduction	O
events	O
and	O
was	O
concomitant	O
with	O
the	O
proteolysis	O
of	O
alphaIIbH	B-protein
.	O

THE	NULL
JOURNAL	NULL
or	NULL
BIOLOGICAL	NULL
CHEMISTRY	NULL
©	NULL
1997	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Biochemistry	NULL
and	NULL
Molecular	NULL
Biology	NULL
,	NULL
Inc.	NULL
Vol	NULL
.	NULL

272	NULL
,	NULL
No	NULL
.	NULL

17	NULL
,	NULL
Issue	NULL
of	NULL
April	NULL
25	NULL
,	NULL
pp	NULL
.	NULL

11636-11647	NULL
,	NULL
1997	NULL
Printed	NULL
in	NULL
U.S.A.	NULL
Human	NULL
Neutrophil	NULL
Elastase	NULL
Proteolytically	NULL
Activates	NULL
the	NULL
Platelet	NULL
Integrin	NULL
through	NULL
Cleavage	NULL
of	NULL
the	NULL
Carboxyl	NULL
Terminus	NULL
of	NULL
the	NULL
@	NULL
,	NULL
Subunit	NULL
Heavy	NULL
Chain	NULL
INVOLVEMENT	NULL
IN	NULL
THE	NULL
POTENTIATION	NULL
OF	NULL
PLATELET	NULL
AGGREGATION*®	NULL
(	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
November	NULL
14	NULL
,	NULL
1996	NULL
,	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
,	NULL
January	NULL
16	NULL
,	NULL
1997	NULL
)	NULL
Mustapha	NULL
Dominique	NULL
Pidard	NULL
$	NULL
1	NULL
,	NULL
Viviane	NULL
Balloyt	NULL
,	NULL
Mare	NULL
Moniatte|**	NULL
,	NULL
Nelly	NULL
Kieffer	NULL
#	NULL
{	NULL
§§	NULL
,	NULL
Alain	NULL
Van	NULL
Dorsselaer|**	NULL
,	NULL
and	NULL
Michel	NULL
Chignard	NULL
?	NULL

From	NULL
the	NULL
{	NULL
Unité	NULL
de	NULL
Pharmacologie	NULL
Cellulaire	NULL
,	NULL
Unité	NULL
Associée	NULL
IP/	NULL
INSERM	NULL
285	NULL
,	NULL
Institut	NULL
Pasteur	NULL
,	NULL
Paris	NULL
,	NULL
the	NULL
Laboratoire	NULL
de	NULL
Spectrométrie	NULL
de	NULL
Masse	NULL
Bioorganique	NULL
,	NULL
Institut	NULL
de	NULL
Chimie	NULL
,	NULL
Strasbourg	NULL
,	NULL
France	NULL
,	NULL
and	NULL
the	NULL
Franco-Luxembourgeois	NULL
de	NULL
Recherche	NULL
Biomédicale	NULL
,	NULL
Centre	NULL
Universitaire	NULL
,	NULL
Grand-Duchy	NULL
,	NULL
Luxembourg	NULL
Neutrophil	NULL
elastase	NULL
(	NULL
NE	NULL
)	NULL
and	NULL
cathepsin	NULL
G	NULL
are	NULL
two	NULL
serine	NULL
proteinases	NULL
released	NULL
concomitantly	NULL
by	NULL
stimulated	NULL
polymorphonuclear	NULL
neutrophils	NULL
.	NULL

We	NULL
previously	NULL
demonstrated	NULL
that	NULL
while	NULL
NE	NULL
by	NULL
itself	NULL
does	NULL
not	NULL
activate	NULL
human	NULL
platelets	NULL
,	NULL
it	NULL
strongly	NULL
enhances	NULL
the	NULL
weak	NULL
aggregation	NULL
induced	NULL
by	NULL
a	NULL
threshold	NULL
concentration	NULL
of	NULL
cathepsin	NULL
G	NULL
(	NULL
threshold	NULL
of	NULL
cathepsin	NULL
G	NULL
)	NULL
(	NULL
Renesto	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Chignard	NULL
,	NULL
M.	NULL
(	NULL
1993	NULL
)	NULL
Blood	NULL
82	NULL
,	NULL
139-144	NULL
)	NULL
.	NULL

The	NULL
aim	NULL
of	NULL
this	NULL
study	NULL
was	NULL
to	NULL
delineate	NULL
the	NULL
molecular	NULL
mechanisms	NULL
involved	NULL
in	NULL
this	NULL
potentiation	NULL
process	NULL
.	NULL

Two	NULL
main	NULL
pieces	NULL
of	NULL
data	NULL
prompted	NULL
us	NULL
to	NULL
focus	NULL
on	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
platelet	NULL
fibrinogen	NULL
receptor	NULL
,	NULL
the	NULL
a	NULL
,	NULL
f	NULL
,	NULL
integrin	NULL
.	NULL

First	NULL
,	NULL
previous	NULL
studies	NULL
have	NULL
shown	NULL
this	NULL
integrin	NULL
to	NULL
be	NULL
particularly	NULL
prone	NULL
to	NULL
proteolytic	NULL
regulation	NULL
of	NULL
its	NULL
function	NULL
.	NULL

Second	NULL
,	NULL
we	NULL
found	NULL
that	NULL
the	NULL
potentiating	NULL
activity	NULL
of	NULL
NE	NULL
on	NULL
the	NULL
threshold	NULL
of	NULL
cathepsin	NULL
G-induced	NULL
platelet	NULL
aggregation	NULL
was	NULL
strictly	NULL
dependent	NULL
on	NULL
the	NULL
presence	NULL
of	NULL
exogenous	NULL
fibrinogen	NULL
.	NULL

Using	NULL
flow	NULL
cytometry	NULL
analysis	NULL
,	NULL
NE	NULL
was	NULL
shown	NULL
to	NULL
trigger	NULL
a	NULL
time-dependent	NULL
binding	NULL
of	NULL
PAC-1	NULL
and	NULL
AP-5	NULL
,	NULL
two	NULL
monoclonal	NULL
antibodies	NULL
specific	NULL
for	NULL
the	NULL
activated	NULL
and	NULL
ligand-occupied	NULL
conformers	NULL
of	NULL
a	NULL
;	NULL
,	NULL
B	NULL
;	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
poten-tiated	NULL
aggregation	NULL
was	NULL
shown	NULL
to	NULL
result	NULL
from	NULL
an	NULL
increased	NULL
capacity	NULL
of	NULL
platelets	NULL
to	NULL
bind	NULL
fibrinogen	NULL
.	NULL

Indeed	NULL
,	NULL
the	NULL
combination	NULL
of	NULL
NE	NULL
and	NULL
threshold	NULL
of	NULL
cathepsin	NULL
G	NULL
increased	NULL
the	NULL
binding	NULL
of	NULL
PAC-1	NULL
~5.5-fold	NULL
over	NULL
basal	NULL
values	NULL
measured	NULL
on	NULL
nontreated	NULL
platelets	NULL
,	NULL
whereas	NULL
this	NULL
binding	NULL
raised	NULL
only	NULL
by	NULL
~3-fold	NULL
in	NULL
threshold	NULL
of	NULL
cathepsin	NULL
G-stimulated	NULL
platelets	NULL
(	NULL
p	NULL
<	NULL
0.05	NULL
)	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
phosphatidic	NULL
acid	NULL
accumulation	NULL
,	NULL
pleckstrin	NULL
phosphorylation	NULL
,	NULL
and	NULL
calcium	NULL
mobilization	NULL
produced	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
NE	NULL
and	NULL
threshold	NULL
of	NULL
cathepsin	NULL
G	NULL
were	NULL
not	NULL
significantly	NULL
different	NULL
from	NULL
those	NULL
measured	NULL
with	NULL
threshold	NULL
of	NULL
cathepsin	NULL
G	NULL
alone	NULL
(	NULL
p	NULL
>	NULL
0.05	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
phospholipase	NULL
C/protein	NULL
kinase	NULL
C	NULL
pathway	NULL
is	NULL
not	NULL
involved	NULL
in	NULL
the	NULL
potentiation	NULL
of	NULL
aggregation	NULL
.	NULL

The	NULL
foregoing	NULL
data	NULL
,	NULL
as	NULL
*	NULL
The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

§	NULL
Supported	NULL
by	NULL
grants	NULL
from	NULL
the	NULL
Ministére	NULL
de	NULL
la	NULL
Recherche	NULL
et	NULL
de	NULL
Enseignement	NULL
Supérieur	NULL
and	NULL
the	NULL
Association	NULL
pour	NULL
la	NULL
Recherche	NULL
sur	NULL
le	NULL
Cancer	NULL
(	NULL
ARC	NULL
)	NULL
,	NULL
France	NULL
.	NULL

To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
:	NULL
Unité	NULL
de	NULL
Pharmacologie	NULL
Cellulaire	NULL
,	NULL
Unité	NULL
associée	NULL
IP/INSERM	NULL
285	NULL
,	NULL
Institut	NULL
Pasteur	NULL
,	NULL
25	NULL
,	NULL
rue	NULL
du	NULL
Dr	NULL
Roux	NULL
,	NULL
F-75015	NULL
,	NULL
Paris	NULL
,	NULL
France	NULL
.	NULL

Tel	NULL
.	NULL

:	NULL
33-1-45-68-86-88	NULL
;	NULL
Fax	NULL
:	NULL
883-1-45-68-87-08	NULL
;	NULL
E-mail	NULL
:	NULL
msitahar	NULL
@	NULL
pasteur.fr	NULL
.	NULL

|	NULL
Supported	NULL
by	NULL
the	NULL
Centre	NULL
National	NULL
de	NULL
la	NULL
Recherche	NULL
Scientifique	NULL
.	NULL

**	NULL
Supported	NULL
by	NULL
BioAvenir	NULL
(	NULL
Rhone-Poulenc	NULL
Santé	NULL
)	NULL
,	NULL
France	NULL
.	NULL

§§	NULL
Supported	NULL
by	NULL
the	NULL
Centre	NULL
de	NULL
Recherche	NULL
Public-Santé	NULL
,	NULL
Luxembourg	NULL
,	NULL
by	NULL
the	NULL
Centre	NULL
National	NULL
de	NULL
la	NULL
Recherche	NULL
Scientifique	NULL
,	NULL
France	NULL
,	NULL
and	NULL
by	NULL
the	NULL
EC	NULL
Biomed	NULL
Grant	NULL
CT	NULL
9831685	NULL
.	NULL

11636	NULL
well	NULL
as	NULL
the	NULL
requirement	NULL
of	NULL
catalytically	NULL
active	NULL
NE	NULL
to	NULL
trigger	NULL
«	NULL
;	NULL
,	NULL
,	NULL
B	NULL
;	NULL
activation	NULL
and	NULL
potentiate	NULL
threshold	NULL
of	NULL
cathepsin	NULL
G-initiated	NULL
platelet	NULL
aggregation	NULL
,	NULL
led	NULL
us	NULL
to	NULL
examine	NULL
whether	NULL
the	NULL
structure	NULL
of	NULL
this	NULL
integrin	NULL
was	NULL
affected	NULL
by	NULL
NE	NULL
.	NULL

Immunoblot	NULL
and	NULL
flow	NULL
cytometry	NULL
analysis	NULL
revealed	NULL
a	NULL
limited	NULL
proteolysis	NULL
of	NULL
the	NULL
carboxyl	NULL
terminus	NULL
of	NULL
the	NULL
a	NULL
;	NULL
f	NULL
,	NULL
subunit	NULL
heavy	NULL
chain	NULL
(	NULL
any	NULL
)	NULL
,	NULL
as	NULL
judged	NULL
by	NULL
the	NULL
disappearance	NULL
of	NULL
the	NULL
epitope	NULL
for	NULL
the	NULL
monoclonal	NULL
antibody	NULL
PMI-1	NULL
.	NULL

Mass	NULL
spectrometry	NULL
studies	NULL
performed	NULL
on	NULL
a	NULL
synthetic	NULL
peptide	NULL
mapping	NULL
over	NULL
the	NULL
cleavage	NULL
domain	NULL
of	NULL
«	NULL
,	NULL
H	NULL
predicted	NULL
the	NULL
site	NULL
of	NULL
proteolysis	NULL
as	NULL
located	NULL
between	NULL
Val	NULL
``	NULL
``	NULL
``	NULL
and	NULL
Asp**	NULL
``	NULL
.	NULL

Treatment	NULL
by	NULL
NE	NULL
of	NULL
ATP-depleted	NULL
platelets	NULL
or	NULL
Chinese	NULL
hamster	NULL
ovary	NULL
cells	NULL
expressing	NULL
human	NULL
recombinant	NULL
a	NULL
;	NULL
,	NULL
;	NULL
clearly	NULL
established	NULL
that	NULL
activation	NULL
of	NULL
the	NULL
integrin	NULL
was	NULL
independent	NULL
of	NULL
signal	NULL
transduction	NULL
events	NULL
and	NULL
was	NULL
concomitant	NULL
with	NULL
the	NULL
proteolysis	NULL
of	NULL
«	NULL
py	NULL
.	NULL

In	NULL
support	NULL
of	NULL
this	NULL
latter	NULL
observation	NULL
,	NULL
a	NULL
close	NULL
correlation	NULL
was	NULL
observed	NULL
between	NULL
the	NULL
kinetics	NULL
of	NULL
proteolysis	NULL
of	NULL
amg	NULL
on	NULL
platelets	NULL
and	NULL
that	NULL
of	NULL
expression	NULL
of	NULL
the	NULL
ligand	NULL
binding	NULL
activity	NULL
of	NULL
o	NULL
,	NULL
f	NULL
;	NULL
=	NULL
0.902	NULL
,	NULL
p	NULL
However	NULL
,	NULL
only	NULL
a	NULL
subpopulation	NULL
(	NULL
~25	NULL
%	NULL
)	NULL
of	NULL
the	NULL
proteolyzed	NULL
a	NULL
;	NULL
,	NULL
,	NULL
,	NULL
B	NULL
;	NULL
appeared	NULL
to	NULL
fully	NULL
express	NULL
the	NULL
ligand	NULL
binding	NULL
capacity	NULL
.	NULL

Altogether	NULL
,	NULL
these	NULL
results	NULL
demonstrate	NULL
that	NULL
NE	NULL
up-regulates	NULL
the	NULL
fibrinogen	NULL
binding	NULL
activity	NULL
of	NULL
through	NULL
a	NULL
restricted	NULL
proteolysis	NULL
of	NULL
the	NULL
aj	NULL
,	NULL
,	NULL
subunit	NULL
,	NULL
and	NULL
that	NULL
this	NULL
process	NULL
is	NULL
relevant	NULL
for	NULL
the	NULL
potentiation	NULL
of	NULL
platelet	NULL
aggregation	NULL
.	NULL

Thrombosis	NULL
and	NULL
inflammation	NULL
are	NULL
processes	NULL
which	NULL
result	NULL
from	NULL
complex	NULL
relationships	NULL
between	NULL
various	NULL
vascular	NULL
cell	NULL
types	NULL
,	NULL
i.e	NULL
.	NULL

endothelial	NULL
cells	NULL
,	NULL
leukocytes	NULL
,	NULL
and	NULL
platelets	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

As	NULL
part	NULL
of	NULL
such	NULL
a	NULL
cell	NULL
cooperation	NULL
network	NULL
,	NULL
polymorphonuclear	NULL
neutrophils	NULL
contribute	NULL
to	NULL
vessel	NULL
injury	NULL
not	NULL
only	NULL
by	NULL
their	NULL
own	NULL
,	NULL
but	NULL
also	NULL
through	NULL
interactions	NULL
with	NULL
platelets	NULL
.	NULL

Thus	NULL
,	NULL
neutrophils	NULL
are	NULL
found	NULL
admixed	NULL
with	NULL
platelets	NULL
in	NULL
the	NULL
core	NULL
of	NULL
vascular	NULL
occlusions	NULL
in	NULL
several	NULL
experimental	NULL
models	NULL
(	NULL
1	NULL
,	NULL
3	NULL
)	NULL
,	NULL
and	NULL
more	NULL
importantly	NULL
,	NULL
a	NULL
neutrophil-dependent	NULL
platelet	NULL
deposition	NULL
has	NULL
been	NULL
described	NULL
in	NULL
arterial	NULL
injuries	NULL
(	NULL
4-6	NULL
)	NULL
.	NULL

Neutrophil-mediated	NULL
platelet	NULL
activation	NULL
can	NULL
be	NULL
demonstrated	NULL
in	NULL
vitro	NULL
by	NULL
adding	NULL
specific	NULL
neutrophil	NULL
agonists	NULL
such	NULL
as	NULL
the	NULL
formyl-Met-Leu-Phe	NULL
(	NULL
fMLP	NULL
)	NULL
peptide	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor-a	NULL
,	NULL
or	NULL
interleukin-8	NULL
to	NULL
autologous	NULL
neutrophil-platelet	NULL
mixed	NULL
suspensions	NULL
(	NULL
7-10	NULL
)	NULL
.	NULL

Cathepsin	NULL
G	NULL
,	NULL
a	NULL
serine	NULL
proteinase	NULL
stored	NULL
in	NULL
the	NULL
azurophilic	NULL
granules	NULL
of	NULL
neutrophils	NULL
and	NULL
released	NULL
upon	NULL
their	NULL
stimulation	NULL
,	NULL
has	NULL
been	NULL
established	NULL
as	NULL
the	NULL
major	NULL
mediator	NULL
of	NULL
this	NULL
cell-to-cell	NULL
interaction	NULL
(	NULL
11-13	NULL
)	NULL
.	NULL

Acting	NULL
similarly	NULL
to	NULL
a-thrombin	NULL
,	NULL
another	NULL
serine	NULL
proteinase	NULL
agonist	NULL
of	NULL
platelets	NULL
,	NULL
cathepsin	NULL
G-induced	NULL
platelet	NULL
activation	NULL
results	NULL
in	NULL
massive	NULL
exocytosis	NULL
and	NULL
aggregation	NULL
reactions	NULL
.	NULL

The	NULL
This	NULL
paper	NULL
is	NULL
available	NULL
on	NULL
line	NULL
at	NULL
http	NULL
:	NULL
//www-jbc.stanford.edu/jbc/	NULL
0.005	NULL
)	NULL
.	NULL

610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
/810-0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wo	NULL
;	NULL
popeoumog	NULL
am	NULL
,	NULL
pBs	NULL
and	NULL
Platelet	NULL
Activation	NULL
by	NULL
Elastase	NULL
and	NULL
Cathepsin	NULL
G	NULL
potent	NULL
signal	NULL
transduction	NULL
triggered	NULL
by	NULL
this	NULL
neutrophil	NULL
proteinase	NULL
includes	NULL
the	NULL
activation	NULL
of	NULL
an	NULL
as	NULL
yet	NULL
unidentified	NULL
proteinase-activated	NULL
membrane	NULL
receptor	NULL
,	NULL
and	NULL
the	NULL
subsequent	NULL
stimulation	NULL
of	NULL
the	NULL
phospholipase	NULL
C	NULL
(	NULL
PLC	NULL
)	NULL
``	NULL
/protein	NULL
kinase	NULL
C	NULL
(	NULL
PKC	NULL
)	NULL
and	NULL
Ca**	NULL
pathways	NULL
(	NULL
14-16	NULL
)	NULL
.	NULL

Another	NULL
important	NULL
serine	NULL
proteinase	NULL
released	NULL
from	NULL
the	NULL
azurophilic	NULL
granules	NULL
concomitantly	NULL
with	NULL
cathepsin	NULL
G	NULL
is	NULL
neutrophil	NULL
elastase	NULL
(	NULL
NE	NULL
)	NULL
.	NULL

While	NULL
NE	NULL
fails	NULL
to	NULL
trigger	NULL
platelet	NULL
aggregation	NULL
and	NULL
exocytosis	NULL
(	NULL
17-19	NULL
)	NULL
,	NULL
it	NULL
has	NULL
been	NULL
demonstrated	NULL
that	NULL
when	NULL
cathepsin	NULL
G	NULL
and	NULL
NE	NULL
are	NULL
added	NULL
together	NULL
at	NULL
concentrations	NULL
comparable	NULL
to	NULL
those	NULL
released	NULL
by	NULL
fMLP	NULL
-activated	NULL
neutrophils	NULL
,	NULL
NE	NULL
potentiates	NULL
the	NULL
capacity	NULL
of	NULL
platelets	NULL
to	NULL
aggregate	NULL
in	NULL
response	NULL
to	NULL
cathepsin	NULL
G	NULL
(	NULL
18	NULL
,	NULL
19	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
molecular	NULL
mechanism	NULL
underlying	NULL
this	NULL
synergism	NULL
remains	NULL
unknown	NULL
.	NULL

Platelet	NULL
aggregation	NULL
is	NULL
primarily	NULL
mediated	NULL
by	NULL
the	NULL
binding	NULL
of	NULL
the	NULL
bifunctional	NULL
adhesive	NULL
protein	NULL
fibrinogen	NULL
to	NULL
the	NULL
surface	NULL
of	NULL
adjacent	NULL
activated	NULL
platelets	NULL
,	NULL
and	NULL
considerable	NULL
evidence	NULL
has	NULL
established	NULL
the	NULL
integrin	NULL
of	NULL
,	NULL
f	NULL
$	NULL
;	NULL
(	NULL
glycoprotein	NULL
IIb-Illa	NULL
)	NULL
as	NULL
the	NULL
membrane	NULL
receptor	NULL
for	NULL
fibrinogen	NULL
,	NULL
thus	NULL
supporting	NULL
platelet	NULL
aggregation	NULL
(	NULL
for	NULL
review	NULL
,	NULL
see	NULL
Refs	NULL
.	NULL

20-22	NULL
)	NULL
.	NULL

As	NULL
all	NULL
other	NULL
integrin	NULL
receptors	NULL
(	NULL
23	NULL
)	NULL
,	NULL
ony	NULL
,	NULL
B	NULL
;	NULL
is	NULL
made	NULL
of	NULL
two	NULL
non-covalently	NULL
associated	NULL
subunits	NULL
.	NULL

The	NULL
af	NULL
,	NULL
subunit	NULL
is	NULL
made	NULL
of	NULL
two	NULL
disulfide-linked	NULL
glycosylated	NULL
polypeptide	NULL
chains	NULL
originating	NULL
from	NULL
a	NULL
single	NULL
precur-sor	NULL
.	NULL

The	NULL
heavy	NULL
chain	NULL
(	NULL
ap	NULL
,	NULL
relative	NULL
molecular	NULL
mass	NULL
,	NULL
M	NULL
,	NULL
~	NULL
126,000	NULL
)	NULL
is	NULL
entirely	NULL
extracellular	NULL
,	NULL
whereas	NULL
the	NULL
light	NULL
chain	NULL
(	NULL
am	NULL
;	NULL
,	NULL
M	NULL
,	NULL
~	NULL
23,000	NULL
)	NULL
contains	NULL
a	NULL
single	NULL
transmembrane	NULL
domain	NULL
.	NULL

The	NULL
B	NULL
;	NULL
,	NULL
subunit	NULL
(	NULL
M	NULL
,	NULL
~	NULL
110,000	NULL
)	NULL
is	NULL
made	NULL
of	NULL
one	NULL
glycosylated	NULL
polypeptide	NULL
chain	NULL
with	NULL
a	NULL
single	NULL
transmembrane	NULL
domain	NULL
,	NULL
and	NULL
presents	NULL
a	NULL
complex	NULL
pattern	NULL
of	NULL
intramolecular	NULL
disulfide	NULL
bonds	NULL
within	NULL
its	NULL
large	NULL
extracellular	NULL
domain	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Although	NULL
anyf	NULL
;	NULL
is	NULL
constitutively	NULL
expressed	NULL
on	NULL
the	NULL
platelet	NULL
plasma	NULL
membrane	NULL
,	NULL
the	NULL
receptor	NULL
normally	NULL
acquires	NULL
its	NULL
capacity	NULL
to	NULL
bind	NULL
fibrinogen	NULL
only	NULL
upon	NULL
platelet	NULL
activation	NULL
.	NULL

An	NULL
inside-out	NULL
signaling	NULL
process	NULL
is	NULL
likely	NULL
responsible	NULL
for	NULL
converting	NULL
this	NULL
integrin	NULL
from	NULL
a	NULL
low-affin-ity	NULL
to	NULL
a	NULL
high-affinity	NULL
membrane	NULL
receptor	NULL
for	NULL
fibrinogen	NULL
,	NULL
through	NULL
conformational	NULL
modifications	NULL
of	NULL
its	NULL
extracellular	NULL
domains	NULL
(	NULL
21	NULL
,	NULL
22	NULL
)	NULL
.	NULL

During	NULL
platelet	NULL
exocytosis	NULL
,	NULL
translocation	NULL
to	NULL
the	NULL
plasma	NULL
membrane	NULL
of	NULL
the	NULL
fraction	NULL
of	NULL
af	NULL
,	NULL
;	NULL
complexes	NULL
associated	NULL
with	NULL
the	NULL
internal	NULL
a-granules	NULL
(	NULL
24	NULL
)	NULL
is	NULL
another	NULL
mean	NULL
for	NULL
increasing	NULL
the	NULL
capacity	NULL
of	NULL
activated	NULL
platelets	NULL
to	NULL
bind	NULL
fibrinogen	NULL
(	NULL
25	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
an	NULL
alternative	NULL
pathway	NULL
for	NULL
activation	NULL
of	NULL
o	NULL
,	NULL
f	NULL
;	NULL
at	NULL
the	NULL
surface	NULL
of	NULL
platelets	NULL
could	NULL
be	NULL
a	NULL
proteolytic	NULL
modification	NULL
of	NULL
the	NULL
extracellular	NULL
regions	NULL
of	NULL
this	NULL
receptor	NULL
.	NULL

Thus	NULL
,	NULL
exposure	NULL
of	NULL
platelets	NULL
to	NULL
pancreatic	NULL
or	NULL
leukocyte	NULL
elastases	NULL
(	NULL
26	NULL
,	NULL
27	NULL
)	NULL
or	NULL
to	NULL
a-chymo-trypsin	NULL
(	NULL
28-30	NULL
)	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
induce	NULL
the	NULL
irreversible	NULL
expression	NULL
of	NULL
fibrinogen-binding	NULL
sites	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
intracellular	NULL
activation	NULL
.	NULL

In	NULL
view	NULL
of	NULL
these	NULL
data	NULL
,	NULL
and	NULL
considering	NULL
the	NULL
potential	NULL
physiopathological	NULL
importance	NULL
of	NULL
the	NULL
process	NULL
,	NULL
the	NULL
aim	NULL
of	NULL
the	NULL
present	NULL
study	NULL
was	NULL
to	NULL
delineate	NULL
the	NULL
molecular	NULL
mechanism	NULL
(	NULL
s	NULL
)	NULL
involved	NULL
in	NULL
the	NULL
potentiation	NULL
exerted	NULL
by	NULL
NE	NULL
on	NULL
cathepsin	NULL
G-induced	NULL
platelet	NULL
aggregation	NULL
.	NULL

For	NULL
this	NULL
purpose	NULL
,	NULL
we	NULL
considered	NULL
both	NULL
the	NULL
possible	NULL
involvement	NULL
of	NULL
intracellular	NULL
signaling	NULL
pathways	NULL
,	NULL
and	NULL
the	NULL
changes	NULL
in	NULL
the	NULL
structure	NULL
and	NULL
biological	NULL
activity	NULL
of	NULL
the	NULL
integrin	NULL
brought	NULL
about	NULL
by	NULL
NE	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
cathepsin	NULL
G.	NULL
MATERIALS	NULL
AND	NULL
METHODS	NULL
Antibodies	NULL
and	NULL
Reagents	NULL
Except	NULL
for	NULL
the	NULL
monoclonal	NULL
antibody	NULL
PAC-1	NULL
,	NULL
which	NULL
was	NULL
provided	NULL
by	NULL
the	NULL
University	NULL
Cell	NULL
Center	NULL
of	NULL
Pennsylvania	NULL
(	NULL
Philadelphia	NULL
,	NULL
PA	NULL
)	NULL
,	NULL
the	NULL
*	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
PLC	NULL
,	NULL
phospholipase	NULL
C	NULL
;	NULL
NE	NULL
,	NULL
neutrophil	NULL
elastase	NULL
;	NULL
threshold	NULL
of	NULL
cathepsin	NULL
G	NULL
,	NULL
threshold	NULL
concentration	NULL
of	NULL
cathepsin	NULL
G	NULL
;	NULL
PKC	NULL
,	NULL
protein	NULL
kinase	NULL
C	NULL
;	NULL
P47	NULL
,	NULL
pleckstrin	NULL
;	NULL
MALDI-TOF	NULL
,	NULL
matrix-assisted	NULL
laser	NULL
desorption/ionization-time	NULL
of	NULL
flight	NULL
;	NULL
LIBS	NULL
,	NULL
ligand-induced	NULL
binding	NULL
site	NULL
;	NULL
CHO	NULL
,	NULL
Chinese	NULL
hamster	NULL
ovary	NULL
;	NULL
PAGE	NULL
,	NULL
polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
;	NULL
PMSF	NULL
,	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
;	NULL
PGI	NULL
;	NULL
,	NULL
,	NULL
prosta-glandin	NULL
I	NULL
,	NULL
;	NULL
PtdOH	NULL
,	NULL
phosphatidic	NULL
acid	NULL
;	NULL
5-HT	NULL
,	NULL
5-hydroxytryptamine	NULL
.	NULL

11637	NULL
murine	NULL
monoclonal	NULL
and	NULL
rabbit	NULL
polyclonal	NULL
domain-specific	NULL
antibodies	NULL
used	NULL
in	NULL
this	NULL
study	NULL
and	NULL
listed	NULL
in	NULL
Table	NULL
I	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
Scripps	NULL
Research	NULL
Institute	NULL
(	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
:	NULL
PMI-1	NULL
and	NULL
the	NULL
polyclonal	NULL
antiserum	NULL
raised	NULL
against	NULL
the	NULL
peptide	NULL
V41	NULL
(	NULL
designated	NULL
anti-V41	NULL
)	NULL
were	NULL
kindly	NULL
supplied	NULL
by	NULL
Dr.	NULL
M.	NULL
H.	NULL
Ginsberg	NULL
,	NULL
AP-2	NULL
and	NULL
AP-5	NULL
were	NULL
generous	NULL
gifts	NULL
from	NULL
Dr.	NULL
T.	NULL
J.	NULL
Kunicki	NULL
,	NULL
and	NULL
the	NULL
polyclonal	NULL
antiserum	NULL
IIb-10	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
S.	NULL
E.	NULL
D'Souza	NULL
.	NULL

Rabbit	NULL
polyclonal	NULL
antisera	NULL
against	NULL
purified	NULL
SDS-denaturated	NULL
whole	NULL
a	NULL
,	NULL
or	NULL
B	NULL
;	NULL
(	NULL
designated	NULL
as	NULL
anti-op	NULL
,	NULL
and	NULL
anti-B	NULL
,	NULL
)	NULL
have	NULL
been	NULL
previously	NULL
described	NULL
and	NULL
characterized	NULL
(	NULL
80	NULL
)	NULL
.	NULL

Negative	NULL
control	NULL
IgG	NULL
or	NULL
IgM	NULL
isotype	NULL
antibodies	NULL
were	NULL
from	NULL
Sigma	NULL
and	NULL
DAKO	NULL
(	NULL
Glostrup	NULL
,	NULL
Denmark	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

Fluorescein	NULL
isothiocyanate-conju-gated	NULL
anti-IgG	NULL
or	NULL
anti-IgM	NULL
were	NULL
obtained	NULL
from	NULL
DAKO	NULL
and	NULL
Sigma	NULL
,	NULL
respectively	NULL
.	NULL

Reagents	NULL
for	NULL
SDS-PAGE	NULL
were	NULL
from	NULL
Bio-Rad	NULL
.	NULL

Nitrocellulose	NULL
membranes	NULL
(	NULL
0.45	NULL
um	NULL
pores	NULL
)	NULL
were	NULL
from	NULL
Schleicher	NULL
and	NULL
Schuell	NULL
(	NULL
Dassel	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

Affinity-purified	NULL
staphylococcal	NULL
***I-Protein	NULL
A	NULL
and	NULL
carrier-free	NULL
sodium	NULL
[	NULL
**	NULL
``	NULL
Iliodide	NULL
were	NULL
from	NULL
Amersham	NULL
International	NULL
ple	NULL
(	NULL
Little	NULL
Chalfont	NULL
,	NULL
United	NULL
Kingdom	NULL
)	NULL
.	NULL

The	NULL
PKC	NULL
inhibitor	NULL
GF	NULL
109208X	NULL
was	NULL
a	NULL
kind	NULL
gift	NULL
from	NULL
Dr.	NULL
J.	NULL
Kirilovsky	NULL
(	NULL
Laboratoire	NULL
Glaxo-Wellcome	NULL
,	NULL
Les	NULL
Ulis	NULL
,	NULL
France	NULL
)	NULL
.	NULL

This	NULL
compound	NULL
was	NULL
dissolved	NULL
in	NULL
Me	NULL
,	NULL
SO	NULL
(	NULL
which	NULL
final	NULL
concentration	NULL
in	NULL
platelets	NULL
was	NULL
less	NULL
than	NULL
0.5	NULL
%	NULL
,	NULL
v/v	NULL
)	NULL
.	NULL

Eglin	NULL
C	NULL
was	NULL
generously	NULL
provided	NULL
by	NULL
Dr.	NULL
H.	NULL
P.	NULL
Schnebli	NULL
(	NULL
Ciba-Geigy	NULL
Research	NULL
,	NULL
Basel	NULL
,	NULL
Switzerland	NULL
)	NULL
.	NULL

Blood	NULL
was	NULL
obtained	NULL
from	NULL
the	NULL
Centre	NULL
National	NULL
de	NULL
Transfusion	NULL
Sanguine	NULL
(	NULL
Paris	NULL
,	NULL
France	NULL
)	NULL
.	NULL

Fibrinogen	NULL
(	NULL
Grade	NULL
L	NULL
)	NULL
was	NULL
purchased	NULL
from	NULL
Kabi	NULL
(	NULL
Stockolm	NULL
,	NULL
Sweden	NULL
)	NULL
and	NULL
treated	NULL
with	NULL
diisopropyl	NULL
fluorophos-phate	NULL
to	NULL
inactivate	NULL
coagulant	NULL
contaminants	NULL
and	NULL
subsequently	NULL
dialyzed	NULL
to	NULL
remove	NULL
the	NULL
free	NULL
inhibitor	NULL
.	NULL

N-Succinyl-	NULL
(	NULL
Ala	NULL
)	NULL
,	NULL
-Pro-Phe-p-nitroanilide	NULL
(	NULL
a	NULL
cathepsin	NULL
G	NULL
substrate	NULL
)	NULL
,	NULL
N-succinyl-	NULL
(	NULL
Ala	NULL
)	NULL
,	NULL
-p-nitroanilide	NULL
(	NULL
a	NULL
NE	NULL
substrate	NULL
)	NULL
,	NULL
2-deoxy-D-glucose	NULL
,	NULL
sodium	NULL
azide	NULL
(	NULL
NaN	NULL
,	NULL
)	NULL
,	NULL
glucono-6-lactone	NULL
,	NULL
the	NULL
proteinase	NULL
inhibitors	NULL
phenyImethylsulfonyl	NULL
fluoride	NULL
(	NULL
PMSF	NULL
)	NULL
,	NULL
benzamidine	NULL
,	NULL
leupeptin	NULL
,	NULL
soybean	NULL
trypsin	NULL
inhibitor	NULL
and	NULL
aprotinin	NULL
were	NULL
from	NULL
Sigma	NULL
.	NULL

Iscove	NULL
's	NULL
buffer	NULL
was	NULL
from	NULL
BioWhittaker	NULL
(	NULL
Belgium	NULL
)	NULL
.	NULL

The	NULL
peptide	NULL
FPQPPVNPLKVDWGL	NULL
(	NULL
using	NULL
the	NULL
single-letter	NULL
code	NULL
for	NULL
amino	NULL
acids	NULL
)	NULL
,	NULL
corresponding	NULL
to	NULL
the	NULL
sequence	NULL
827-841	NULL
of	NULL
the	NULL
ayy	NULL
,	NULL
subunit	NULL
heavy	NULL
chain	NULL
,	NULL
was	NULL
synthesized	NULL
by	NULL
Neosystem	NULL
Laboratoire	NULL
(	NULL
Strasbourg	NULL
,	NULL
France	NULL
)	NULL
.	NULL

All	NULL
other	NULL
reagents	NULL
were	NULL
obtained	NULL
as	NULL
indicated	NULL
in	NULL
Si-Tahar	NULL
et	NULL
al	NULL
.	NULL

(	NULL
16	NULL
)	NULL
.	NULL

Purification	NULL
of	NULL
Neutrophil	NULL
Cathepsin	NULL
G	NULL
and	NULL
NE	NULL
Cathepsin	NULL
G	NULL
and	NULL
NE	NULL
were	NULL
purified	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
16	NULL
)	NULL
,	NULL
using	NULL
a	NULL
two-step	NULL
chromatographic	NULL
procedure	NULL
(	NULL
aprotinin-Sepharose	NULL
affinity	NULL
and	NULL
CM-Trisacryl	NULL
ion-exchange	NULL
)	NULL
.	NULL

The	NULL
purity	NULL
of	NULL
the	NULL
neutrophil	NULL
proteinases	NULL
was	NULL
assessed	NULL
by	NULL
SDS-PAGE	NULL
.	NULL

Moreover	NULL
,	NULL
it	NULL
was	NULL
verified	NULL
that	NULL
cathepsin	NULL
G	NULL
and	NULL
NE	NULL
preparations	NULL
were	NULL
devoid	NULL
of	NULL
each	NULL
others	NULL
proteinase	NULL
by	NULL
monitoring	NULL
spectrophotometrically	NULL
the	NULL
hydrolysis	NULL
of	NULL
N-succinyl-	NULL
(	NULL
Ala	NULL
)	NULL
,	NULL
-Pro-Phe-p-nitroanilide	NULL
and	NULL
N-succinyl-	NULL
(	NULL
Ala	NULL
)	NULL
,	NULL
-p-nitroanilide	NULL
induced	NULL
by	NULL
purified	NULL
NE	NULL
and	NULL
cathepsin	NULL
G	NULL
,	NULL
respectively	NULL
.	NULL

For	NULL
the	NULL
determination	NULL
of	NULL
their	NULL
active	NULL
site	NULL
concentrations	NULL
,	NULL
a	NULL
constant	NULL
amount	NULL
of	NULL
the	NULL
enzymes	NULL
were	NULL
reacted	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
increasing	NULL
amounts	NULL
of	NULL
titrated	NULL
,	NULL
-antitrypsin	NULL
and	NULL
extrapolation	NULL
of	NULL
the	NULL
concentrations	NULL
were	NULL
performed	NULL
using	NULL
linear	NULL
regression	NULL
analysis	NULL
.	NULL

To	NULL
block	NULL
the	NULL
catalytic	NULL
site	NULL
of	NULL
NE	NULL
,	NULL
the	NULL
purified	NULL
proteinase	NULL
(	NULL
70	NULL
uM	NULL
)	NULL
was	NULL
incubated	NULL
for	NULL
60	NULL
min	NULL
at	NULL
25	NULL
°C	NULL
with	NULL
PMSF	NULL
(	NULL
1.25	NULL
mM	NULL
)	NULL
,	NULL
and	NULL
the	NULL
mixture	NULL
was	NULL
subsequently	NULL
dialyzed	NULL
to	NULL
remove	NULL
the	NULL
free	NULL
inhibitor	NULL
.	NULL

PMSF-treated	NULL
NE	NULL
was	NULL
shown	NULL
to	NULL
be	NULL
proteolytically	NULL
inactive	NULL
by	NULL
testing	NULL
the	NULL
lack	NULL
of	NULL
hydrolysis	NULL
of	NULL
its	NULL
specific	NULL
synthetic	NULL
substrate	NULL
.	NULL

Preparation	NULL
and	NULL
Labeling	NULL
of	NULL
Platelets	NULL
Blood	NULL
was	NULL
obtained	NULL
from	NULL
healthy	NULL
adult	NULL
volunteers	NULL
without	NULL
any	NULL
med-ication	NULL
.	NULL

The	NULL
platelet-rich	NULL
plasma	NULL
was	NULL
isolated	NULL
by	NULL
centrifugation	NULL
of	NULL
blood	NULL
at	NULL
180	NULL
x	NULL
g	NULL
for	NULL
20	NULL
min	NULL
and	NULL
incubated	NULL
with	NULL
5-	NULL
[	NULL
'*CJHT	NULL
(	NULL
0.05	NULL
mCi/ml	NULL
)	NULL
for	NULL
80	NULL
min	NULL
at	NULL
87	NULL
°C	NULL
.	NULL

For	NULL
protein	NULL
phosphorylation	NULL
and	NULL
phospholipid	NULL
metabolism	NULL
studies	NULL
,	NULL
platelets	NULL
were	NULL
labeled	NULL
with	NULL
acid	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Then	NULL
,	NULL
labeled	NULL
platelets	NULL
were	NULL
washed	NULL
by	NULL
two	NULL
successive	NULL
centrifugations	NULL
(	NULL
1,600	NULL
X	NULL
g	NULL
,	NULL
10	NULL
min	NULL
)	NULL
and	NULL
resuspended	NULL
in	NULL
Tyrode	NULL
's	NULL
buffer	NULL
(	NULL
composition	NULL
,	NULL
mM	NULL
:	NULL
NaCl	NULL
,	NULL
187.0	NULL
;	NULL
KCl	NULL
,	NULL
2.68	NULL
;	NULL
NaHCO	NULL
,	NULL
11.9	NULL
;	NULL
NaH	NULL
,	NULL
PO	NULL
,	NULL
,	NULL
0.42	NULL
;	NULL
CaCl	NULL
,	NULL
,	NULL
2.0	NULL
;	NULL
MgCl	NULL
,	NULL
,	NULL
1.0	NULL
;	NULL
glucose	NULL
,	NULL
5.5	NULL
;	NULL
Hepes	NULL
,	NULL
5.0	NULL
;	NULL
and	NULL
bovine	NULL
serum	NULL
albumin	NULL
,	NULL
0.85	NULL
%	NULL
,	NULL
pH	NULL
7.4	NULL
)	NULL
supplemented	NULL
with	NULL
PGI	NULL
,	NULL
(	NULL
0.25	NULL
uM	NULL
)	NULL
and	NULL
heparin	NULL
(	NULL
50	NULL
units/ml	NULL
)	NULL
.	NULL

Before	NULL
the	NULL
last	NULL
centrifugation	NULL
,	NULL
the	NULL
platelet	NULL
pellet	NULL
was	NULL
resuspended	NULL
in	NULL
the	NULL
same	NULL
buffer	NULL
without	NULL
heparin	NULL
.	NULL

The	NULL
final	NULL
pellet	NULL
was	NULL
resuspended	NULL
in	NULL
Tyrode	NULL
's	NULL
buffer	NULL
such	NULL
that	NULL
the	NULL
final	NULL
platelet	NULL
concentration	NULL
was	NULL
4	NULL
X	NULL
10°/ml	NULL
.	NULL

The	NULL
entire	NULL
procedure	NULL
was	NULL
performed	NULL
at	NULL
37	NULL
°C	NULL
and	NULL
isolated	NULL
platelets	NULL
were	NULL
maintained	NULL
at	NULL
this	NULL
temperature	NULL
until	NULL
use	NULL
.	NULL

Generation	NULL
of	NULL
Stable	NULL
CHO	NULL
Cells	NULL
Expressing	NULL
Human	NULL
e	NULL
;	NULL
;	NULL
,	NULL
B	NULL
;	NULL
(	NULL
CHO	NULL
!	NULL

The	NULL
full-length	NULL
cDNA	NULL
encoding	NULL
wild	NULL
type	NULL
human	NULL
a	NULL
,	NULL
(	NULL
85	NULL
)	NULL
or	NULL
human	NULL
B	NULL
,	NULL
(	NULL
86	NULL
)	NULL
were	NULL
inserted	NULL
into	NULL
the	NULL
pBJ1	NULL
expression	NULL
vector	NULL
and	NULL
cotransfected	NULL
into	NULL
CHO	NULL
dhfr	NULL
(	NULL
neg	NULL
)	NULL
cells	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
87	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
20	NULL
ug	NULL
of	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
/810-0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wo	NULL
;	NULL
popeoumog	NULL
11638	NULL
each	NULL
a	NULL
;	NULL
p	NULL
,	NULL
and	NULL
B	NULL
,	NULL
cDNA	NULL
and	NULL
2	NULL
ug	NULL
of	NULL
dihydrofolate	NULL
reductase	NULL
plasmid	NULL
(	NULL
pMDR901	NULL
)	NULL
were	NULL
mixed	NULL
with	NULL
40	NULL
ug	NULL
of	NULL
LipofectAMINE	NULL
in	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
200	NULL
ul	NULL
and	NULL
added	NULL
to	NULL
the	NULL
cells	NULL
.	NULL

After	NULL
a	NULL
48-h	NULL
incubation	NULL
of	NULL
the	NULL
cells	NULL
in	NULL
Iscove	NULL
's	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
heat-inactivated	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
nucleoside-free	NULL
a-minimal	NULL
essential	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
dialyzed	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
used	NULL
as	NULL
selective	NULL
medium	NULL
.	NULL

Positive	NULL
transfectants	NULL
were	NULL
selected	NULL
for	NULL
cell	NULL
surface	NULL
expression	NULL
of	NULL
recombinant	NULL
using	NULL
the	NULL
complex	NULL
specific	NULL
,	NULL
B	NULL
;	NULL
monoclonal	NULL
antibody	NULL
AP-2	NULL
(	NULL
82	NULL
)	NULL
and	NULL
goat	NULL
anti-mouse	NULL
IgG-coated	NULL
immu-nomagnetic	NULL
beads	NULL
.	NULL

Cells	NULL
were	NULL
further	NULL
grown	NULL
to	NULL
confluence	NULL
in	NULL
T75	NULL
or	NULL
T25	NULL
flasks	NULL
in	NULL
Iscove	NULL
's	NULL
buffer	NULL
supplemented	NULL
with	NULL
glutamine	NULL
,	NULL
penicillin	NULL
,	NULL
strep-tomycin	NULL
,	NULL
and	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
and	NULL
routinely	NULL
passaged	NULL
after	NULL
detachment	NULL
using	NULL
EDTA	NULL
buffer	NULL
(	NULL
composition	NULL
,	NULL
mM	NULL
:	NULL
NaCl	NULL
,	NULL
126	NULL
;	NULL
KCl	NULL
,	NULL
5	NULL
;	NULL
EDTA	NULL
,	NULL
10	NULL
;	NULL
HEPES	NULL
,	NULL
50	NULL
,	NULL
pH	NULL
7.4	NULL
)	NULL
.	NULL

Aggregation	NULL
and	NULL
Secretion	NULL
Measurements	NULL
Platelet	NULL
aggregation	NULL
in	NULL
0.5-ml	NULL
aliquots	NULL
(	NULL
4	NULL
X	NULL
10°	NULL
platelets/ml	NULL
)	NULL
was	NULL
recorded	NULL
at	NULL
37°C	NULL
using	NULL
a	NULL
Dual	NULL
Aggro-Meter	NULL
(	NULL
Chrono-Log	NULL
Corp.	NULL
,	NULL
Hav-ertown	NULL
,	NULL
PA	NULL
)	NULL
under	NULL
constant	NULL
stirring	NULL
(	NULL
1,100	NULL
rpm	NULL
)	NULL
.	NULL

Samples	NULL
were	NULL
preincubated	NULL
with	NULL
imipramine	NULL
(	NULL
1	NULL
uM	NULL
)	NULL
to	NULL
prevent	NULL
the	NULL
re-uptake	NULL
of	NULL
released	NULL
5-	NULL
[	NULL
'CJHT	NULL
and	NULL
with	NULL
fibrinogen	NULL
(	NULL
0.7	NULL
mg/m	NULL
!	NULL
)	NULL

for	NULL
2	NULL
min	NULL
before	NULL
stimulation	NULL
.	NULL

Activation	NULL
was	NULL
initiated	NULL
by	NULL
addition	NULL
of	NULL
cathepsin	NULL
G	NULL
,	NULL
NE	NULL
,	NULL
or	NULL
a	NULL
threshold	NULL
concentration	NULL
of	NULL
cathepsin	NULL
G	NULL
(	NULL
threshold	NULL
of	NULL
cathepsin	NULL
G	NULL
)	NULL
preceded	NULL
by	NULL
NE	NULL
for	NULL
10	NULL
s	NULL
,	NULL
and	NULL
the	NULL
variations	NULL
in	NULL
light	NULL
transmission	NULL
were	NULL
continuously	NULL
recorded	NULL
.	NULL

The	NULL
5-	NULL
[	NULL
'*C	NULL
)	NULL
HT-	NULL
or	NULL
P-labeled	NULL
platelets	NULL
were	NULL
transferred	NULL
to	NULL
tubes	NULL
containing	NULL
125	NULL
ul	NULL
of	NULL
a	NULL
stopping	NULL
solution	NULL
made	NULL
of	NULL
77	NULL
mM	NULL
EDTA	NULL
,	NULL
155	NULL
mM	NULL
NaCl	NULL
,	NULL
33	NULL
%	NULL
formaldehyde	NULL
(	NULL
1:9:8	NULL
,	NULL
v/v	NULL
)	NULL
,	NULL
or	NULL
1.8	NULL
ml	NULL
of	NULL
ice-cold	NULL
chloroform	NULL
,	NULL
methanol	NULL
,	NULL
12	NULL
M	NULL
HCl	NULL
,	NULL
0.1	NULL
M	NULL
EDTA	NULL
(	NULL
20:40:1:2	NULL
,	NULL
v/v	NULL
)	NULL
,	NULL
respectively	NULL
,	NULL
to	NULL
terminate	NULL
the	NULL
reaction	NULL
.	NULL

Supernatants	NULL
containing	NULL
released	NULL
5-	NULL
[	NULL
*CJHT	NULL
were	NULL
mixed	NULL
with	NULL
scintillation	NULL
fluid	NULL
for	NULL
measuring	NULL
radioactiv-ity	NULL
.	NULL

Aggregation	NULL
was	NULL
expressed	NULL
as	NULL
the	NULL
percent	NULL
of	NULL
changes	NULL
in	NULL
light	NULL
transmission	NULL
and	NULL
the	NULL
5-	NULL
[	NULL
'*CJHT	NULL
release	NULL
was	NULL
expressed	NULL
as	NULL
the	NULL
percent	NULL
of	NULL
total	NULL
5-	NULL
[	NULL
'	NULL
C	NULL
]	NULL
JHT	NULL
platelet	NULL
content	NULL
.	NULL

Protein	NULL
Phosphorylation	NULL
and	NULL
Polyphosphoinositide	NULL
Metabolism	NULL
Chloroform/distillated	NULL
water	NULL
(	NULL
0.5	NULL
volume	NULL
of	NULL
each	NULL
)	NULL
was	NULL
added	NULL
to	NULL
*°P-labeled	NULL
platelets	NULL
diluted	NULL
in	NULL
the	NULL
stopping	NULL
organic	NULL
solution	NULL
(	NULL
see	NULL
above	NULL
)	NULL
.	NULL

This	NULL
suspension	NULL
was	NULL
vigorously	NULL
shaken	NULL
and	NULL
centrifuged	NULL
for	NULL
10	NULL
min	NULL
at	NULL
10	NULL
°C	NULL
.	NULL

The	NULL
upper	NULL
aqueous	NULL
phase	NULL
was	NULL
discarded	NULL
.	NULL

Proteins	NULL
,	NULL
concentrated	NULL
at	NULL
the	NULL
interface	NULL
,	NULL
were	NULL
solubilized	NULL
according	NULL
to	NULL
the	NULL
procedure	NULL
of	NULL
Laemm1i	NULL
(	NULL
38	NULL
)	NULL
.	NULL

Radiolabeled	NULL
proteins	NULL
were	NULL
then	NULL
subjected	NULL
to	NULL
SDS-PAGE	NULL
using	NULL
a	NULL
12.5	NULL
%	NULL
resolving	NULL
gel	NULL
and	NULL
a	NULL
5	NULL
%	NULL
stacking	NULL
gel	NULL
.	NULL

After	NULL
staining	NULL
,	NULL
dried	NULL
gels	NULL
were	NULL
exposed	NULL
to	NULL
a	NULL
Molecular	NULL
Dynamics	NULL
(	NULL
MD	NULL
;	NULL
Evry	NULL
,	NULL
France	NULL
)	NULL
Phosphor-Imaging	NULL
screen	NULL
.	NULL

Concurrently	NULL
,	NULL
the	NULL
lower	NULL
chloroformic	NULL
phase	NULL
was	NULL
evap-orated	NULL
,	NULL
washed	NULL
according	NULL
to	NULL
Jolles	NULL
et	NULL
al	NULL
.	NULL

(	NULL
89	NULL
)	NULL
,	NULL
and	NULL
resuspended	NULL
in	NULL
chloroform	NULL
.	NULL

Phosphoinositides	NULL
and	NULL
phosphatidic	NULL
acid	NULL
(	NULL
PtdOH	NULL
)	NULL
were	NULL
separated	NULL
by	NULL
thin	NULL
layer	NULL
chromatography	NULL
using	NULL
chloroform/acetone/metha-nol/acetic	NULL
acid/water	NULL
(	NULL
40:15:18:12:7	NULL
,	NULL
v/v	NULL
)	NULL
as	NULL
the	NULL
migration	NULL
solvent	NULL
.	NULL

Upon	NULL
drying	NULL
,	NULL
the	NULL
chromatography	NULL
plates	NULL
were	NULL
also	NULL
exposed	NULL
to	NULL
a	NULL
PhosphorIm-aging	NULL
screen	NULL
.	NULL

PLC	NULL
and	NULL
PKC	NULL
activities	NULL
were	NULL
evaluated	NULL
by	NULL
quantifying	NULL
the	NULL
radioactive	NULL
signals	NULL
associated	NULL
to	NULL
PtdOH	NULL
and	NULL
pleckstrin	NULL
,	NULL
respectively	NULL
,	NULL
using	NULL
an	NULL
MD	NULL
PhosphorImager	NULL
coupled	NULL
to	NULL
the	NULL
ImageQuant	NULL
software	NULL
(	NULL
version	NULL
38.8	NULL
)	NULL
.	NULL

Calcium	NULL
Flux	NULL
Measurements	NULL
Platelets	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
above	NULL
with	NULL
slight	NULL
modifications	NULL
.	NULL

Following	NULL
the	NULL
resuspension	NULL
in	NULL
Tyrode	NULL
's	NULL
buffer	NULL
supplemented	NULL
with	NULL
pros-tacyclin	NULL
and	NULL
heparin	NULL
,	NULL
platelets	NULL
were	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
at	NULL
37	NULL
°C	NULL
with	NULL
3	NULL
uM	NULL
Fura	NULL
2-acetoxymethylester	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
the	NULL
final	NULL
platelet	NULL
concentration	NULL
was	NULL
adjusted	NULL
to	NULL
4	NULL
X	NULL
10	NULL
``	NULL
/ml	NULL
in	NULL
Tyrode	NULL
's	NULL
buffer	NULL
.	NULL

The	NULL
basal	NULL
fluorescence	NULL
of	NULL
a	NULL
l-ml	NULL
aliquot	NULL
of	NULL
cell	NULL
suspensions	NULL
was	NULL
monitored	NULL
under	NULL
stirring	NULL
with	NULL
a	NULL
spectrofluorimeter	NULL
Jobin	NULL
Yvon	NULL
JY	NULL
3D	NULL
(	NULL
Paris	NULL
,	NULL
France	NULL
)	NULL
thermostatted	NULL
at	NULL
37°C	NULL
.	NULL

Fluorescence	NULL
excitation	NULL
and	NULL
emission	NULL
wavelengths	NULL
were	NULL
340	NULL
and	NULL
510	NULL
nm	NULL
,	NULL
respectively	NULL
.	NULL

Platelets	NULL
preincubated	NULL
for	NULL
2	NULL
min	NULL
were	NULL
challenged	NULL
with	NULL
cathepsin	NULL
G	NULL
,	NULL
NE	NULL
,	NULL
or	NULL
combinations	NULL
of	NULL
both	NULL
proteinases	NULL
,	NULL
and	NULL
the	NULL
changes	NULL
in	NULL
fluorescence	NULL
were	NULL
recorded	NULL
for	NULL
2	NULL
min	NULL
.	NULL

Flow	NULL
Cytometry	NULL
Analysis	NULL
Analysis	NULL
of	NULL
Washed	NULL
Platelets-Cell	NULL
samples	NULL
were	NULL
treated	NULL
as	NULL
for	NULL
platelet	NULL
aggregation	NULL
analysis	NULL
,	NULL
except	NULL
for	NULL
those	NULL
used	NULL
to	NULL
analyze	NULL
the	NULL
binding	NULL
of	NULL
PAC-1	NULL
,	NULL
for	NULL
which	NULL
exogenous	NULL
fibrinogen	NULL
was	NULL
omitted	NULL
as	NULL
this	NULL
natural	NULL
ligand	NULL
of	NULL
the	NULL
activated	NULL
@	NULL
,	NULL
,	NULL
B	NULL
,	NULL
may	NULL
competitively	NULL
inhibit	NULL
the	NULL
binding	NULL
of	NULL
PAC-1	NULL
(	NULL
81	NULL
)	NULL
.	NULL

In	NULL
any	NULL
case	NULL
,	NULL
once	NULL
the	NULL
agonist	NULL
has	NULL
been	NULL
added	NULL
,	NULL
the	NULL
stirring	NULL
was	NULL
allowed	NULL
for	NULL
only	NULL
5	NULL
s	NULL
to	NULL
homogenize	NULL
the	NULL
milieu	NULL
,	NULL
then	NULL
samples	NULL
were	NULL
incubated	NULL
undisturbed	NULL
for	NULL
different	NULL
periods	NULL
of	NULL
time	NULL
at	NULL
37	NULL
°C	NULL
to	NULL
prevent	NULL
platelet	NULL
aggregate	NULL
formation	NULL
,	NULL
which	NULL
would	NULL
interfere	NULL
with	NULL
the	NULL
flow	NULL
cytometry	NULL
analysis	NULL
.	NULL

The	NULL
reaction	NULL
was	NULL
stopped	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
5	NULL
uM	NULL
eglin	NULL
am	NULL
,	NULL
pBs	NULL
and	NULL
Platelet	NULL
Activation	NULL
by	NULL
Elastase	NULL
and	NULL
Cathepsin	NULL
G	NULL
C	NULL
,	NULL
an	NULL
inhibitor	NULL
of	NULL
cathepsin	NULL
G	NULL
and	NULL
NE	NULL
(	NULL
40	NULL
)	NULL
and	NULL
2	NULL
mM	NULL
PMSF	NULL
.	NULL

Platelets	NULL
were	NULL
then	NULL
immediately	NULL
fixed	NULL
with	NULL
1	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
formaldehyde	NULL
for	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Following	NULL
the	NULL
fixation	NULL
,	NULL
all	NULL
samples	NULL
were	NULL
diluted	NULL
10-fold	NULL
in	NULL
Tyrode	NULL
's	NULL
buffer	NULL
and	NULL
then	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4	NULL
°C	NULL
with	NULL
saturating	NULL
concentrations	NULL
of	NULL
purified	NULL
PAC-1	NULL
(	NULL
2	NULL
pg/ml	NULL
)	NULL
,	NULL
AP-2	NULL
(	NULL
1	NULL
ug/ml	NULL
)	NULL
,	NULL
PMI-1	NULL
(	NULL
5	NULL
ug/ml	NULL
)	NULL
,	NULL
AP-5	NULL
ascitic	NULL
fluid	NULL
(	NULL
diluted	NULL
1/1000	NULL
)	NULL
,	NULL
or	NULL
with	NULL
nonimmune	NULL
IgG	NULL
or	NULL
IgM	NULL
as	NULL
control	NULL
isotypes	NULL
.	NULL

Incubations	NULL
were	NULL
done	NULL
in	NULL
conical	NULL
bottom	NULL
96-well	NULL
plastic	NULL
plates	NULL
with	NULL
4	NULL
X	NULL
10°	NULL
cells/well	NULL
.	NULL

After	NULL
centrifugation	NULL
of	NULL
the	NULL
plates	NULL
at	NULL
80	NULL
%	NULL
g	NULL
for	NULL
10	NULL
min	NULL
at	NULL
4°C	NULL
,	NULL
platelets	NULL
were	NULL
washed	NULL
twice	NULL
in	NULL
Tyrode	NULL
's	NULL
buffer	NULL
and	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4	NULL
°C	NULL
with	NULL
the	NULL
corresponding	NULL
second	NULL
fluorescein	NULL
isothiocyanate-labeled	NULL
antibody	NULL
at	NULL
optimal	NULL
concen-tration	NULL
.	NULL

Finally	NULL
,	NULL
platelets	NULL
were	NULL
centrifuged	NULL
as	NULL
above	NULL
,	NULL
resuspended	NULL
in	NULL
the	NULL
same	NULL
buffer	NULL
,	NULL
and	NULL
stored	NULL
at	NULL
4	NULL
°C	NULL
in	NULL
the	NULL
dark	NULL
until	NULL
flow	NULL
cytometric	NULL
assays	NULL
were	NULL
performed	NULL
within	NULL
the	NULL
next	NULL
24	NULL
h.	NULL
It	NULL
is	NULL
of	NULL
note	NULL
that	NULL
when	NULL
platelets	NULL
were	NULL
to	NULL
be	NULL
tested	NULL
for	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
PMI-1	NULL
epitope	NULL
,	NULL
they	NULL
were	NULL
first	NULL
incubated	NULL
with	NULL
the	NULL
proteinase	NULL
,	NULL
then	NULL
with	NULL
5	NULL
mM	NULL
EDTA	NULL
for	NULL
15	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
to	NULL
maximally	NULL
expose	NULL
the	NULL
PMI-1	NULL
epitope	NULL
(	NULL
41	NULL
)	NULL
,	NULL
before	NULL
to	NULL
be	NULL
fixed	NULL
and	NULL
processed	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Analysis	NULL
of	NULL
CHO	NULL
!	NULL

Cells-Cells	NULL
were	NULL
harvested	NULL
from	NULL
culture	NULL
flasks	NULL
using	NULL
EDTA	NULL
buffer	NULL
and	NULL
washed	NULL
once	NULL
in	NULL
Iscove	NULL
's	NULL
buffer	NULL
without	NULL
fetal	NULL
calf	NULL
serum	NULL
and	NULL
then	NULL
in	NULL
Tyrode	NULL
's	NULL
buffer	NULL
.	NULL

The	NULL
final	NULL
pellet	NULL
was	NULL
resuspended	NULL
in	NULL
this	NULL
latter	NULL
buffer	NULL
such	NULL
that	NULL
the	NULL
final	NULL
concentration	NULL
was	NULL
10	NULL
``	NULL
cells/ml	NULL
.	NULL

Then	NULL
,	NULL
cells	NULL
were	NULL
incubated	NULL
for	NULL
3	NULL
min	NULL
at	NULL
37	NULL
°C	NULL
with	NULL
400	NULL
nM	NULL
NE	NULL
or	NULL
550	NULL
nM	NULL
cathepsin	NULL
G	NULL
under	NULL
gentle	NULL
shaking	NULL
.	NULL

The	NULL
reaction	NULL
was	NULL
stopped	NULL
and	NULL
part	NULL
of	NULL
the	NULL
cells	NULL
further	NULL
fixed	NULL
with	NULL
1	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
formaldehyde	NULL
,	NULL
whereas	NULL
nonfixed	NULL
cells	NULL
were	NULL
used	NULL
for	NULL
immunoblot	NULL
analysis	NULL
(	NULL
see	NULL
below	NULL
)	NULL
.	NULL

Next	NULL
,	NULL
10°	NULL
fixed	NULL
CHO/o	NULL
;	NULL
p	NULL
,	NULL
f	NULL
,	NULL
cells	NULL
were	NULL
processed	NULL
for	NULL
PAC-1	NULL
or	NULL
AP-2	NULL
or	NULL
control	NULL
isotype	NULL
antibodies	NULL
binding	NULL
as	NULL
described	NULL
for	NULL
platelets	NULL
.	NULL

In	NULL
all	NULL
cases	NULL
,	NULL
samples	NULL
were	NULL
analyzed	NULL
using	NULL
a	NULL
FACScan	NULL
flow	NULL
cytometer	NULL
(	NULL
Becton	NULL
Dickinson	NULL
Immunocytometry	NULL
System	NULL
,	NULL
Mountain	NULL
View	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Binding	NULL
of	NULL
the	NULL
different	NULL
domain-specific	NULL
anti-	NULL
,	NULL
B	NULL
,	NULL
antibodies	NULL
to	NULL
their	NULL
epitopes	NULL
is	NULL
expressed	NULL
as	NULL
the	NULL
fold	NULL
increase	NULL
in	NULL
median	NULL
fluorescence	NULL
intensity	NULL
over	NULL
basal	NULL
values	NULL
measured	NULL
on	NULL
nontreated	NULL
cells	NULL
,	NULL
following	NULL
subtraction	NULL
of	NULL
the	NULL
background	NULL
binding	NULL
measured	NULL
with	NULL
the	NULL
control	NULL
isotypes	NULL
.	NULL

Binding	NULL
of	NULL
``	NULL
**I-Labeled	NULL
Monoclonal	NULL
Antibodies	NULL
The	NULL
monoclonal	NULL
antibodies	NULL
PMI-1	NULL
and	NULL
AP-5	NULL
were	NULL
purified	NULL
to	NULL
homogeneity	NULL
from	NULL
ascitic	NULL
fluids	NULL
by	NULL
conventional	NULL
Protein	NULL
A-	NULL
or	NULL
Protein	NULL
G-Sepharose	NULL
chromatography	NULL
,	NULL
and	NULL
labeled	NULL
with	NULL
'*	NULL
``	NULL
I	NULL
to	NULL
a	NULL
specific	NULL
activity	NULL
of	NULL
~4.5	NULL
X	NULL
10	NULL
``	NULL
becquerels/ug	NULL
of	NULL
IgG	NULL
using	NULL
the	NULL
chloramine	NULL
T	NULL
procedure	NULL
(	NULL
82	NULL
,	NULL
41	NULL
)	NULL
.	NULL

Platelets	NULL
were	NULL
exposed	NULL
to	NULL
NE	NULL
(	NULL
400	NULL
nM	NULL
)	NULL
in	NULL
an	NULL
aggregometer	NULL
cuvette	NULL
for	NULL
increasing	NULL
periods	NULL
of	NULL
time	NULL
(	NULL
up	NULL
to	NULL
3	NULL
min	NULL
)	NULL
,	NULL
and	NULL
the	NULL
proteinase	NULL
was	NULL
blocked	NULL
by	NULL
addition	NULL
of	NULL
eglin	NULL
C	NULL
and	NULL
PMSF	NULL
as	NULL
for	NULL
flow	NULL
cytometry	NULL
analysis	NULL
.	NULL

Control	NULL
platelet	NULL
suspensions	NULL
were	NULL
treated	NULL
similarly	NULL
except	NULL
that	NULL
NE	NULL
was	NULL
absent	NULL
.	NULL

Platelets	NULL
were	NULL
immediately	NULL
distributed	NULL
(	NULL
final	NULL
concentration	NULL
,	NULL
2	NULL
X	NULL
10	NULL
%	NULL
/m1l	NULL
)	NULL
in	NULL
a	NULL
Tyrode	NULL
's	NULL
medium	NULL
containing	NULL
either	NULL
divalent	NULL
cations	NULL
or	NULL
EDTA	NULL
(	NULL
final	NULL
concentration	NULL
,	NULL
3	NULL
mM	NULL
)	NULL
,	NULL
and	NULL
either	NULL
one	NULL
of	NULL
the	NULL
'*	NULL
``	NULL
I-labeled	NULL
antibodies	NULL
.	NULL

Incubations	NULL
were	NULL
performed	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
45	NULL
min	NULL
,	NULL
and	NULL
platelet-bound	NULL
antibodies	NULL
were	NULL
separated	NULL
from	NULL
unbound	NULL
by	NULL
layering	NULL
triplicate	NULL
50-4l	NULL
aliquots	NULL
of	NULL
the	NULL
cell	NULL
suspensions	NULL
on	NULL
0.5	NULL
ml	NULL
of	NULL
20	NULL
%	NULL
sucrose	NULL
made	NULL
in	NULL
Tyrode	NULL
's	NULL
medium	NULL
,	NULL
and	NULL
centrifugation	NULL
for	NULL
5	NULL
min	NULL
at	NULL
14,000	NULL
x	NULL
g.	NULL
The	NULL
supernatant	NULL
and	NULL
sucrose	NULL
were	NULL
aspirated	NULL
,	NULL
and	NULL
the	NULL
platelet	NULL
pellets	NULL
at	NULL
the	NULL
bottom	NULL
of	NULL
the	NULL
tube	NULL
cut	NULL
and	NULL
counted	NULL
for	NULL
**	NULL
``	NULL
I	NULL
in	NULL
a	NULL
1282	NULL
Compugamma	NULL
CS	NULL
counter	NULL
(	NULL
LKB	NULL
Wallac	NULL
,	NULL
Turku	NULL
,	NULL
Finland	NULL
)	NULL
.	NULL

Binding	NULL
of	NULL
**°I-AP-5	NULL
on	NULL
NE-treated	NULL
platelets	NULL
,	NULL
which	NULL
reflected	NULL
fibrinogen	NULL
binding	NULL
to	NULL
the	NULL
activated	NULL
a	NULL
;	NULL
,	NULL
B	NULL
,	NULL
integrin	NULL
(	NULL
88	NULL
)	NULL
,	NULL
was	NULL
performed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
divalent	NULL
cations	NULL
.	NULL

Under	NULL
similar	NULL
conditions	NULL
,	NULL
binding	NULL
to	NULL
control	NULL
nontreated	NULL
platelets	NULL
was	NULL
negligible	NULL
,	NULL
as	NULL
previously	NULL
reported	NULL
(	NULL
83	NULL
)	NULL
,	NULL
and	NULL
increased	NULL
linearly	NULL
as	NULL
a	NULL
constant	NULL
fraction	NULL
(	NULL
0.7	NULL
%	NULL
)	NULL
of	NULL
the	NULL
antibody	NULL
input	NULL
.	NULL

This	NULL
was	NULL
taken	NULL
as	NULL
nonspecific	NULL
binding	NULL
.	NULL

Maximal	NULL
binding	NULL
of	NULL
'*°I-AP-5	NULL
was	NULL
measured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
EDTA	NULL
(	NULL
83	NULL
)	NULL
and	NULL
found	NULL
to	NULL
saturate	NULL
at	NULL
25	NULL
ug/ml	NULL
IgG	NULL
;	NULL
this	NULL
concentration	NULL
was	NULL
used	NULL
throughout	NULL
all	NULL
subsequent	NULL
experiments	NULL
.	NULL

Binding	NULL
of	NULL
'*°I-PMI-1	NULL
on	NULL
NE-treated	NULL
platelets	NULL
,	NULL
which	NULL
measured	NULL
the	NULL
proteolysis	NULL
of	NULL
the	NULL
of	NULL
,	NULL
B	NULL
,	NULL
integrin	NULL
(	NULL
see	NULL
``	NULL
Results	NULL
``	NULL
)	NULL
,	NULL
was	NULL
performed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
EDTA	NULL
,	NULL
to	NULL
maximize	NULL
the	NULL
exposure	NULL
of	NULL
the	NULL
PMI-1	NULL
epitope	NULL
on	NULL
the	NULL
platelet	NULL
surface	NULL
(	NULL
41	NULL
)	NULL
.	NULL

In	NULL
preliminary	NULL
experiments	NULL
,	NULL
the	NULL
nonspecific	NULL
binding	NULL
was	NULL
measured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
50-fold	NULL
excess	NULL
of	NULL
unlabeled	NULL
antibody	NULL
,	NULL
and	NULL
found	NULL
to	NULL
represent	NULL
a	NULL
constant	NULL
fraction	NULL
(	NULL
0.25	NULL
%	NULL
)	NULL
of	NULL
the	NULL
antibody	NULL
input	NULL
.	NULL

Maximal	NULL
binding	NULL
of	NULL
'*°I-PMI-1	NULL
was	NULL
measured	NULL
on	NULL
control	NULL
platelets	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
EDTA	NULL
and	NULL
found	NULL
to	NULL
saturate	NULL
at	NULL
250	NULL
ug/ml	NULL
IgG	NULL
;	NULL
this	NULL
concentration	NULL
was	NULL
used	NULL
throughout	NULL
all	NULL
subsequent	NULL
experiments	NULL
.	NULL

Isotherm	NULL
binding	NULL
of	NULL
increasing	NULL
amounts	NULL
of	NULL
'*5T-labeled	NULL
antibodies	NULL
to	NULL
nontreated	NULL
or	NULL
NE-treated	NULL
platelets	NULL
for	NULL
1	NULL
min	NULL
showed	NULL
that	NULL
the	NULL
K	NULL
,	NULL
,	NULL
of	NULL
each	NULL
antibody	NULL
for	NULL
its	NULL
epitope	NULL
was	NULL
unchanged	NULL
following	NULL
proteolysis	NULL
of	NULL
ayy	NULL
,	NULL
B	NULL
,	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

All	NULL
data	NULL
are	NULL
reported	NULL
as	NULL
specific	NULL
binding	NULL
,	NULL
i.e	NULL
.	NULL

total	NULL
binding	NULL
corrected	NULL
for	NULL
the	NULL
nonspecific	NULL
as	NULL
defined	NULL
above	NULL
.	NULL

610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
/810-0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wo	NULL
;	NULL
popeoumog	NULL
am	NULL
,	NULL
pBs	NULL
and	NULL
Platelet	NULL
Activation	NULL
by	NULL
Elastase	NULL
and	NULL
Cathepsin	NULL
G	NULL
SDS-PAGE	NULL
and	NULL
Immunoblot	NULL
Analysis	NULL
At	NULL
the	NULL
end	NULL
of	NULL
the	NULL
exposure	NULL
of	NULL
platelets	NULL
to	NULL
proteinases	NULL
in	NULL
the	NULL
aggregometer	NULL
cuvettes	NULL
,	NULL
and	NULL
after	NULL
addition	NULL
of	NULL
eglin	NULL
C	NULL
and	NULL
PMSF	NULL
to	NULL
block	NULL
the	NULL
enzymatic	NULL
activity	NULL
of	NULL
cathepsin	NULL
G	NULL
and/or	NULL
NE	NULL
,	NULL
200	NULL
pl	NULL
of	NULL
platelet	NULL
suspensions	NULL
were	NULL
rapidly	NULL
centrifuged	NULL
at	NULL
12,000	NULL
%	NULL
g	NULL
for	NULL
4	NULL
min	NULL
.	NULL

The	NULL
supernatant	NULL
was	NULL
carefully	NULL
removed	NULL
and	NULL
the	NULL
platelet	NULL
pellets	NULL
were	NULL
resuspended	NULL
in	NULL
the	NULL
initial	NULL
volume	NULL
with	NULL
10	NULL
mM	NULL
Tris/HCl	NULL
,	NULL
150	NULL
mm	NULL
NaCl	NULL
,	NULL
3	NULL
mm	NULL
EDTA	NULL
,	NULL
pH	NULL
6.8	NULL
,	NULL
and	NULL
cells	NULL
were	NULL
solubilized	NULL
by	NULL
addition	NULL
of	NULL
a	NULL
one-fifth	NULL
volume	NULL
of	NULL
12	NULL
%	NULL
(	NULL
w/v	NULL
)	NULL
SDS	NULL
and	NULL
30	NULL
mM	NULL
N-ethylmaleimide	NULL
in	NULL
10	NULL
mM	NULL
Tris/HCl	NULL
,	NULL
pH	NULL
6.8	NULL
,	NULL
and	NULL
heated	NULL
at	NULL
100	NULL
°C	NULL
for	NULL
5	NULL
min	NULL
.	NULL

SDS-PAGE	NULL
was	NULL
performed	NULL
according	NULL
to	NULL
the	NULL
procedure	NULL
of	NULL
Laemm	NULL
!	NULL

i	NULL
(	NULL
88	NULL
)	NULL
.	NULL

When	NULL
needed	NULL
,	NULL
disulfide	NULL
bonds	NULL
were	NULL
reduced	NULL
prior	NULL
to	NULL
electrophoresis	NULL
by	NULL
adding	NULL
5	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
2-mercaptoethanol	NULL
to	NULL
the	NULL
samples	NULL
.	NULL

For	NULL
CHO/a	NULL
,	NULL
fB	NULL
,	NULL
cells	NULL
solubilization	NULL
,	NULL
1-38	NULL
X	NULL
10°	NULL
nonfixed	NULL
cells	NULL
pretreated	NULL
or	NULL
not	NULL
with	NULL
NE	NULL
or	NULL
cathepsin	NULL
G	NULL
as	NULL
described	NULL
above	NULL
were	NULL
centrifuged	NULL
for	NULL
4	NULL
min	NULL
at	NULL
12,000	NULL
X	NULL
g.	NULL
After	NULL
discarding	NULL
the	NULL
supernatant	NULL
,	NULL
the	NULL
cell	NULL
pellets	NULL
were	NULL
resuspended	NULL
at	NULL
10	NULL
``	NULL
cells/ml	NULL
in	NULL
a	NULL
lysis	NULL
medium	NULL
(	NULL
final	NULL
concentrations	NULL
,	NULL
mM	NULL
:	NULL
Tris	NULL
,	NULL
10	NULL
;	NULL
NaCl	NULL
,	NULL
150	NULL
;	NULL
EDTA	NULL
,	NULL
3	NULL
;	NULL
N-ethylmaleimide	NULL
,	NULL
5	NULL
;	NULL
PMSF	NULL
,	NULL
1	NULL
;	NULL
benzamidine	NULL
,	NULL
5	NULL
;	NULL
leupeptin	NULL
,	NULL
0.1	NULL
;	NULL
soybean	NULL
trypsin	NULL
inhibitor	NULL
,	NULL
0.0014	NULL
,	NULL
pH	NULL
7.4	NULL
)	NULL
to	NULL
which	NULL
10	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
Triton	NULL
X-100	NULL
was	NULL
added	NULL
for	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
1	NULL
%	NULL
.	NULL

Protein	NULL
extraction	NULL
was	NULL
performed	NULL
at	NULL
4	NULL
°C	NULL
for	NULL
30	NULL
min	NULL
with	NULL
occasional	NULL
vortexing	NULL
,	NULL
then	NULL
the	NULL
extract	NULL
cleared	NULL
from	NULL
cells	NULL
debris	NULL
and	NULL
nucleus	NULL
by	NULL
a	NULL
15-min	NULL
centrifugation	NULL
at	NULL
12,000	NULL
X	NULL
g	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
supernatant	NULL
was	NULL
then	NULL
solubilized	NULL
with	NULL
SDS-N-ethylmaleimide	NULL
,	NULL
and	NULL
the	NULL
extract	NULL
processed	NULL
for	NULL
SDS-PAGE	NULL
.	NULL

Electrophoresis	NULL
was	NULL
performed	NULL
after	NULL
loading	NULL
each	NULL
well	NULL
on	NULL
gels	NULL
with	NULL
10	NULL
or	NULL
20	NULL
ug	NULL
of	NULL
total	NULL
platelet	NULL
or	NULL
cell	NULL
proteins	NULL
,	NULL
respectively	NULL
;	NULL
then	NULL
proteins	NULL
were	NULL
transferred	NULL
to	NULL
nitrocellulose	NULL
membranes	NULL
and	NULL
probed	NULL
by	NULL
immunoblotting	NULL
using	NULL
specific	NULL
antibodies	NULL
exactly	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
30	NULL
)	NULL
,	NULL
and	NULL
as	NULL
specified	NULL
in	NULL
the	NULL
figure	NULL
legends	NULL
.	NULL

Bound	NULL
antibodies	NULL
were	NULL
detected	NULL
following	NULL
incubation	NULL
of	NULL
the	NULL
membranes	NULL
with	NULL
*I-Protein	NULL
A	NULL
(	NULL
diluted	NULL
1/1000	NULL
)	NULL
and	NULL
autoradiography	NULL
on	NULL
Kodak	NULL
X-Omat	NULL
MA	NULL
or	NULL
AR	NULL
films	NULL
(	NULL
Kodak-Pathé	NULL
,	NULL
Paris	NULL
,	NULL
France	NULL
)	NULL
for	NULL
various	NULL
periods	NULL
of	NULL
time	NULL
(	NULL
0.25	NULL
to	NULL
4	NULL
days	NULL
)	NULL
.	NULL

For	NULL
M	NULL
,	NULL
determinations	NULL
,	NULL
polyacrylamide	NULL
gels	NULL
were	NULL
calibrated	NULL
using	NULL
standard	NULL
proteins	NULL
with	NULL
M	NULL
,	NULL
in	NULL
the	NULL
range	NULL
200,000	NULL
to	NULL
14,400	NULL
.	NULL

Matrix-assisted	NULL
Laser	NULL
Desorption	NULL
/	NULL
Ionization-Time	NULL
of	NULL
Flight	NULL
(	NULL
MALDI-TOF	NULL
)	NULL
Analysis	NULL
The	NULL
site	NULL
of	NULL
cleavage	NULL
by	NULL
NE	NULL
was	NULL
searched	NULL
by	NULL
MALDI-TOF	NULL
mass	NULL
spectrometry	NULL
on	NULL
a	NULL
15-mer	NULL
peptide	NULL
,	NULL
designated	NULL
peptide	NULL
827-841	NULL
,	NULL
corresponding	NULL
to	NULL
the	NULL
amino	NULL
acid	NULL
sequence	NULL
Phe*	NULL
``	NULL
``	NULL
-Leu	NULL
``	NULL
'	NULL
of	NULL
the	NULL
subunit	NULL
(	NULL
85	NULL
)	NULL
.	NULL

Enzymatic	NULL
digestion	NULL
assay	NULL
was	NULL
performed	NULL
at	NULL
37	NULL
°C	NULL
with	NULL
NE	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
400	NULL
nM	NULL
and	NULL
the	NULL
peptide	NULL
827-841	NULL
at	NULL
525	NULL
uM	NULL
in	NULL
200	NULL
mM	NULL
Tris	NULL
acetate	NULL
,	NULL
pH	NULL
7.4	NULL
.	NULL

Following	NULL
different	NULL
incubation	NULL
periods	NULL
,	NULL
a	NULL
1-ul	NULL
aliquot	NULL
was	NULL
withdrawn	NULL
from	NULL
the	NULL
reaction	NULL
medium	NULL
and	NULL
diluted	NULL
in	NULL
0.1	NULL
%	NULL
aqueous	NULL
trifluoroacetic	NULL
acid	NULL
,	NULL
a	NULL
solution	NULL
that	NULL
quenches	NULL
the	NULL
enzyme	NULL
reaction	NULL
by	NULL
lowering	NULL
the	NULL
pH	NULL
to	NULL
~8	NULL
.	NULL

The	NULL
stability	NULL
of	NULL
the	NULL
substrate	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
NE	NULL
was	NULL
assessed	NULL
under	NULL
the	NULL
same	NULL
conditions	NULL
.	NULL

The	NULL
diluted	NULL
medium	NULL
was	NULL
then	NULL
submitted	NULL
to	NULL
MALDI-TOF	NULL
measurement	NULL
.	NULL

Samples	NULL
were	NULL
prepared	NULL
as	NULL
follows	NULL
:	NULL
1	NULL
pl	NULL
of	NULL
a	NULL
4-a-cyano-4-hydroxy-frans-cinnamic	NULL
acid	NULL
was	NULL
deposited	NULL
on	NULL
a	NULL
stainless	NULL
steel	NULL
probe	NULL
and	NULL
allowed	NULL
to	NULL
evaporate	NULL
quickly	NULL
.	NULL

About	NULL
0.5	NULL
ul	NULL
of	NULL
the	NULL
dilute	NULL
digest	NULL
solution	NULL
was	NULL
then	NULL
deposited	NULL
on	NULL
the	NULL
matrix	NULL
surface	NULL
and	NULL
allowed	NULL
to	NULL
air	NULL
dry	NULL
.	NULL

At	NULL
last	NULL
,	NULL
the	NULL
sample	NULL
was	NULL
washed	NULL
according	NULL
to	NULL
Vorm	NULL
et	NULL
al	NULL
.	NULL

(	NULL
42	NULL
)	NULL
with	NULL
0.5	NULL
%	NULL
aqueous	NULL
trifluoroacetic	NULL
acid	NULL
.	NULL

Mass	NULL
spectra	NULL
were	NULL
obtained	NULL
using	NULL
a	NULL
Bruker	NULL
Biflex	NULL
MALDI-TOF	NULL
mass	NULL
spectrometer	NULL
(	NULL
Bremen	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

The	NULL
average	NULL
error	NULL
on	NULL
the	NULL
MALDI-TOF	NULL
derived	NULL
mass	NULL
is	NULL
theoretically	NULL
0.1	NULL
%	NULL
,	NULL
i.e	NULL
.	NULL

1.7	NULL
Da	NULL
in	NULL
our	NULL
mass	NULL
range	NULL
.	NULL

However	NULL
,	NULL
the	NULL
difference	NULL
between	NULL
the	NULL
experimental	NULL
mass	NULL
and	NULL
the	NULL
calculated	NULL
average	NULL
isotopic	NULL
mass	NULL
of	NULL
our	NULL
peptide	NULL
was	NULL
usually	NULL
less	NULL
than	NULL
0.5	NULL
Da	NULL
.	NULL

Hence	NULL
,	NULL
the	NULL
sequence	NULL
of	NULL
the	NULL
peptide	NULL
(	NULL
s	NULL
)	NULL
resulting	NULL
from	NULL
cleavage	NULL
by	NULL
NE	NULL
could	NULL
be	NULL
unambiguously	NULL
derived	NULL
from	NULL
their	NULL
masses	NULL
.	NULL

The	NULL
instrument	NULL
was	NULL
calibrated	NULL
prior	NULL
to	NULL
each	NULL
measurement	NULL
with	NULL
the	NULL
monoprotonated	NULL
molecular	NULL
ions	NULL
from	NULL
a	NULL
standard	NULL
mixture	NULL
of	NULL
angiotensin	NULL
II	NULL
,	NULL
ACTH	NULL
18-89	NULL
,	NULL
and	NULL
bovine	NULL
insulin	NULL
.	NULL

The	NULL
sequences	NULL
of	NULL
the	NULL
proteolytic	NULL
fragments	NULL
were	NULL
predicted	NULL
using	NULL
the	NULL
MacProMass	NULL
1.2	NULL
software	NULL
(	NULL
Beckman	NULL
Research	NULL
In-stitute	NULL
,	NULL
Duarte	NULL
,	NULL
CA	NULL
)	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
the	NULL
known	NULL
sequence	NULL
of	NULL
the	NULL
initial	NULL
peptide	NULL
and	NULL
the	NULL
determined	NULL
molecular	NULL
masses	NULL
of	NULL
the	NULL
fragment	NULL
(	NULL
s	NULL
)	NULL
.	NULL

Statistics	NULL
Results	NULL
are	NULL
expressed	NULL
as	NULL
mean	NULL
+	NULL
S.E	NULL
.	NULL

for	NULL
the	NULL
indicated	NULL
number	NULL
of	NULL
independently	NULL
performed	NULL
experiments	NULL
.	NULL

Statistical	NULL
significance	NULL
between	NULL
the	NULL
different	NULL
values	NULL
was	NULL
analyzed	NULL
by	NULL
Student	NULL
's	NULL
f-test	NULL
for	NULL
unpaired	NULL
data	NULL
with	NULL
a	NULL
threshold	NULL
of	NULL
p	NULL
=	NULL
0.05	NULL
.	NULL

The	NULL
standard	NULL
linear	NULL
regression	NULL
analysis	NULL
was	NULL
applied	NULL
to	NULL
correlate	NULL
the	NULL
different	NULL
parameters	NULL
using	NULL
the	NULL
Statview	NULL
512	NULL
``	NULL
software	NULL
(	NULL
BrainPower	NULL
Inc.	NULL
,	NULL
Calabasas	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

11639	NULL
RESULTS	NULL
Characteristics	NULL
of	NULL
the	NULL
Potentiation	NULL
by	NULL
NE	NULL
of	NULL
Cathepsin	NULL
G-induced	NULL
Platelet	NULL
Activation-As	NULL
previously	NULL
established	NULL
(	NULL
11	NULL
,	NULL
16	NULL
)	NULL
,	NULL
cathepsin	NULL
G	NULL
alone	NULL
added	NULL
to	NULL
platelet	NULL
suspensions	NULL
at	NULL
the	NULL
optimal	NULL
concentration	NULL
of	NULL
550	NULL
nw	NULL
acts	NULL
as	NULL
a	NULL
strong	NULL
platelet	NULL
agonist	NULL
inducing	NULL
extensive	NULL
platelet	NULL
aggregation	NULL
(	NULL
83.5	NULL
+	NULL
5.6	NULL
%	NULL
,	NULL
n	NULL
=	NULL
5	NULL
)	NULL
,	NULL
accompanied	NULL
by	NULL
a	NULL
marked	NULL
exocytosis	NULL
of	NULL
intracellular	NULL
granules	NULL
as	NULL
judged	NULL
by	NULL
the	NULL
release	NULL
of	NULL
5-	NULL
[	NULL
'*C	NULL
]	NULL
HT	NULL
from	NULL
dense	NULL
granules	NULL
(	NULL
76.2	NULL
+	NULL
1.6	NULL
%	NULL
,	NULL
n	NULL
=	NULL
5	NULL
;	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
panels	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

For	NULL
each	NULL
tested	NULL
platelet	NULL
suspension	NULL
,	NULL
we	NULL
determined	NULL
the	NULL
threshold	NULL
of	NULL
cathepsin	NULL
G	NULL
as	NULL
that	NULL
resulted	NULL
in	NULL
platelet	NULL
shape	NULL
change	NULL
followed	NULL
by	NULL
5-10	NULL
%	NULL
of	NULL
increase	NULL
in	NULL
light	NULL
transmission	NULL
within	NULL
3	NULL
min	NULL
of	NULL
stirring	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
panels	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

This	NULL
concentration	NULL
was	NULL
always	NULL
within	NULL
the	NULL
range	NULL
150	NULL
to	NULL
180	NULL
nm	NULL
.	NULL

Under	NULL
these	NULL
conditions	NULL
,	NULL
exocytosis	NULL
remained	NULL
minimal	NULL
at	NULL
3	NULL
min	NULL
,	NULL
with	NULL
3.1	NULL
+	NULL
0.8	NULL
%	NULL
of	NULL
5-	NULL
[	NULL
'*C	NULL
]	NULL
HT	NULL
release	NULL
(	NULL
n	NULL
=	NULL
5	NULL
;	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
panel	NULL
B	NULL
)	NULL
.	NULL

Platelet	NULL
suspensions	NULL
stirred	NULL
for	NULL
3	NULL
min	NULL
with	NULL
400	NULL
nM	NULL
NE	NULL
(	NULL
and	NULL
up	NULL
to	NULL
800	NULL
nM	NULL
)	NULL
showed	NULL
no	NULL
evidence	NULL
for	NULL
aggregate	NULL
formation	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
panel	NULL
A	NULL
)	NULL
and	NULL
exocytosis	NULL
of	NULL
internal	NULL
granules	NULL
was	NULL
barely	NULL
detectable	NULL
(	NULL
0.8	NULL
+	NULL
0.3	NULL
%	NULL
release	NULL
of	NULL
5-	NULL
[	NULL
'*CJHT	NULL
,	NULL
n	NULL
=	NULL
5	NULL
)	NULL
,	NULL
in	NULL
agreement	NULL
with	NULL
previous	NULL
reports	NULL
(	NULL
17-19	NULL
)	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
addition	NULL
of	NULL
400	NULL
nm	NULL
.	NULL

NE	NULL
10	NULL
s	NULL
before	NULL
stimulation	NULL
of	NULL
platelets	NULL
with	NULL
threshold	NULL
of	NULL
cathepsin	NULL
G	NULL
resulted	NULL
in	NULL
an	NULL
extensive	NULL
aggregation	NULL
,	NULL
similar	NULL
to	NULL
that	NULL
induced	NULL
by	NULL
the	NULL
optimal	NULL
concentration	NULL
of	NULL
cathepsin	NULL
G	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
panels	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

The	NULL
potentiation	NULL
exerted	NULL
by	NULL
NE	NULL
on	NULL
threshold	NULL
of	NULL
cathepsin	NULL
G-induced	NULL
platelet	NULL
aggregation	NULL
was	NULL
already	NULL
detectable	NULL
with	NULL
100	NULL
nm	NULL
NE	NULL
,	NULL
and	NULL
was	NULL
maximal	NULL
in	NULL
the	NULL
range	NULL
200-800	NULL
nm	NULL
NE	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
panel	NULL
B	NULL
)	NULL
.	NULL

Increasing	NULL
the	NULL
period	NULL
of	NULL
exposure	NULL
of	NULL
platelets	NULL
to	NULL
NE	NULL
to	NULL
180	NULL
s	NULL
before	NULL
threshold	NULL
of	NULL
cathepsin	NULL
G	NULL
had	NULL
no	NULL
further	NULL
effect	NULL
on	NULL
the	NULL
extent	NULL
of	NULL
potentiation	NULL
(	NULL
not	NULL
shown	NULL
and	NULL
Ref	NULL
.	NULL

18	NULL
)	NULL
.	NULL

Major	NULL
observations	NULL
in	NULL
these	NULL
experiments	NULL
were	NULL
that	NULL
(	NULL
i	NULL
)	NULL
whereas	NULL
aggregation	NULL
induced	NULL
by	NULL
550	NULL
nm	NULL
cathepsin	NULL
G	NULL
was	NULL
associated	NULL
with	NULL
an	NULL
extensive	NULL
granule	NULL
exocytosis	NULL
,	NULL
the	NULL
aggregation	NULL
induced	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
100-800	NULL
nm	NULL
NE	NULL
with	NULL
threshold	NULL
of	NULL
cathepsin	NULL
G	NULL
was	NULL
accompanied	NULL
by	NULL
a	NULL
limited	NULL
release	NULL
of	NULL
granule	NULL
contents	NULL
,	NULL
varying	NULL
from	NULL
4.7	NULL
+	NULL
1.4	NULL
%	NULL
to	NULL
a	NULL
maximum	NULL
of	NULL
25.9	NULL
+	NULL
0.9	NULL
%	NULL
secretion	NULL
of	NULL
5-	NULL
[	NULL
'*CJHT	NULL
(	NULL
n	NULL
=	NULL
5	NULL
;	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
panel	NULL
B	NULL
)	NULL
;	NULL
and	NULL
(	NULL
ii	NULL
)	NULL
the	NULL
potentiating	NULL
activity	NULL
of	NULL
NE	NULL
on	NULL
threshold	NULL
of	NULL
cathepsin	NULL
G-induced	NULL
platelet	NULL
aggregation	NULL
was	NULL
strictly	NULL
dependent	NULL
on	NULL
the	NULL
presence	NULL
of	NULL
exogenous	NULL
fibrinogen	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
panels	NULL
A	NULL
and	NULL
C	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
Platelet	NULL
Fibrinogen	NULL
Receptor	NULL
by	NULL
NE	NULL
and	NULL
Cathepsin	NULL
G-Previous	NULL
reports	NULL
have	NULL
shown	NULL
that	NULL
platelet	NULL
exposure	NULL
to	NULL
various	NULL
serine	NULL
proteinases	NULL
,	NULL
including	NULL
elastases	NULL
,	NULL
induces	NULL
expression	NULL
of	NULL
fibrinogen	NULL
binding	NULL
sites	NULL
(	NULL
26	NULL
,	NULL
27	NULL
)	NULL
.	NULL

This	NULL
,	NULL
together	NULL
with	NULL
the	NULL
requirement	NULL
for	NULL
exogenous	NULL
fibrinogen	NULL
for	NULL
the	NULL
potentiation	NULL
of	NULL
platelet	NULL
aggregation	NULL
(	NULL
the	NULL
present	NULL
work	NULL
)	NULL
led	NULL
us	NULL
to	NULL
consider	NULL
that	NULL
the	NULL
synergism	NULL
resulting	NULL
from	NULL
the	NULL
combination	NULL
of	NULL
NE	NULL
and	NULL
threshold	NULL
of	NULL
cathepsin	NULL
G	NULL
could	NULL
be	NULL
exerted	NULL
at	NULL
the	NULL
level	NULL
of	NULL
the	NULL
,	NULL
B	NULL
;	NULL
integrin	NULL
,	NULL
the	NULL
platelet	NULL
fibrinogen	NULL
receptor	NULL
.	NULL

We	NULL
first	NULL
evaluated	NULL
whether	NULL
NE	NULL
could	NULL
modify	NULL
by	NULL
itself	NULL
the	NULL
surface	NULL
expression	NULL
and	NULL
the	NULL
biological	NULL
activity	NULL
of	NULL
off	NULL
;	NULL
on	NULL
platelets	NULL
by	NULL
using	NULL
flow	NULL
cytometry	NULL
analysis	NULL
with	NULL
a	NULL
panel	NULL
of	NULL
monoclonal	NULL
antibodies	NULL
specific	NULL
for	NULL
distinct	NULL
conformations	NULL
of	NULL
this	NULL
integrin	NULL
(	NULL
see	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

These	NULL
included	NULL
AP-2	NULL
,	NULL
an	NULL
aJ	NULL
,	NULL
B	NULL
;	NULL
complex-specific	NULL
antibody	NULL
reacting	NULL
with	NULL
both	NULL
the	NULL
resting	NULL
and	NULL
active	NULL
forms	NULL
of	NULL
the	NULL
receptor	NULL
(	NULL
82	NULL
)	NULL
,	NULL
PAC-1	NULL
,	NULL
which	NULL
binds	NULL
at	NULL
one	NULL
fibrinogen-binding	NULL
site	NULL
on	NULL
«	NULL
ip	NULL
,	NULL
;	NULL
and	NULL
only	NULL
recognizes	NULL
the	NULL
active	NULL
conformation	NULL
of	NULL
the	NULL
receptor	NULL
(	NULL
31	NULL
)	NULL
,	NULL
and	NULL
AP-5	NULL
,	NULL
an	NULL
anti-ligand-induced	NULL
binding	NULL
site	NULL
(	NULL
LIBS	NULL
)	NULL
which	NULL
specifically	NULL
reveals	NULL
the	NULL
active	NULL
and	NULL
fibrinogen-occupied	NULL
integrin	NULL
(	NULL
33	NULL
)	NULL
.	NULL

As	NULL
mentioned	NULL
under	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
,	NULL
``	NULL
when	NULL
platelets	NULL
were	NULL
to	NULL
be	NULL
tested	NULL
with	NULL
PAC-1	NULL
,	NULL
prior	NULL
incubation	NULL
with	NULL
NE	NULL
was	NULL
without	NULL
exogenous	NULL
fibrinogen	NULL
,	NULL
while	NULL
analysis	NULL
of	NULL
the	NULL
binding	NULL
of	NULL
AP-5	NULL
was	NULL
necessarily	NULL
performed	NULL
on	NULL
platelets	NULL
incubated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
fibrinogen	NULL
.	NULL

As	NULL
illustrated	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
exposure	NULL
of	NULL
platelet	NULL
suspensions	NULL
to	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
/810-0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wo	NULL
;	NULL
popeoumog	NULL
11640	NULL
amm	NULL
,	NULL
fBs	NULL
and	NULL
Platelet	NULL
Activation	NULL
by	NULL
Elastase	NULL
and	NULL
Cathepsin	NULL
G	NULL
+	NULL
exogenous	NULL
-	NULL
exogenous	NULL
Fibrinogen	NULL
1	NULL
min	NULL
A	NULL
||	NULL
C	NULL
Fibrinogen	NULL
2	NULL
o	NULL
<	NULL
«	NULL
LJ	NULL
fe	NULL
I	NULL
&	NULL
550	NULL
nM	NULL
Cat	NULL
.	NULL

G	NULL
400	NULL
nM	NULL
NE	NULL
thCat	NULL
.	NULL

G	NULL
400	NULL
nM	NULL
NE	NULL
400	NULL
nM	NULL
NE	NULL
+	NULL
thCat	NULL
.	NULL

G	NULL
+	NULL
thCat	NULL
.	NULL

G	NULL
B	NULL
100	NULL
AGGREGATION	NULL
5-	NULL
HT	NULL
RELEASE	NULL
n	NULL
Bo	NULL
pr	NULL
w	NULL
2	NULL
0	NULL
60	NULL
_	NULL
5	NULL
Luu	NULL
o	NULL
40	NULL
|i	NULL
-I	NULL
Luu	NULL
20	NULL
-	NULL
G3	NULL
a	NULL
.	NULL

0	NULL
we	NULL
0	NULL
100	NULL
200	NULL
400	NULL
800	NULL
:	NULL
NE	NULL
(	NULL
nM	NULL
)	NULL
550	NULL
nM	NULL
Cat	NULL
.	NULL

6	NULL
+	NULL
thCat	NULL
.	NULL

G	NULL
Fic	NULL
.	NULL

1	NULL
.	NULL

Characteristics	NULL
of	NULL
the	NULL
potentiation	NULL
by	NULL
NE	NULL
of	NULL
platelet	NULL
activation	NULL
induced	NULL
by	NULL
cathepsin	NULL
G.	NULL
Washed	NULL
human	NULL
5-	NULL
[	NULL
'*C	NULL
)	NULL
HT-labeled	NULL
platelets	NULL
(	NULL
0.5	NULL
ml	NULL
,	NULL
4	NULL
X	NULL
10°	NULL
cells/ml	NULL
)	NULL
stirred	NULL
at	NULL
37	NULL
°C	NULL
were	NULL
preincubated	NULL
for	NULL
2	NULL
min	NULL
with	NULL
1	NULL
uM	NULL
imipramine	NULL
.	NULL

Reaction	NULL
with	NULL
proteinases	NULL
were	NULL
then	NULL
followed	NULL
for	NULL
3	NULL
min	NULL
.	NULL

Panel	NULL
A	NULL
,	NULL
tracings	NULL
of	NULL
platelet	NULL
aggregation	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
exogenous	NULL
fibrinogen	NULL
(	NULL
0.7	NULL
mg/m	NULL
!	NULL
)	NULL

after	NULL
challenge	NULL
with	NULL
550	NULL
nM	NULL
cathepsin	NULL
G	NULL
,	NULL
an	NULL
optimal	NULL
concentration	NULL
of	NULL
NE	NULL
(	NULL
400	NULL
nM	NULL
)	NULL
,	NULL
a	NULL
threshold	NULL
concentration	NULL
of	NULL
cathepsin	NULL
G	NULL
(	NULL
thCat	NULL
G	NULL
,	NULL
150-180	NULL
nM	NULL
)	NULL
,	NULL
or	NULL
threshold	NULL
of	NULL
cathepsin	NULL
G	NULL
preceded	NULL
by	NULL
400	NULL
nM	NULL
NE	NULL
for	NULL
10	NULL
s.	NULL
Panel	NULL
B	NULL
,	NULL
platelet	NULL
aggregation	NULL
and	NULL
5-	NULL
[	NULL
'	NULL
``	NULL
*CJHT	NULL
secretion	NULL
performed	NULL
under	NULL
identical	NULL
conditions	NULL
,	NULL
except	NULL
that	NULL
the	NULL
potentiation	NULL
was	NULL
evaluated	NULL
with	NULL
increasing	NULL
concentrations	NULL
of	NULL
NE	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
percentage	NULL
of	NULL
maximal	NULL
light	NULL
transmission	NULL
and	NULL
as	NULL
the	NULL
percentage	NULL
of	NULL
the	NULL
total	NULL
5-	NULL
[	NULL
'*CJHT	NULL
granule	NULL
content	NULL
,	NULL
respectively	NULL
,	NULL
and	NULL
are	NULL
means	NULL
+	NULL
S.E	NULL
.	NULL

of	NULL
five	NULL
experiments	NULL
conducted	NULL
with	NULL
cells	NULL
from	NULL
different	NULL
donors	NULL
.	NULL

Panel	NULL
C	NULL
,	NULL
a	NULL
representative	NULL
tracing	NULL
of	NULL
three	NULL
distinct	NULL
experiments	NULL
of	NULL
aggregation	NULL
initiated	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
NE	NULL
and	NULL
threshold	NULL
of	NULL
cathepsin	NULL
G	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
exogenous	NULL
fibrinogen	NULL
.	NULL

TaBLE	NULL
I	NULL
Domain-specific	NULL
ayy	NULL
B	NULL
,	NULL
antibodies	NULL
used	NULL
in	NULL
this	NULL
study	NULL
Name	NULL
Mone/polyclonal	NULL
Isotype	NULL
Specificity	NULL
on	NULL
om	NULL
,	NULL
$	NULL
B3	NULL
Refs	NULL
.	NULL

PAC-1	NULL
Monoclonal	NULL
IgM	NULL
RGD*-binding	NULL
site	NULL
81	NULL
AP-2	NULL
Monoclonal	NULL
IgG1	NULL
Complexed	NULL
form	NULL
of	NULL
ap	NULL
,	NULL
and	NULL
B	NULL
;	NULL
82	NULL
AP-5	NULL
Monoclonal	NULL
IgG1	NULL
LIBS®	NULL
on	NULL
the	NULL
amino	NULL
terminus	NULL
of	NULL
B	NULL
;	NULL
33	NULL
PMI-1	NULL
Monoclonal	NULL
IgG1	NULL
LIBS	NULL
on	NULL
the	NULL
carboxyl	NULL
terminus	NULL
of	NULL
34	NULL
IIb-10	NULL
Polyclonal	NULL
Amino	NULL
terminus	NULL
of	NULL
Gmy	NULL
80	NULL
Anti-V41	NULL
Polyclonal	NULL
Amino	NULL
terminus	NULL
of	NULL
Gn	NULL
,	NULL
``	NULL
34	NULL
*	NULL
RGD	NULL
,	NULL
Arg-Gly-Asp	NULL
adhesion	NULL
motif	NULL
present	NULL
in	NULL
fibrinogen	NULL
(	NULL
20	NULL
)	NULL
.	NULL

®	NULL
LIBS	NULL
,	NULL
ligand-induced	NULL
binding	NULL
site	NULL
.	NULL

°	NULL
Cmp	NULL
Cpr	NULL
,	NULL
extracellular	NULL
heavy	NULL
chain	NULL
and	NULL
transmembrane	NULL
light	NULL
chain	NULL
,	NULL
respectively	NULL
,	NULL
of	NULL
the	NULL
apy	NULL
,	NULL
subunit	NULL
.	NULL

400	NULL
nm	NULL
NE	NULL
at	NULL
37	NULL
°C	NULL
,	NULL
a	NULL
concentration	NULL
which	NULL
triggers	NULL
a	NULL
maximal	NULL
potentiation	NULL
of	NULL
threshold	NULL
of	NULL
cathepsin	NULL
G-induced	NULL
platelet	NULL
aggregation	NULL
,	NULL
resulted	NULL
in	NULL
a	NULL
rapid	NULL
transition	NULL
of	NULL
the	NULL
a	NULL
,	NULL
,	NULL
B	NULL
,	NULL
conformation	NULL
reflecting	NULL
activation	NULL
of	NULL
the	NULL
receptor	NULL
and	NULL
binding	NULL
of	NULL
its	NULL
ligand	NULL
.	NULL

Indeed	NULL
,	NULL
a	NULL
time-dependent	NULL
increase	NULL
in	NULL
binding	NULL
of	NULL
PAC-1	NULL
occurred	NULL
within	NULL
10	NULL
s	NULL
of	NULL
exposure	NULL
to	NULL
NE	NULL
,	NULL
and	NULL
reached	NULL
a	NULL
plateau	NULL
after	NULL
1	NULL
min	NULL
(	NULL
panel	NULL
A	NULL
)	NULL
.	NULL

A	NULL
similar	NULL
increase	NULL
in	NULL
the	NULL
binding	NULL
of	NULL
AP-5	NULL
was	NULL
observed	NULL
,	NULL
with	NULL
a	NULL
plateau	NULL
after	NULL
2	NULL
min	NULL
of	NULL
exposure	NULL
to	NULL
NE	NULL
(	NULL
panel	NULL
B	NULL
)	NULL
.	NULL

At	NULL
3	NULL
min	NULL
,	NULL
binding	NULL
of	NULL
PAC-1	NULL
and	NULL
AP-5	NULL
on	NULL
NE-treated	NULL
platelets	NULL
was	NULL
increased	NULL
about	NULL
2.3-fold	NULL
(	NULL
n	NULL
=	NULL
8	NULL
,	NULL
p	NULL
<	NULL
0.001	NULL
)	NULL
and	NULL
3	NULL
.	NULL

4-fold	NULL
(	NULL
n	NULL
=	NULL
4	NULL
,	NULL
p	NULL
<	NULL
0.05	NULL
)	NULL
,	NULL
respectively	NULL
,	NULL
compared	NULL
with	NULL
nontreated	NULL
platelets	NULL
.	NULL

However	NULL
,	NULL
binding	NULL
of	NULL
these	NULL
antibodies	NULL
on	NULL
NE	NULL
treated	NULL
platelets	NULL
was	NULL
approximately	NULL
3.5-fold	NULL
lower	NULL
than	NULL
that	NULL
measured	NULL
on	NULL
platelets	NULL
optimally	NULL
stimulated	NULL
with	NULL
550	NULL
nm	NULL
cathepsin	NULL
G	NULL
(	NULL
compare	NULL
panels	NULL
A	NULL
and	NULL
C	NULL
,	NULL
and	NULL
B	NULL
and	NULL
D	NULL
)	NULL
.	NULL

Such	NULL
a	NULL
difference	NULL
can	NULL
be	NULL
largely	NULL
explained	NULL
by	NULL
the	NULL
ability	NULL
of	NULL
a	NULL
high	NULL
concentration	NULL
of	NULL
cathepsin	NULL
G	NULL
to	NULL
induce	NULL
platelet	NULL
shape	NULL
change	NULL
and	NULL
extensive	NULL
exocytosis	NULL
of	NULL
a-granules	NULL
(	NULL
43	NULL
)	NULL
,	NULL
thus	NULL
allowing	NULL
the	NULL
translocation	NULL
of	NULL
the	NULL
internal	NULL
fraction	NULL
of	NULL
ay	NULL
,	NULL
,	NULL
B	NULL
;	NULL
,	NULL
complexes	NULL
to	NULL
the	NULL
plasma	NULL
membrane	NULL
(	NULL
25	NULL
)	NULL
.	NULL

Indeed	NULL
,	NULL
binding	NULL
of	NULL
AP-2	NULL
to	NULL
platelets	NULL
activated	NULL
with	NULL
550	NULL
nw	NULL
cathepsin	NULL
G	NULL
for	NULL
3	NULL
min	NULL
was	NULL
increased	NULL
by	NULL
92.7	NULL
+	NULL
16.8	NULL
%	NULL
when	NULL
compared	NULL
with	NULL
nontreated	NULL
platelets	NULL
(	NULL
n	NULL
=	NULL
7	NULL
,	NULL
p	NULL
<	NULL
0.001	NULL
;	NULL
see	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
panel	NULL
B	NULL
)	NULL
,	NULL
an	NULL
increase	NULL
similar	NULL
to	NULL
that	NULL
measured	NULL
on	NULL
platelets	NULL
activated	NULL
with	NULL
0.5	NULL
IU/ml	NULL
thrombin	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
/810-0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wo	NULL
;	NULL
popeoumog	NULL
am	NULL
,	NULL
pBs	NULL
and	NULL
Platelet	NULL
Activation	NULL
by	NULL
Elastase	NULL
and	NULL
Cathepsin	NULL
G	NULL
ELASTASE	NULL
CATHEPSIN	NULL
G	NULL
€	NULL
S	NULL
C	NULL
1s	NULL
Ga	NULL
2.5	NULL
t	NULL
C	NULL
H	NULL
“	NULL
3	NULL
o	NULL
0	NULL
T	NULL
47	NULL
2	NULL
5	NULL
a	NULL
8	NULL
2.0	NULL
-o	NULL
5	NULL
3	NULL
}	NULL
CG	NULL
1.	NULL
oa	NULL
.	NULL

c	NULL
3	NULL
$	NULL
2	NULL
L	NULL
L	NULL
1	NULL
L	NULL
~	NULL
1.90	NULL
1	NULL
8	NULL
B	NULL
(	NULL
g	NULL
4.0	NULL
F	NULL
(	NULL
5	NULL
3	NULL
4	NULL
o	NULL
3	NULL
3.0	NULL
F	NULL
5	NULL
8	NULL
9	NULL
{	NULL
Dl	NULL
.	NULL

$	NULL
2.0	NULL
F	NULL
<	NULL
$	NULL
g	NULL
1.0	NULL
L	NULL
L	NULL
L	NULL
T	NULL
L	NULL
L	NULL
e	NULL
0	NULL
30	NULL
60	NULL
90	NULL
120	NULL
150	NULL
180	NULL
180	NULL
TIME	NULL
(	NULL
sec	NULL
)	NULL
Fic	NULL
.	NULL

2	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
platelet	NULL
fibrinogen	NULL
receptor	NULL
by	NULL
NE	NULL
and	NULL
cathepsin	NULL
G.	NULL
Unstirred	NULL
platelets	NULL
were	NULL
preincubated	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
panels	NULL
A	NULL
and	NULL
C	NULL
)	NULL
or	NULL
presence	NULL
(	NULL
panels	NULL
B	NULL
and	NULL
D	NULL
)	NULL
of	NULL
exogenous	NULL
fibrinogen	NULL
(	NULL
0.7	NULL
mg/m	NULL
!	NULL
)	NULL

to	NULL
analyze	NULL
PAC-1	NULL
or	NULL
AP-5	NULL
antibodies	NULL
binding	NULL
,	NULL
respectively	NULL
.	NULL

Reactions	NULL
were	NULL
initiated	NULL
by	NULL
adding	NULL
400	NULL
nM	NULL
NE	NULL
(	NULL
panels	NULL
A	NULL
and	NULL
B	NULL
)	NULL
or	NULL
550	NULL
nM	NULL
cathepsin	NULL
G	NULL
(	NULL
panels	NULL
C	NULL
and	NULL
D	NULL
)	NULL
and	NULL
stopped	NULL
at	NULL
different	NULL
times	NULL
with	NULL
5	NULL
uM	NULL
eglin	NULL
C	NULL
and	NULL
2	NULL
mM	NULL
PMSF	NULL
.	NULL

Binding	NULL
of	NULL
PAC-1	NULL
and	NULL
AP-5	NULL
to	NULL
platelets	NULL
were	NULL
then	NULL
measured	NULL
by	NULL
flow	NULL
cytometry	NULL
and	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
fold-increase	NULL
in	NULL
median	NULL
fluorescence	NULL
intensity	NULL
over	NULL
basal	NULL
values	NULL
measured	NULL
on	NULL
nontreated	NULL
platelets	NULL
.	NULL

Results	NULL
are	NULL
means	NULL
+	NULL
S.E	NULL
.	NULL

of	NULL
four	NULL
to	NULL
eight	NULL
experiments	NULL
conducted	NULL
with	NULL
cells	NULL
from	NULL
different	NULL
donors	NULL
.	NULL

(	NULL
98.9	NULL
+	NULL
9.2	NULL
%	NULL
,	NULL
n	NULL
=	NULL
8	NULL
,	NULL
p	NULL
<	NULL
0.001	NULL
)	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
the	NULL
increase	NULL
in	NULL
AP-2	NULL
binding	NULL
to	NULL
platelets	NULL
exposed	NULL
to	NULL
400	NULL
nM	NULL
NE	NULL
was	NULL
only	NULL
9.6	NULL
+	NULL
5.0	NULL
%	NULL
and	NULL
remained	NULL
nonsignificant	NULL
(	NULL
n	NULL
=	NULL
8	NULL
,	NULL
p	NULL
>	NULL
0.05	NULL
;	NULL
see	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
panel	NULL
B	NULL
)	NULL
.	NULL

Involvement	NULL
of	NULL
the	NULL
Activation	NULL
of	NULL
a	NULL
;	NULL
,	NULL
B3	NULL
by	NULL
NE	NULL
in	NULL
the	NULL
Potentiation	NULL
of	NULL
Threshold	NULL
of	NULL
Cathepsin	NULL
G-induced	NULL
Platelet	NULL
Aggrega-tion-Considering	NULL
that	NULL
NE	NULL
is	NULL
able	NULL
to	NULL
up-regulate	NULL
the	NULL
biological	NULL
activity	NULL
of	NULL
the	NULL
plasma	NULL
membrane	NULL
ap	NULL
,	NULL
;	NULL
integrin	NULL
,	NULL
we	NULL
assumed	NULL
that	NULL
the	NULL
potentiation	NULL
by	NULL
NE	NULL
of	NULL
platelet	NULL
aggregation	NULL
induced	NULL
by	NULL
threshold	NULL
of	NULL
cathepsin	NULL
G	NULL
resulted	NULL
from	NULL
an	NULL
increased	NULL
capacity	NULL
of	NULL
the	NULL
platelet	NULL
surface	NULL
to	NULL
bind	NULL
fibrinogen	NULL
.	NULL

To	NULL
examine	NULL
this	NULL
hypoth-esis	NULL
,	NULL
platelet	NULL
suspensions	NULL
were	NULL
challenged	NULL
for	NULL
3	NULL
min	NULL
with	NULL
400	NULL
nM	NULL
NE	NULL
,	NULL
threshold	NULL
of	NULL
cathepsin	NULL
G	NULL
,	NULL
or	NULL
a	NULL
combination	NULL
of	NULL
both	NULL
proteinases	NULL
,	NULL
before	NULL
being	NULL
processed	NULL
for	NULL
analysis	NULL
of	NULL
AP-2	NULL
and	NULL
PAC-1	NULL
binding	NULL
by	NULL
flow	NULL
cytometry	NULL
,	NULL
the	NULL
latter	NULL
antibody	NULL
being	NULL
taken	NULL
as	NULL
a	NULL
fibrinogen-like	NULL
probe	NULL
.	NULL

Thus	NULL
,	NULL
combination	NULL
of	NULL
the	NULL
two	NULL
proteinases	NULL
increased	NULL
the	NULL
binding	NULL
of	NULL
PAC-1	NULL
~5.5-fold	NULL
,	NULL
while	NULL
activation	NULL
of	NULL
platelets	NULL
with	NULL
550	NULL
nM	NULL
cathepsin	NULL
G	NULL
increased	NULL
PAC-1	NULL
binding	NULL
~7.5-fold	NULL
,	NULL
these	NULL
values	NULL
being	NULL
not	NULL
statistically	NULL
different	NULL
(	NULL
p	NULL
>	NULL
0.05	NULL
,	NULL
n	NULL
=	NULL
3	NULL
)	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
the	NULL
increase	NULL
in	NULL
PAC-1	NULL
binding	NULL
induced	NULL
at	NULL
3	NULL
min	NULL
by	NULL
threshold	NULL
of	NULL
cathepsin	NULL
G	NULL
alone	NULL
was	NULL
~3-fold	NULL
above	NULL
the	NULL
background	NULL
binding	NULL
measured	NULL
for	NULL
nontreated	NULL
platelets	NULL
,	NULL
a	NULL
value	NULL
similar	NULL
to	NULL
that	NULL
measured	NULL
for	NULL
NE-treated	NULL
platelets	NULL
in	NULL
this	NULL
series	NULL
of	NULL
experiments	NULL
(	NULL
p	NULL
>	NULL
0.05	NULL
;	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
panel	NULL
A	NULL
)	NULL
.	NULL

Of	NULL
note	NULL
is	NULL
that	NULL
PAC-1	NULL
binding	NULL
to	NULL
platelets	NULL
activated	NULL
with	NULL
either	NULL
threshold	NULL
of	NULL
cathepsin	NULL
G	NULL
alone	NULL
or	NULL
with	NULL
the	NULL
combination	NULL
of	NULL
NE	NULL
and	NULL
threshold	NULL
of	NULL
cathepsin	NULL
G	NULL
was	NULL
significantly	NULL
different	NULL
(	NULL
p	NULL
<	NULL
0.05	NULL
,	NULL
n	NULL
=	NULL
3	NULL
)	NULL
.	NULL

When	NULL
platelet	NULL
suspensions	NULL
were	NULL
similarly	NULL
treated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
exogenous	NULL
fibrinogen	NULL
,	NULL
then	NULL
evaluated	NULL
for	NULL
the	NULL
binding	NULL
of	NULL
AP-5	NULL
as	NULL
a	NULL
marker	NULL
of	NULL
ligand-occupied	NULL
am	NULL
,	NULL
{	NULL
Bs	NULL
,	NULL
similar	NULL
profiles	NULL
were	NULL
obtained	NULL
(	NULL
not	NULL
illustrated	NULL
)	NULL
.	NULL

Strikingly	NULL
,	NULL
the	NULL
strong	NULL
potentiating	NULL
effect	NULL
of	NULL
NE	NULL
on	NULL
threshold	NULL
of	NULL
cathepsin	NULL
G-induced	NULL
platelet	NULL
aggregation	NULL
occurred	NULL
despite	NULL
a	NULL
11641	NULL
PAC-1	NULL
BINDING	NULL
(	NULL
enjea	NULL
feseq	NULL
1eao	NULL
eseaout-pj0	NULL
}	NULL
)	NULL
ONIQNIA	NULL
2-dY	NULL
Fic	NULL
.	NULL

3	NULL
.	NULL

Involvement	NULL
of	NULL
the	NULL
activation	NULL
of	NULL
a	NULL
,	NULL
,	NULL
,	NULL
by	NULL
NE	NULL
in	NULL
the	NULL
potentiation	NULL
of	NULL
threshold	NULL
of	NULL
cathepsin	NULL
G-induced	NULL
platelet	NULL
activation	NULL
.	NULL

Unstirred	NULL
platelets	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
exogenous	NULL
fibrinogen	NULL
.	NULL

Reactions	NULL
were	NULL
initiated	NULL
by	NULL
adding	NULL
400	NULL
nM	NULL
NE	NULL
,	NULL
threshold	NULL
of	NULL
cathepsin	NULL
G	NULL
(	NULL
150-180	NULL
nM	NULL
)	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
NE	NULL
,	NULL
or	NULL
550	NULL
nM	NULL
cathepsin	NULL
G.	NULL
Reactions	NULL
were	NULL
followed	NULL
for	NULL
3	NULL
min	NULL
and	NULL
stopped	NULL
with	NULL
eglin	NULL
C	NULL
and	NULL
PMSF	NULL
.	NULL

Bindings	NULL
of	NULL
PAC-1	NULL
(	NULL
panel	NULL
A	NULL
)	NULL
and	NULL
AP-2	NULL
(	NULL
panel	NULL
B	NULL
)	NULL
measured	NULL
by	NULL
flow	NULL
cytometry	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
fold	NULL
increase	NULL
in	NULL
median	NULL
fluorescence	NULL
intensity	NULL
over	NULL
basal	NULL
values	NULL
measured	NULL
on	NULL
nontreated	NULL
platelets	NULL
.	NULL

Results	NULL
are	NULL
means	NULL
+	NULL
S.E	NULL
.	NULL

of	NULL
three	NULL
experiments	NULL
conducted	NULL
with	NULL
cells	NULL
from	NULL
different	NULL
donors	NULL
.	NULL

thCat.G	NULL
,	NULL
threshold	NULL
of	NULL
concentration	NULL
of	NULL
cathepsin	NULL
G.	NULL
limited	NULL
expression	NULL
of	NULL
the	NULL
internal	NULL
«	NULL
,	NULL
f	NULL
;	NULL
fraction	NULL
at	NULL
the	NULL
plasma	NULL
membrane	NULL
,	NULL
as	NULL
measured	NULL
by	NULL
the	NULL
binding	NULL
of	NULL
AP-2	NULL
which	NULL
was	NULL
identical	NULL
to	NULL
that	NULL
initiated	NULL
by	NULL
threshold	NULL
of	NULL
cathepsin	NULL
G	NULL
alone	NULL
(	NULL
~1.3-fold	NULL
increase	NULL
over	NULL
basal	NULL
value	NULL
under	NULL
both	NULL
conditions	NULL
,	NULL
p	NULL
>	NULL
0.05	NULL
;	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
panel	NULL
B	NULL
)	NULL
.	NULL

Role	NULL
of	NULL
the	NULL
Platelet	NULL
Intracellular	NULL
Signaling	NULL
in	NULL
the	NULL
Potentiation	NULL
Induced	NULL
by	NULL
the	NULL
Combination	NULL
of	NULL
NE	NULL
and	NULL
Cathepsin	NULL
G-The	NULL
enhanced	NULL
exposure	NULL
of	NULL
fibrinogen-binding	NULL
sites	NULL
induced	NULL
by	NULL
NE	NULL
could	NULL
be	NULL
potentially	NULL
explained	NULL
by	NULL
the	NULL
ability	NULL
of	NULL
this	NULL
proteinase	NULL
to	NULL
enhance	NULL
intracellular	NULL
signals	NULL
by	NULL
which	NULL
cathepsin	NULL
G	NULL
normally	NULL
initiates	NULL
platelet	NULL
activation	NULL
and	NULL
thus	NULL
up-regulates	NULL
the	NULL
activity	NULL
of	NULL
aip,3	NULL
.	NULL

It	NULL
has	NULL
been	NULL
demonstrated	NULL
(	NULL
14-16	NULL
)	NULL
that	NULL
the	NULL
interrelated	NULL
elements	NULL
of	NULL
the	NULL
PLC-Ca**-PKC	NULL
pathway	NULL
act	NULL
in	NULL
concert	NULL
to	NULL
mediate	NULL
such	NULL
a	NULL
cell	NULL
response	NULL
.	NULL

Thus	NULL
,	NULL
as	NULL
indicated	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
an	NULL
optimal	NULL
concentration	NULL
of	NULL
cathepsin	NULL
G	NULL
(	NULL
550	NULL
nM	NULL
)	NULL
triggered	NULL
extensive	NULL
activation	NULL
of	NULL
the	NULL
PLC	NULL
and	NULL
PKC	NULL
pathways	NULL
,	NULL
as	NULL
measured	NULL
through	NULL
PtdOH	NULL
accumulation	NULL
(	NULL
panel	NULL
A	NULL
)	NULL
and	NULL
phosphorylation	NULL
of	NULL
pleckstrin	NULL
,	NULL
a	NULL
47-kDa	NULL
protein	NULL
(	NULL
P47	NULL
)	NULL
which	NULL
is	NULL
the	NULL
main	NULL
substrate	NULL
for	NULL
PKC	NULL
in	NULL
platelets	NULL
(	NULL
44	NULL
)	NULL
(	NULL
panel	NULL
B	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
activation	NULL
of	NULL
PLC	NULL
and	NULL
PKC	NULL
was	NULL
accompanied	NULL
by	NULL
a	NULL
massive	NULL
increase	NULL
in	NULL
cytosolic	NULL
Ca**	NULL
(	NULL
panel	NULL
C	NULL
)	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
activation	NULL
of	NULL
platelets	NULL
with	NULL
threshold	NULL
of	NULL
cathepsin	NULL
G	NULL
resulted	NULL
in	NULL
a	NULL
detectable	NULL
but	NULL
limited	NULL
metabolic	NULL
activation	NULL
compared	NULL
with	NULL
550	NULL
nm	NULL
cathepsin	NULL
G.	NULL
On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
exposure	NULL
of	NULL
platelets	NULL
to	NULL
NE	NULL
alone	NULL
at	NULL
concentrations	NULL
up	NULL
to	NULL
800	NULL
nx	NULL
failed	NULL
to	NULL
initiate	NULL
PLC	NULL
or	NULL
PKC	NULL
activities	NULL
or	NULL
intracellular	NULL
Ca	NULL
``	NULL
*	NULL
movements	NULL
.	NULL

Finally	NULL
,	NULL
and	NULL
more	NULL
importantly	NULL
,	NULL
stimulation	NULL
of	NULL
platelets	NULL
with	NULL
the	NULL
combination	NULL
of	NULL
400	NULL
nm	NULL
NE	NULL
and	NULL
threshold	NULL
of	NULL
cathepsin	NULL
G	NULL
resulted	NULL
in	NULL
an	NULL
activation	NULL
which	NULL
was	NULL
not	NULL
different	NULL
with	NULL
that	NULL
produced	NULL
by	NULL
threshold	NULL
of	NULL
cathepsin	NULL
G	NULL
alone	NULL
(	NULL
values	NULL
of	NULL
fold-increase	NULL
over	NULL
basal	NULL
signals	NULL
were	NULL
2.25	NULL
+	NULL
0.25	NULL
and	NULL
2.63	NULL
+	NULL
0.14	NULL
(	NULL
n	NULL
=	NULL
4	NULL
)	NULL
for	NULL
PtdOH	NULL
accumulation	NULL
,	NULL
respectively	NULL
,	NULL
and	NULL
1.26	NULL
+	NULL
0.05	NULL
and	NULL
1.24	NULL
+	NULL
0.02	NULL
(	NULL
n	NULL
=	NULL
4	NULL
)	NULL
for	NULL
P47	NULL
phosphorylation	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
determined	NULL
that	NULL
the	NULL
activation	NULL
of	NULL
an	NULL
,	NULL
fBs3	NULL
by	NULL
NE	NULL
was	NULL
not	NULL
blocked	NULL
by	NULL
substances	NULL
known	NULL
to	NULL
prevent	NULL
platelet	NULL
activation	NULL
.	NULL

Table	NULL
II	NULL
shows	NULL
that	NULL
pre-treatment	NULL
of	NULL
platelets	NULL
with	NULL
GF	NULL
109203X	NULL
%	NULL
,	NULL
a	NULL
specific	NULL
PKC	NULL
inhibitor	NULL
(	NULL
45	NULL
)	NULL
,	NULL
or	NULL
with	NULL
PGI	NULL
,	NULL
a	NULL
potent	NULL
activator	NULL
of	NULL
platelet	NULL
adenylate	NULL
cyclase	NULL
and	NULL
inhibitor	NULL
of	NULL
a	NULL
,	NULL
,	NULL
;	NULL
metabolic	NULL
activation	NULL
(	NULL
46	NULL
)	NULL
,	NULL
had	NULL
no	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
/810-0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wo	NULL
;	NULL
popeoumog	NULL
11642	NULL
PTdOH	NULL
Accumulation	NULL
(	NULL
fold-increase	NULL
over	NULL
basal	NULL
value	NULL
)	NULL
P47	NULL
Phosphorylation	NULL
(	NULL
fold-increase	NULL
over	NULL
basal	NULL
value	NULL
)	NULL
0.5	NULL
1.5	NULL
25	NULL
3.50	NULL
4.5	NULL
55	NULL
65	NULL
05	NULL
1.0	NULL
15	NULL
2.0	NULL
550	NULL
nMCat	NULL
.	NULL

G	NULL
P	NULL
thCat	NULL
.	NULL

G	NULL
P	NULL
400	NULL
nM	NULL
NE	NULL
800	NULL
nm	NULL
NC	NULL
F	NULL
400	NULL
nM	NULL
NE	NULL
+	NULL
thCat	NULL
.	NULL

G	NULL
«	NULL
[	NULL
-C	NULL
thCat	NULL
.	NULL

G	NULL
=o	NULL
FLUORESCENCE	NULL
mom	NULL
a	NULL
_	NULL
7	NULL
I	NULL
3	NULL
S	NULL
57	NULL
O	NULL
550	NULL
nM	NULL
Cat	NULL
.	NULL

G	NULL
400	NULL
nM	NULL
NE	NULL
400	NULL
nM	NULL
NE	NULL
+	NULL
thCat	NULL
.	NULL

G	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

Lack	NULL
of	NULL
involvement	NULL
of	NULL
the	NULL
platelet	NULL
intracellular	NULL
signaling	NULL
in	NULL
the	NULL
potentiation	NULL
induced	NULL
by	NULL
NE	NULL
.	NULL

Platelets	NULL
labeled	NULL
with	NULL
*°P	NULL
(	NULL
0.5	NULL
ml	NULL
,	NULL
4	NULL
X	NULL
10°	NULL
cells/ml	NULL
)	NULL
or	NULL
loaded	NULL
with	NULL
Fura	NULL
2	NULL
(	NULL
1	NULL
ml	NULL
,	NULL
4	NULL
X	NULL
10°	NULL
cells/ml	NULL
)	NULL
were	NULL
preincubated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
exogenous	NULL
fibrinogen	NULL
and	NULL
stimulated	NULL
for	NULL
3	NULL
min	NULL
as	NULL
indicated	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
fold	NULL
increase	NULL
of	NULL
the	NULL
radioactivity	NULL
associated	NULL
with	NULL
PHdOH	NULL
(	NULL
Panel	NULL
A	NULL
)	NULL
or	NULL
P47	NULL
(	NULL
Panel	NULL
B	NULL
)	NULL
in	NULL
treated	NULL
platelets	NULL
over	NULL
basal	NULL
values	NULL
measured	NULL
on	NULL
nontreated	NULL
cells	NULL
.	NULL

Data	NULL
are	NULL
means	NULL
+	NULL
S.E	NULL
.	NULL

of	NULL
four	NULL
experiments	NULL
conducted	NULL
with	NULL
platelets	NULL
from	NULL
different	NULL
donors	NULL
.	NULL

The	NULL
variations	NULL
in	NULL
fluorescence	NULL
reflecting	NULL
changes	NULL
of	NULL
intracellular	NULL
Ca	NULL
``	NULL
*	NULL
concentrations	NULL
were	NULL
monitored	NULL
for	NULL
2	NULL
min	NULL
(	NULL
panel	NULL
C	NULL
)	NULL
.	NULL

Tracings	NULL
are	NULL
representative	NULL
of	NULL
two	NULL
distinct	NULL
experiments	NULL
performed	NULL
in	NULL
duplicate	NULL
.	NULL

thCat	NULL
.	NULL

G	NULL
,	NULL
threshold	NULL
of	NULL
concentration	NULL
of	NULL
cathepsin	NULL
G.	NULL
II	NULL
Effect	NULL
of	NULL
drugs	NULL
on	NULL
NE-	NULL
and	NULL
thrombin-induced	NULL
expression	NULL
of	NULL
the	NULL
activated	NULL
or	NULL
,	NULL
,	NULL
B	NULL
,	NULL
conformer	NULL
GF	NULL
109203X	NULL
and	NULL
PGI	NULL
,	NULL
were	NULL
preincubated	NULL
with	NULL
platelets	NULL
at	NULL
37	NULL
°C	NULL
for	NULL
30	NULL
s	NULL
and	NULL
for	NULL
2	NULL
min	NULL
,	NULL
respectively	NULL
,	NULL
before	NULL
stimulation	NULL
with	NULL
the	NULL
proteinases	NULL
for	NULL
3	NULL
min	NULL
.	NULL

PAC-1	NULL
binding	NULL
analysis	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

2	NULL
and	NULL
is	NULL
expressed	NULL
as	NULL
the	NULL
percentage	NULL
of	NULL
the	NULL
control	NULL
median	NULL
fluorescence	NULL
intensity	NULL
measured	NULL
in	NULL
NE-	NULL
or	NULL
thrombin-stimulated	NULL
platelets	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
drugs	NULL
.	NULL

Results	NULL
are	NULL
mean	NULL
+	NULL
S.E	NULL
.	NULL

of	NULL
the	NULL
indicated	NULL
number	NULL
of	NULL
experiments	NULL
conducted	NULL
with	NULL
cells	NULL
from	NULL
different	NULL
donors	NULL
.	NULL

Drug	NULL
NE	NULL
(	NULL
400	NULL
nm	NULL
)	NULL
GF	NULL
109203X	NULL
(	NULL
7.5	NULL
um	NULL
)	NULL
-	NULL
114.9	NULL
+	NULL
11.0	NULL
%	NULL
(	NULL
n	NULL
=	NULL
8	NULL
)	NULL
PGI	NULL
,	NULL
(	NULL
10	NULL
um	NULL
)	NULL
124.6	NULL
+	NULL
8.7	NULL
%	NULL
(	NULL
n	NULL
=	NULL
4	NULL
)	NULL
Thrombin	NULL
(	NULL
0.5	NULL
IU/ml	NULL
)	NULL
28.7	NULL
+	NULL
5.5	NULL
%	NULL
(	NULL
n	NULL
=	NULL
8	NULL
)	NULL
28.8	NULL
+	NULL
1.9	NULL
%	NULL
(	NULL
n	NULL
=	NULL
5	NULL
)	NULL
inhibitory	NULL
effect	NULL
on	NULL
the	NULL
capacity	NULL
of	NULL
400	NULL
nm	NULL
NE	NULL
to	NULL
activate	NULL
«	NULL
m	NULL
,	NULL
B3	NULL
,	NULL
as	NULL
evaluated	NULL
by	NULL
the	NULL
binding	NULL
of	NULL
PAC-1	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
and	NULL
as	NULL
expected	NULL
,	NULL
both	NULL
GF	NULL
109203X	NULL
and	NULL
PGI	NULL
,	NULL
were	NULL
potent	NULL
inhibitors	NULL
of	NULL
the	NULL
expression	NULL
of	NULL
activated	NULL
am	NULL
,	NULL
fB3	NULL
on	NULL
the	NULL
surface	NULL
of	NULL
platelets	NULL
stimulated	NULL
with	NULL
0.5	NULL
IU/ml	NULL
thrombin	NULL
(	NULL
45	NULL
,	NULL
46	NULL
)	NULL
.	NULL

Altogether	NULL
,	NULL
these	NULL
data	NULL
clearly	NULL
indicate	NULL
that	NULL
the	NULL
potentiating	NULL
effect	NULL
of	NULL
NE	NULL
on	NULL
threshold	NULL
of	NULL
cathepsin	NULL
G-induced	NULL
platelet	NULL
aggregation	NULL
is	NULL
not	NULL
related	NULL
to	NULL
an	NULL
increased	NULL
intracellular	NULL
signaling	NULL
involving	NULL
the	NULL
PLC	NULL
,	NULL
PKC	NULL
,	NULL
and	NULL
Ca**	NULL
components	NULL
.	NULL

Effects	NULL
of	NULL
NE	NULL
on	NULL
the	NULL
Structure	NULL
of	NULL
major	NULL
feature	NULL
in	NULL
our	NULL
study	NULL
was	NULL
that	NULL
PMSF	NULL
-inactivated	NULL
NE	NULL
was	NULL
totally	NULL
unable	NULL
to	NULL
either	NULL
up-regulate	NULL
the	NULL
activity	NULL
of	NULL
o	NULL
,	NULL
f	NULL
;	NULL
as	NULL
measured	NULL
by	NULL
the	NULL
binding	NULL
of	NULL
PAC-1	NULL
(	NULL
2.3	NULL
+	NULL
0.2-	NULL
versus	NULL
1.1	NULL
+	NULL
0.1-fold	NULL
increase	NULL
(	NULL
n	NULL
=	NULL
3	NULL
)	NULL
over	NULL
basal	NULL
values	NULL
with	NULL
intact	NULL
and	NULL
PMSF-treated	NULL
NE	NULL
,	NULL
respec-tively	NULL
)	NULL
,	NULL
or	NULL
to	NULL
potentiate	NULL
cathepsin	NULL
G-induced	NULL
platelet	NULL
aggregation	NULL
(	NULL
not	NULL
shown	NULL
and	NULL
Ref	NULL
.	NULL

19	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
proteolytic	NULL
activity	NULL
of	NULL
NE	NULL
is	NULL
required	NULL
for	NULL
both	NULL
processes	NULL
.	NULL

This	NULL
,	NULL
together	NULL
with	NULL
the	NULL
known	NULL
susceptibility	NULL
of	NULL
ayy	NULL
,	NULL
3	NULL
;	NULL
to	NULL
proteolysis	NULL
by	NULL
serine	NULL
proteinases	NULL
(	NULL
26-30	NULL
)	NULL
and	NULL
the	NULL
absence	NULL
of	NULL
intracellular	NULL
metabolic	NULL
activation	NULL
by	NULL
NE	NULL
(	NULL
see	NULL
above	NULL
)	NULL
,	NULL
prompted	NULL
us	NULL
to	NULL
examine	NULL
whether	NULL
the	NULL
integrin	NULL
structure	NULL
was	NULL
affected	NULL
by	NULL
this	NULL
proteinase	NULL
under	NULL
our	NULL
experimental	NULL
conditions	NULL
.	NULL

Panel	NULL
A	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
illustrates	NULL
the	NULL
analysis	NULL
of	NULL
the	NULL
B	NULL
;	NULL
,	NULL
and	NULL
am	NULL
,	NULL
subunits	NULL
separated	NULL
on	NULL
7-12	NULL
%	NULL
gradient	NULL
acrylamide	NULL
gels	NULL
follow	NULL
am	NULL
,	NULL
pBs	NULL
and	NULL
Platelet	NULL
Activation	NULL
by	NULL
Elastase	NULL
and	NULL
Cathepsin	NULL
G	NULL
ing	NULL
reduction	NULL
of	NULL
intra-	NULL
or	NULL
interchain	NULL
disulfide	NULL
bonds	NULL
,	NULL
and	NULL
probed	NULL
with	NULL
polyclonal	NULL
rabbit	NULL
antisera	NULL
raised	NULL
against	NULL
each	NULL
of	NULL
the	NULL
whole	NULL
subunit	NULL
.	NULL

When	NULL
compared	NULL
with	NULL
nontreated	NULL
control	NULL
platelets	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
platelets	NULL
exposed	NULL
to	NULL
400	NULL
nm	NULL
NE	NULL
for	NULL
3	NULL
min	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
showed	NULL
no	NULL
proteolytic	NULL
modification	NULL
of	NULL
the	NULL
B	NULL
;	NULL
,	NULL
subunit	NULL
(	NULL
M	NULL
,	NULL
~	NULL
118,000	NULL
)	NULL
,	NULL
whose	NULL
mobility	NULL
and	NULL
intensity	NULL
remained	NULL
unchanged	NULL
.	NULL

Only	NULL
longer	NULL
exposure	NULL
(	NULL
15	NULL
min	NULL
)	NULL
to	NULL
400	NULL
nM	NULL
NE	NULL
,	NULL
or	NULL
to	NULL
higher	NULL
concentrations	NULL
of	NULL
proteinase	NULL
(	NULL
1.2	NULL
uM	NULL
)	NULL
resulted	NULL
in	NULL
the	NULL
appearance	NULL
of	NULL
a	NULL
minor	NULL
membrane-associated	NULL
fragment	NULL
of	NULL
B	NULL
;	NULL
with	NULL
M	NULL
,	NULL
~	NULL
66,000	NULL
(	NULL
not	NULL
shown	NULL
and	NULL
Ref	NULL
.	NULL

27	NULL
)	NULL
.	NULL

Under	NULL
the	NULL
conditions	NULL
of	NULL
electrophoresis	NULL
used	NULL
in	NULL
this	NULL
experiment	NULL
,	NULL
the	NULL
af	NULL
,	NULL
,	NULL
subunit	NULL
could	NULL
be	NULL
clearly	NULL
resolved	NULL
into	NULL
its	NULL
two	NULL
heavy	NULL
and	NULL
light	NULL
polypeptide	NULL
chains	NULL
(	NULL
amy	NULL
,	NULL
M	NULL
,	NULL
~	NULL
126,000	NULL
,	NULL
and	NULL
M	NULL
,	NULL
~	NULL
25,000	NULL
)	NULL
.	NULL

appeared	NULL
to	NULL
be	NULL
unchanged	NULL
for	NULL
both	NULL
its	NULL
mobility	NULL
and	NULL
intensity	NULL
in	NULL
NE-treated	NULL
platelets	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
the	NULL
oy	NULL
subunit	NULL
migrated	NULL
as	NULL
a	NULL
broader	NULL
band	NULL
in	NULL
platelets	NULL
exposed	NULL
to	NULL
NE	NULL
(	NULL
Zane	NULL
2	NULL
)	NULL
,	NULL
as	NULL
compared	NULL
with	NULL
nontreated	NULL
platelets	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
with	NULL
a	NULL
component	NULL
(	NULL
indicated	NULL
by	NULL
the	NULL
open	NULL
arrowhead	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
panel	NULL
A	NULL
)	NULL
running	NULL
slightly	NULL
ahead	NULL
of	NULL
the	NULL
intact	NULL
mp	NULL
.	NULL

More	NULL
detailed	NULL
immunoblot	NULL
analysis	NULL
of	NULL
the	NULL
opy	NULL
subunit	NULL
was	NULL
performed	NULL
following	NULL
reduced	NULL
SDS-PAGE	NULL
on	NULL
highly	NULL
resolutive	NULL
5	NULL
%	NULL
acrylamide	NULL
gels	NULL
,	NULL
using	NULL
a	NULL
panel	NULL
of	NULL
domain-specific	NULL
ap	NULL
,	NULL
,	NULL
antibodies	NULL
(	NULL
see	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

As	NULL
illustrated	NULL
in	NULL
panel	NULL
!	NULL

B	NULL
of	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
the	NULL
polyclonal	NULL
antiserum	NULL
clearly	NULL
identified	NULL
two	NULL
molecular	NULL
species	NULL
in	NULL
NE-treated	NULL
platelets	NULL
(	NULL
Zane	NULL
2	NULL
)	NULL
,	NULL
showing	NULL
approximately	NULL
equal	NULL
intensity	NULL
,	NULL
one	NULL
corresponding	NULL
to	NULL
the	NULL
intact	NULL
amp	NULL
(	NULL
M	NULL
,	NULL
~	NULL
128,000	NULL
)	NULL
as	NULL
seen	NULL
in	NULL
control	NULL
untreated	NULL
platelets	NULL
(	NULL
Zane	NULL
1	NULL
)	NULL
,	NULL
and	NULL
the	NULL
second	NULL
to	NULL
a	NULL
membrane-bound	NULL
proteolytic	NULL
fragment	NULL
with	NULL
M	NULL
,	NULL
~	NULL
123,000	NULL
,	NULL
designated	NULL
amp	NULL
,	NULL
.	NULL

On	NULL
several	NULL
platelet	NULL
samples	NULL
exposed	NULL
to	NULL
NE	NULL
under	NULL
identical	NULL
conditions	NULL
,	NULL
the	NULL
mean	NULL
M	NULL
,	NULL
difference	NULL
between	NULL
amy	NULL
and	NULL
@	NULL
npy	NULL
;	NULL
was	NULL
6,470	NULL
+	NULL
290	NULL
(	NULL
n	NULL
=	NULL
15	NULL
)	NULL
.	NULL

Considering	NULL
that	NULL
amp	NULL
is	NULL
entirely	NULL
extracellular	NULL
,	NULL
such	NULL
a	NULL
limited	NULL
proteolysis	NULL
must	NULL
have	NULL
occurred	NULL
at	NULL
one	NULL
or	NULL
both	NULL
extremities	NULL
of	NULL
the	NULL
polypeptide	NULL
chain	NULL
.	NULL

The	NULL
polyclonal	NULL
rabbit	NULL
antiserum	NULL
IIb-10	NULL
,	NULL
recognizing	NULL
the	NULL
opp	NULL
amino-terminal	NULL
Leu	NULL
-Pro'*	NULL
sequence	NULL
(	NULL
80	NULL
)	NULL
,	NULL
reacted	NULL
equally	NULL
with	NULL
the	NULL
intact	NULL
omy	NULL
and	NULL
the	NULL
fragment	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
the	NULL
murine	NULL
monoclonal	NULL
antibody	NULL
PMI-1	NULL
,	NULL
which	NULL
recognizes	NULL
the	NULL
aonpp	NULL
carboxyl-terminal	NULL
Pro	NULL
%	NULL
*-Arg*	NULL
``	NULL
°	NULL
sequence	NULL
(	NULL
84	NULL
)	NULL
,	NULL
was	NULL
reactive	NULL
with	NULL
the	NULL
residual	NULL
intact	NULL
amy	NULL
in	NULL
NE-treated	NULL
platelets	NULL
,	NULL
but	NULL
totally	NULL
unreactive	NULL
with	NULL
apy	NULL
;	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
panel	NULL
B	NULL
)	NULL
.	NULL

To	NULL
ascertain	NULL
that	NULL
proteolysis	NULL
was	NULL
limited	NULL
to	NULL
opy	NULL
,	NULL
similar	NULL
experiments	NULL
were	NULL
performed	NULL
on	NULL
unreduced	NULL
samples	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
panel	NULL
C	NULL
)	NULL
.	NULL

Here	NULL
,	NULL
the	NULL
anti-omy	NULL
,	NULL
antiserum	NULL
identified	NULL
the	NULL
native	NULL
of	NULL
,	NULL
,	NULL
subunit	NULL
(	NULL
Ge	NULL
.	NULL

disulfide-linked	NULL
ay	NULL
and	NULL
appy	NULL
;	NULL
)	NULL
in	NULL
nontreated	NULL
samples	NULL
with	NULL
M	NULL
,	NULL
~	NULL
143,000	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

With	NULL
NE-treated	NULL
platelets	NULL
(	NULL
Zane	NULL
2	NULL
)	NULL
,	NULL
a	NULL
second	NULL
component	NULL
could	NULL
be	NULL
distinguished	NULL
slightly	NULL
ahead	NULL
of	NULL
intact	NULL
ap	NULL
,	NULL
.	NULL

This	NULL
component	NULL
,	NULL
designated	NULL
anm	NULL
,	NULL
had	NULL
M	NULL
,	NULL
~	NULL
137,000	NULL
.	NULL

The	NULL
a	NULL
,	NULL
light	NULL
chain	NULL
within	NULL
the	NULL
am	NULL
,	NULL
,	NULL
membrane-bound	NULL
proteolytic	NULL
species	NULL
was	NULL
shown	NULL
to	NULL
have	NULL
an	NULL
intact	NULL
amino	NULL
terminus	NULL
by	NULL
the	NULL
normal	NULL
reactivity	NULL
of	NULL
of	NULL
,	NULL
with	NULL
the	NULL
anti-V4l	NULL
polyclonal	NULL
antiserum	NULL
,	NULL
which	NULL
recognizes	NULL
the	NULL
amino-terminal	NULL
GIn®*°-Arg*	NULL
``	NULL
``	NULL
sequence	NULL
of	NULL
expr	NULL
,	NULL
(	NULL
34	NULL
)	NULL
.	NULL

Similar	NULL
immunoblot	NULL
analysis	NULL
was	NULL
further	NULL
performed	NULL
on	NULL
SDS	NULL
lysates	NULL
of	NULL
platelets	NULL
treated	NULL
for	NULL
3	NULL
min	NULL
with	NULL
the	NULL
combination	NULL
of	NULL
400	NULL
nm	NULL
NE	NULL
and	NULL
threshold	NULL
of	NULL
cathepsin	NULL
G	NULL
(	NULL
Zanes	NULL
3	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Results	NULL
were	NULL
strictly	NULL
identical	NULL
to	NULL
those	NULL
obtained	NULL
with	NULL
platelets	NULL
treated	NULL
with	NULL
400	NULL
nm	NULL
NE	NULL
alone	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
we	NULL
previously	NULL
demonstrated	NULL
that	NULL
high	NULL
concentrations	NULL
of	NULL
cathepsin	NULL
G	NULL
alone	NULL
have	NULL
no	NULL
proteolytic	NULL
effect	NULL
on	NULL
the	NULL
ap	NULL
,	NULL
{	NULL
;	NULL
integrin	NULL
(	NULL
47	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
data	NULL
indicate	NULL
that	NULL
under	NULL
optimal	NULL
conditions	NULL
of	NULL
potentiation	NULL
by	NULL
NE	NULL
of	NULL
threshold	NULL
of	NULL
cathepsin	NULL
G-initiated	NULL
aggregation	NULL
,	NULL
NE	NULL
specifically	NULL
proteolyzes	NULL
a	NULL
short	NULL
domain	NULL
located	NULL
at	NULL
the	NULL
carboxyl	NULL
terminus	NULL
of	NULL
the	NULL
ai	NULL
,	NULL
»	NULL
polypeptide	NULL
chain	NULL
.	NULL

Since	NULL
the	NULL
above	NULL
data	NULL
pointed	NULL
to	NULL
the	NULL
existence	NULL
of	NULL
a	NULL
specific	NULL
and	NULL
previously	NULL
unreported	NULL
modification	NULL
of	NULL
«	NULL
;	NULL
}	NULL
by	NULL
NE	NULL
,	NULL
we	NULL
sought	NULL
to	NULL
confirm	NULL
that	NULL
it	NULL
occurred	NULL
to	NULL
a	NULL
significant	NULL
extent	NULL
at	NULL
the	NULL
surface	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
/810-0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wo	NULL
;	NULL
popeoumog	NULL
am	NULL
,	NULL
pBs	NULL
and	NULL
Platelet	NULL
Activation	NULL
by	NULL
Elastase	NULL
and	NULL
Cathepsin	NULL
G	NULL
200	NULL
116	NULL
£7	NULL
o	NULL
667	NULL
Fic	NULL
.	NULL

5	NULL
.	NULL

Immunoblot	NULL
analysis	NULL
of	NULL
o	NULL
,	NULL
x	NULL
and	NULL
B	NULL
,	NULL
subunits	NULL
in	NULL
platelets	NULL
treated	NULL
=	NULL
-	NULL
45-by	NULL
NE	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
p3	NULL
threshold	NULL
of	NULL
cathepsin	NULL
G.	NULL
Platelet	NULL
samples	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
exogenous	NULL
fibrinogen	NULL
,	NULL
as	NULL
indicated	NULL
in	NULL
the	NULL
31-legend	NULL
to	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
and	NULL
untreated	NULL
(	NULL
Zanes	NULL
1	NULL
)	NULL
or	NULL
treated	NULL
with	NULL
400	NULL
nM	NULL
NE	NULL
alone	NULL
(	NULL
Zanes	NULL
2	NULL
)	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
threshold	NULL
of	NULL
cathepsin	NULL
G	NULL
(	NULL
Zanes	NULL
3	NULL
)	NULL
.	NULL

Reactions	NULL
were	NULL
followed	NULL
for	NULL
3	NULL
min	NULL
and	NULL
then	NULL
stopped	NULL
with	NULL
eglin	NULL
C	NULL
and	NULL
PMSF	NULL
,	NULL
and	NULL
platelets	NULL
were	NULL
immediately	NULL
sedimented	NULL
and	NULL
solubilized	NULL
with	NULL
SDS	NULL
.	NULL

Disulfides	NULL
bonds	NULL
were	NULL
either	NULL
unreduced	NULL
(	NULL
panel	NULL
C	NULL
)	NULL
or	NULL
reduced	NULL
(	NULL
panels	NULL
A	NULL
and	NULL
B	NULL
)	NULL
with	NULL
2-mercaptoethanol	NULL
prior	NULL
to	NULL
elec-	NULL
B	NULL
trophoresis	NULL
.	NULL

After	NULL
SDS-PAGE	NULL
on	NULL
7-12	NULL
%	NULL
(	NULL
panel	NULL
A	NULL
)	NULL
or	NULL
5	NULL
%	NULL
(	NULL
panel	NULL
B	NULL
and	NULL
C	NULL
)	NULL
acrylam-	NULL
ide	NULL
gels	NULL
and	NULL
transfer	NULL
to	NULL
nitrocellulose	NULL
membranes	NULL
,	NULL
platelet	NULL
proteins	NULL
were	NULL
probed	NULL
with	NULL
polyclonal	NULL
antisera	NULL
against	NULL
200	NULL
the	NULL
or	NULL
B	NULL
,	NULL
subunit	NULL
(	NULL
diluted	NULL
1/1000	NULL
)	NULL
,	NULL
the	NULL
polyclonal	NULL
antiserum	NULL
IIb-10	NULL
(	NULL
diluted	NULL
1/100	NULL
)	NULL
,	NULL
the	NULL
monoclonal	NULL
PMI-1	NULL
(	NULL
10	NULL
ug/ml	NULL
)	NULL
followed	NULL
by	NULL
a	NULL
polyclonal	NULL
rabbit	NULL
anti-mouse	NULL
IgG	NULL
(	NULL
10	NULL
ug/ml	NULL
)	NULL
,	NULL
or	NULL
the	NULL
polyclonal	NULL
anti-V41	NULL
antiserum	NULL
(	NULL
diluted	NULL
1/200	NULL
)	NULL
.	NULL

Bound	NULL
antibodies	NULL
were	NULL
revealed	NULL
by	NULL
incu-	NULL
97.4	NULL
bation	NULL
with	NULL
'*	NULL
``	NULL
I-Protein	NULL
A	NULL
(	NULL
diluted	NULL
1/1000	NULL
)	NULL
followed	NULL
by	NULL
autoradiography	NULL
.	NULL

Mo	NULL
lecular	NULL
masses	NULL
were	NULL
calculated	NULL
with	NULL
re	NULL
spect	NULL
to	NULL
calibration	NULL
standard	NULL
proteins	NULL
in	NULL
cluded	NULL
in	NULL
each	NULL
gel	NULL
.	NULL

@	NULL
ppy	NULL
;	NULL
y	NULL
22d	NULL
@	NULL
r	NULL
represent	NULL
the	NULL
membrane-associated	NULL
pro	NULL
21.547	NULL
Mr	NULL
x	NULL
10	NULL
3	NULL
teolytic	NULL
fragments	NULL
of	NULL
@	NULL
py	NULL
and	NULL
@	NULL
C	NULL
respectively	NULL
.	NULL

200	NULL
ig	NULL
O	NULL
+-tas	NULL
k_	NULL
=	NULL
416	NULL
97.4	NULL
of	NULL
platelets	NULL
.	NULL

Platelet	NULL
suspensions	NULL
were	NULL
thus	NULL
exposed	NULL
to	NULL
400	NULL
nx	NULL
NE	NULL
for	NULL
increasing	NULL
periods	NULL
of	NULL
time	NULL
(	NULL
up	NULL
to	NULL
3	NULL
min	NULL
)	NULL
and	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
to	NULL
quantitate	NULL
the	NULL
binding	NULL
of	NULL
the	NULL
monoclonal	NULL
antibody	NULL
PMI-1	NULL
(	NULL
this	NULL
being	NULL
taken	NULL
as	NULL
a	NULL
marker	NULL
of	NULL
proteolysis	NULL
at	NULL
the	NULL
arp	NULL
carboxyl	NULL
terminus	NULL
)	NULL
since	NULL
the	NULL
PMI-1	NULL
epitope	NULL
should	NULL
be	NULL
lost	NULL
upon	NULL
exposure	NULL
to	NULL
NE	NULL
.	NULL

Results	NULL
indicated	NULL
a	NULL
near	NULL
complete	NULL
disappearance	NULL
of	NULL
the	NULL
PMI-1	NULL
epitope	NULL
on	NULL
NE-treated	NULL
platelets	NULL
,	NULL
with	NULL
a	NULL
binding	NULL
after	NULL
3	NULL
min	NULL
of	NULL
proteolysis	NULL
decreased	NULL
by	NULL
98	NULL
+	NULL
4	NULL
%	NULL
(	NULL
n	NULL
=	NULL
5	NULL
)	NULL
compared	NULL
with	NULL
the	NULL
initial	NULL
value	NULL
measured	NULL
on	NULL
untreated	NULL
platelets	NULL
(	NULL
data	NULL
not	NULL
illustrated	NULL
)	NULL
.	NULL

Localization	NULL
of	NULL
the	NULL
Cleavage	NULL
Site	NULL
(	NULL
s	NULL
)	NULL
for	NULL
NE	NULL
within	NULL
the	NULL
apy	NULL
Carboxyl	NULL
Terminus-Considering	NULL
the	NULL
domain	NULL
of	NULL
om	NULL
,	NULL
,	NULL
proteolyzed	NULL
by	NULL
NE	NULL
(	NULL
see	NULL
above	NULL
)	NULL
,	NULL
the	NULL
relative	NULL
M	NULL
,	NULL
difference	NULL
measured	NULL
between	NULL
onpy	NULL
and	NULL
@	NULL
npy	NULL
;	NULL
(	NULL
~6,500	NULL
)	NULL
,	NULL
and	NULL
the	NULL
fact	NULL
that	NULL
in	NULL
resting	NULL
11643	NULL
Anti-B3	NULL
Anti-allb	NULL
_	NULL
a	NULL
ollbp	NULL
vee	NULL
1	NULL
]	NULL
;	NULL
*PSe-1	NULL
Anti-allb	NULL
IIb-10	NULL
PMI-1	NULL
a	NULL
=	NULL
aww	NULL
--	NULL
<	NULL
ag	NULL
CllDp	NULL
``	NULL
-	NULL
me	NULL
wt	NULL
*	NULL
~	NULL
4516	NULL
)	NULL
,	NULL
Anti-allb	NULL
Anti-	NULL
V41	NULL
platelets	NULL
,	NULL
the	NULL
epitope	NULL
recognized	NULL
by	NULL
PMI-1	NULL
is	NULL
largely	NULL
cryptic	NULL
(	NULL
41	NULL
)	NULL
,	NULL
the	NULL
site	NULL
(	NULL
s	NULL
)	NULL
of	NULL
cleavage	NULL
by	NULL
NE	NULL
were	NULL
searched	NULL
by	NULL
MALDI-TOF	NULL
mass	NULL
spectrometry	NULL
on	NULL
a	NULL
peptide	NULL
corresponding	NULL
to	NULL
the	NULL
sequence	NULL
Phe®	NULL
``	NULL
``	NULL
-Leu	NULL
``	NULL
*	NULL
'	NULL
of	NULL
army	NULL
.	NULL

Indeed	NULL
,	NULL
this	NULL
sequence	NULL
maps	NULL
from	NULL
the	NULL
carboxyl-terminal	NULL
side	NULL
of	NULL
Cys®°	NULL
,	NULL
which	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
linkage	NULL
of	NULL
<	NULL
:	NULL
;	NULL
to	NULL
(	NULL
20	NULL
)	NULL
,	NULL
to	NULL
the	NULL
amino-terminal	NULL
side	NULL
of	NULL
the	NULL
PMI-1	NULL
epitope	NULL
(	NULL
34	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
panel	NULL
B	NULL
)	NULL
.	NULL

The	NULL
lower	NULL
tracing	NULL
in	NULL
panel	NULL
A	NULL
of	NULL
Fig	NULL
.	NULL

6	NULL
shows	NULL
a	NULL
mass	NULL
spectrum	NULL
which	NULL
corresponds	NULL
to	NULL
the	NULL
initial	NULL
undigested	NULL
peptide	NULL
827-841	NULL
,	NULL
with	NULL
a	NULL
mass	NULL
of	NULL
1708.0	NULL
Da	NULL
.	NULL

Upon	NULL
a	NULL
5-min	NULL
incubation	NULL
of	NULL
this	NULL
peptide	NULL
with	NULL
400	NULL
nm	NULL
NE	NULL
(	NULL
upper	NULL
tracing	NULL
in	NULL
panel	NULL
A	NULL
of	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
,	NULL
a	NULL
single	NULL
new	NULL
peptide	NULL
was	NULL
generated	NULL
with	NULL
a	NULL
mass	NULL
of	NULL
1236.8	NULL
Da	NULL
,	NULL
corresponding	NULL
to	NULL
the	NULL
sequence	NULL
This	NULL
indicates	NULL
a	NULL
proteolysis	NULL
of	NULL
the	NULL
initial	NULL
peptide	NULL
at	NULL
a	NULL
unique	NULL
bond	NULL
,	NULL
between	NULL
Val*	NULL
``	NULL
``	NULL
and	NULL
Asp*°*	NULL
.	NULL

Of	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
/810-0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wo	NULL
;	NULL
popeoumog	NULL
11644	NULL
Fig	NULL
.	NULL

6	NULL
.	NULL

Localization	NULL
of	NULL
the	NULL
cleavage	NULL
site	NULL
for	NULL
NE	NULL
within	NULL
the	NULL
carboxyl	NULL
terminus	NULL
of	NULL
the	NULL
a	NULL
;	NULL
,	NULL
subunit	NULL
heavy	NULL
chain	NULL
.	NULL

Panel	NULL
A	NULL
,	NULL
MALDI-TOF	NULL
mass	NULL
spectra	NULL
of	NULL
the	NULL
peptide	NULL
827-841	NULL
,	NULL
corresponding	NULL
to	NULL
the	NULL
amino	NULL
acid	NULL
sequence	NULL
Phe	NULL
``	NULL
to	NULL
Leu	NULL
``	NULL
of	NULL
the	NULL
ap	NULL
,	NULL
q	NULL
subunit	NULL
.	NULL

Lower	NULL
and	NULL
upper	NULL
tracings	NULL
are	NULL
mass	NULL
spectra	NULL
of	NULL
the	NULL
untreated	NULL
peptide	NULL
and	NULL
of	NULL
peptides	NULL
obtained	NULL
after	NULL
a	NULL
5-min	NULL
digestion	NULL
by	NULL
NE	NULL
at	NULL
87	NULL
°C	NULL
,	NULL
pH	NULL
7.4	NULL
,	NULL
respectively	NULL
(	NULL
m/z	NULL
,	NULL
observed	NULL
mass/charge	NULL
)	NULL
.	NULL

Tracings	NULL
are	NULL
representative	NULL
of	NULL
two	NULL
distinct	NULL
experiments	NULL
performed	NULL
in	NULL
duplicate	NULL
.	NULL

Panel	NULL
B	NULL
,	NULL
location	NULL
of	NULL
the	NULL
deduced	NULL
cleavage	NULL
site	NULL
by	NULL
NE	NULL
(	NULL
indicated	NULL
by	NULL
a	NULL
vertical	NULL
arrow	NULL
)	NULL
in	NULL
the	NULL
om	NULL
,	NULL
carboxyl	NULL
terminus	NULL
.	NULL

Epitopes	NULL
of	NULL
the	NULL
PMI-1	NULL
and	NULL
anti-V41	NULL
antibodies	NULL
am	NULL
,	NULL
pBs	NULL
and	NULL
Platelet	NULL
Activation	NULL
by	NULL
Elastase	NULL
and	NULL
Cathepsin	NULL
G	NULL
1236.8	NULL
1	NULL
peptide	NULL
sneak	NULL
x	NULL
___A	NULL
Arbitrary	NULL
Intensity	NULL
1708.0	NULL
peptide	NULL
327-841\4	NULL
peptide	NULL
327-s4\1\4	NULL
J	NULL
al	NULL
_A	NULL
1708.0	NULL
'Time	NULL
:	NULL
5	NULL
min	NULL
600	NULL
800	NULL
1000	NULL
_	NULL
1200	NULL
1400	NULL
_	NULL
1600	NULL
-	NULL
Time	NULL
:	NULL
0	NULL
min	NULL
1800	NULL
m/z	NULL
Anti-V41	NULL
<	NULL
--	NULL
-_-__	NULL
--	NULL
>	NULL
r-I=	NULL
co	NULL
Co	NULL
QIFLPEPEQPSRLQDPVLVS	NULL
60	NULL
880	NULL
OUTSIDE	NULL
INSIDE	NULL
ibu	NULL
within	NULL
the	NULL
oy	NULL
,	NULL
subunit	NULL
are	NULL
also	NULL
indicated	NULL
.	NULL

The	NULL
shaded	NULL
circle	NULL
at	NULL
Ser	NULL
``	NULL
*	NULL
``	NULL
represents	NULL
an	NULL
O-linked	NULL
oligosaccharide	NULL
(	NULL
20	NULL
)	NULL
.	NULL

OiibH	NULL
CAME	NULL
WX	NULL
PEPTIDE	NULL
827-841	NULL
PQPPVNPLKVDWGLPIPSPSPIHPAHHKR	NULL
co	NULL
re	NULL
OU	NULL
I	NULL
«	NULL
©	NULL
989	NULL
338	NULL
-	NULL
3	NULL
&	NULL
$	NULL
-o-o-0	NULL
)	NULL
``	NULL
826	NULL
C	NULL
)	NULL
827	NULL
PMI-1	NULL
(	NULL
CNE	NULL
)	NULL
»	NULL
=	NULL
$	NULL
3	NULL
o	NULL
note	NULL
is	NULL
that	NULL
the	NULL
cleavage	NULL
was	NULL
detectable	NULL
as	NULL
soon	NULL
as	NULL
30	NULL
s	NULL
and	NULL
was	NULL
complete	NULL
at	NULL
10	NULL
min	NULL
,	NULL
without	NULL
detection	NULL
of	NULL
other	NULL
proteolytic	NULL
products	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
shorter	NULL
tetrapeptide	NULL
fragment	NULL
Asp***-Leu	NULL
``	NULL
could	NULL
not	NULL
be	NULL
detected	NULL
under	NULL
our	NULL
experimental	NULL
conditions	NULL
.	NULL

Relationship	NULL
between	NULL
Cleavage	NULL
of	NULL
the	NULL
a	NULL
;	NULL
,	NULL
Subunit	NULL
Heavy	NULL
Chain	NULL
by	NULL
NE	NULL
and	NULL
Activation	NULL
of	NULL
a	NULL
;	NULL
,	NULL
B	NULL
;	NULL
-When	NULL
bindings	NULL
of	NULL
both	NULL
PMI-1	NULL
and	NULL
AP-5	NULL
were	NULL
examined	NULL
by	NULL
flow	NULL
cytometry	NULL
on	NULL
the	NULL
same	NULL
platelet	NULL
samples	NULL
treated	NULL
by	NULL
NE	NULL
,	NULL
a	NULL
relationship	NULL
was	NULL
observed	NULL
between	NULL
the	NULL
time	NULL
course	NULL
of	NULL
proteolysis	NULL
of	NULL
the	NULL
ary	NULL
subunit	NULL
the	NULL
decreasing	NULL
binding	NULL
of	NULL
PMI-1	NULL
)	NULL
and	NULL
that	NULL
of	NULL
the	NULL
ligand	NULL
binding	NULL
capacity	NULL
of	NULL
ay	NULL
,	NULL
B	NULL
;	NULL
(	NULL
i.e	NULL
.	NULL

the	NULL
increasing	NULL
binding	NULL
of	NULL
AP-5	NULL
)	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
further	NULL
support	NULL
this	NULL
inference	NULL
and	NULL
to	NULL
exclude	NULL
an	NULL
activation	NULL
of	NULL
the	NULL
integrin	NULL
resulting	NULL
from	NULL
NE	NULL
acting	NULL
on	NULL
another	NULL
membrane	NULL
structure	NULL
inducing	NULL
signaling	NULL
which	NULL
may	NULL
feed-back	NULL
to	NULL
two	NULL
series	NULL
of	NULL
experiments	NULL
were	NULL
carried	NULL
out	NULL
.	NULL

First	NULL
,	NULL
platelets	NULL
were	NULL
depleted	NULL
in	NULL
cytosolic	NULL
ATP	NULL
by	NULL
incubation	NULL
for	NULL
15	NULL
min	NULL
with	NULL
50	NULL
mm	NULL
2-deoxy-p-glucose	NULL
,	NULL
0.05	NULL
%	NULL
NaN3	NULL
,	NULL
and	NULL
10	NULL
mx	NULL
glucono-8-lactone	NULL
to	NULL
inhibit	NULL
glycolysis	NULL
,	NULL
oxidative	NULL
phosphoryla-tions	NULL
,	NULL
and	NULL
glycogen	NULL
phosphorylase	NULL
,	NULL
respectively	NULL
(	NULL
48	NULL
)	NULL
.	NULL

These	NULL
platelets	NULL
were	NULL
treated	NULL
or	NULL
not	NULL
with	NULL
400	NULL
nm	NULL
NE	NULL
or	NULL
550	NULL
nw	NULL
cathepsin	NULL
G	NULL
for	NULL
3	NULL
min	NULL
,	NULL
and	NULL
PAC-1	NULL
binding	NULL
was	NULL
examined	NULL
by	NULL
flow	NULL
cytometry	NULL
as	NULL
an	NULL
index	NULL
of	NULL
am	NULL
,	NULL
;	NULL
activation	NULL
.	NULL

Results	NULL
showed	NULL
that	NULL
while	NULL
NE-induced	NULL
activation	NULL
of	NULL
the	NULL
fibrinogen	NULL
receptor	NULL
remained	NULL
unchanged	NULL
(	NULL
p	NULL
>	NULL
0.05	NULL
,	NULL
»	NULL
=	NULL
3	NULL
)	NULL
,	NULL
that	NULL
produced	NULL
through	NULL
intracellular	NULL
pathways	NULL
by	NULL
cathepsin	NULL
G	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
was	NULL
inhibited	NULL
by	NULL
78.8	NULL
+	NULL
1.0	NULL
%	NULL
(	NULL
p	NULL
<	NULL
0.001	NULL
,	NULL
n	NULL
=	NULL
3	NULL
)	NULL
.	NULL

Second	NULL
,	NULL
CHO	NULL
cells	NULL
expressing	NULL
human	NULL
ap	NULL
,	NULL
,	NULL
were	NULL
used	NULL
as	NULL
it	NULL
is	NULL
known	NULL
that	NULL
these	NULL
cells	NULL
do	NULL
not	NULL
support	NULL
agonist-induced	NULL
metabolic	NULL
activation	NULL
of	NULL
this	NULL
integrin	NULL
(	NULL
49	NULL
)	NULL
.	NULL

Fig	NULL
.	NULL

7	NULL
indicates	NULL
that	NULL
treatment	NULL
of	NULL
CHO/o	NULL
,	NULL
f3	NULL
cells	NULL
with	NULL
NE	NULL
resulted	NULL
in	NULL
a	NULL
4.2	NULL
+	NULL
0.7-fold	NULL
increase	NULL
over	NULL
basal	NULL
value	NULL
for	NULL
PAC-1	NULL
binding	NULL
(	NULL
n	NULL
=	NULL
2	NULL
)	NULL
.	NULL

This	NULL
was	NULL
specific	NULL
to	NULL
NE	NULL
since	NULL
incubation	NULL
of	NULL
these	NULL
cells	NULL
with	NULL
550	NULL
nm	NULL
cathepsin	NULL
G	NULL
did	NULL
not	NULL
trigger	NULL
any	NULL
increase	NULL
in	NULL
PAC-1	NULL
binding	NULL
.	NULL

Moreover	NULL
,	NULL
this	NULL
process	NULL
did	NULL
not	NULL
result	NULL
from	NULL
an	NULL
increase	NULL
of	NULL
ar	NULL
,	NULL
;	NULL
molecules	NULL
expression	NULL
at	NULL
the	NULL
surface	NULL
of	NULL
cells	NULL
as	NULL
values	NULL
for	NULL
AP-2	NULL
binding	NULL
were	NULL
unchanged	NULL
compared	NULL
with	NULL
nontreated	NULL
cells	NULL
.	NULL

Importantly	NULL
,	NULL
in	NULL
both	NULL
cases	NULL
(	NULL
F.e	NULL
.	NULL

platelets	NULL
pretreated	NULL
with	NULL
metabolic	NULL
inhibitors	NULL
Pro	NULL
-	NULL
Cin	NULL
<	NULL
pmiep	NULL
|	NULL
|	NULL
Gmane	NULL
,	NULL
<	NULL
/i	NULL
-	NULL
CiibHf	NULL
PAC-1	NULL
AP-2	NULL
{	NULL
anjea	NULL
jeseq	NULL
1aao	NULL
ONIQNIA	NULL
AGOBLLNY	NULL
Fic	NULL
.	NULL

7	NULL
.	NULL

Specific	NULL
proteolytic	NULL
activation	NULL
by	NULL
NE	NULL
of	NULL
a	NULL
,	NULL
,	NULL
,	NULL
,	NULL
B	NULL
,	NULL
integrin	NULL
expressed	NULL
in	NULL
CHO	NULL
transfected	NULL
cells	NULL
.	NULL

cells	NULL
were	NULL
incubated	NULL
under	NULL
gentle	NULL
shaking	NULL
with	NULL
400	NULL
nM	NULL
NE	NULL
,	NULL
550	NULL
nM	NULL
cathepsin	NULL
G	NULL
(	NULL
Ca¥	NULL
.	NULL

G	NULL
)	NULL
,	NULL
or	NULL
without	NULL
proteinases	NULL
(	NULL
resting	NULL
)	NULL
for	NULL
3	NULL
min	NULL
.	NULL

Reactions	NULL
were	NULL
stopped	NULL
by	NULL
addition	NULL
of	NULL
eglin	NULL
C	NULL
and	NULL
PMSF	NULL
.	NULL

From	NULL
aliquots	NULL
of	NULL
a	NULL
single	NULL
cell	NULL
sample	NULL
,	NULL
both	NULL
PAC-1	NULL
and	NULL
AP-2	NULL
antibodies	NULL
binding	NULL
(	NULL
lower	NULL
panel	NULL
)	NULL
and	NULL
structure	NULL
of	NULL
the	NULL
(	NULL
uH	NULL
subunit	NULL
(	NULL
upper	NULL
panel	NULL
)	NULL
were	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
and	NULL
SDS-PAGE	NULL
coupled	NULL
to	NULL
immunoblot	NULL
,	NULL
respectively	NULL
.	NULL

Of	NULL
note	NULL
is	NULL
that	NULL
represents	NULL
the	NULL
intracellular	NULL
immature	NULL
op	NULL
,	NULL
subunit	NULL
(	NULL
85	NULL
)	NULL
.	NULL

As	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
Cnppr	NULL
corresponds	NULL
to	NULL
the	NULL
NE	NULL
proteolytic	NULL
fragment	NULL
of	NULL
Gy	NULL
.	NULL

and	NULL
CHO/amy	NULL
,	NULL
f	NULL
;	NULL
cells	NULL
)	NULL
,	NULL
activation	NULL
of	NULL
an	NULL
,	NULL
;	NULL
by	NULL
NE	NULL
was	NULL
accompanied	NULL
by	NULL
an	NULL
extensive	NULL
proteolysis	NULL
of	NULL
any	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

We	NULL
thus	NULL
further	NULL
examined	NULL
whether	NULL
cleavage	NULL
of	NULL
the	NULL
cmp	NULL
subunit	NULL
by	NULL
NE	NULL
quantitatively	NULL
correlates	NULL
with	NULL
the	NULL
activation	NULL
of	NULL
om	NULL
,	NULL
{	NULL
B3	NULL
.	NULL

Direct	NULL
binding	NULL
of	NULL
**°I-AP-5	NULL
and	NULL
**°I-PMI-1	NULL
antibodies	NULL
allowed	NULL
quantitative	NULL
measurements	NULL
of	NULL
the	NULL
number	NULL
of	NULL
NE-acti-vated	NULL
and	NULL
occupied	NULL
af	NULL
,	NULL
;	NULL
molecules	NULL
in	NULL
relation	NULL
to	NULL
the	NULL
number	NULL
of	NULL
proteolyzed	NULL
molecules	NULL
,	NULL
respectively	NULL
.	NULL

Panel	NULL
A	NULL
in	NULL
Fig	NULL
.	NULL

8	NULL
shows	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
/810-0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wo	NULL
;	NULL
popeoumog	NULL
am	NULL
,	NULL
pBs	NULL
and	NULL
Platelet	NULL
Activation	NULL
by	NULL
Elastase	NULL
and	NULL
Cathepsin	NULL
G	NULL
11645	NULL
SOL	NULL
6°	NULL
25	NULL
]	NULL
O	NULL
r-Q	NULL
>	NULL
<	NULL
2.5	NULL
“	NULL
20	NULL
|-D—	NULL
o	NULL
£	NULL
\	NULL
$	NULL
m	NULL
.S	NULL
E	NULL
;	NULL
-	NULL
15	NULL
-	NULL
I	NULL
€	NULL
8	NULL
a	NULL
10	NULL
}	NULL
@	NULL
o	NULL
£	NULL
A	NULL
0	NULL
1	NULL
I	NULL
I	NULL
II	NULL
T	NULL
i_	NULL
r2=	NULL
0.902	NULL
,	NULL
p	NULL
<	NULL
0.005	NULL
L_	NULL
x	NULL
anNnog	NULL
s-ay	NULL
0	NULL
30	NULL
60	NULL
90	NULL
120	NULL
-	NULL
150	NULL
-	NULL
180	NULL
TIME	NULL
(	NULL
sec	NULL
)	NULL
1	NULL
1	NULL
i	NULL
1	NULL
M	NULL
0	NULL
0	NULL
5	NULL
10	NULL
15	NULL
20	NULL
25	NULL
30	NULL
PMI-1	NULL
BOUND	NULL
(	NULL
molecules/	NULL
platelet	NULL
,	NULL
x10	NULL
)	NULL
Fig	NULL
.	NULL

8	NULL
.	NULL

Relationship	NULL
between	NULL
cleavage	NULL
by	NULL
NE	NULL
of	NULL
the	NULL
a	NULL
;	NULL
;	NULL
,	NULL
,	NULL
subunit	NULL
heavy	NULL
chain	NULL
and	NULL
activation	NULL
of	NULL
the	NULL
a	NULL
;	NULL
,	NULL
B	NULL
,	NULL
integrin	NULL
.	NULL

Platelets	NULL
were	NULL
incubated	NULL
with	NULL
exogenous	NULL
fibrinogen	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

Reactions	NULL
were	NULL
initiated	NULL
by	NULL
adding	NULL
400	NULL
nM	NULL
NE	NULL
for	NULL
increasing	NULL
periods	NULL
of	NULL
time	NULL
and	NULL
stopped	NULL
with	NULL
eglin	NULL
C	NULL
and	NULL
PMSF	NULL
.	NULL

From	NULL
aliquots	NULL
of	NULL
a	NULL
single	NULL
platelet	NULL
sample	NULL
,	NULL
specific	NULL
bindings	NULL
of	NULL
'*°I-PMI-1	NULL
and	NULL
**°I-AP-5	NULL
were	NULL
measured	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
,	NULL
``	NULL
and	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
number	NULL
of	NULL
IgG	NULL
molecules	NULL
bound	NULL
per	NULL
platelet	NULL
.	NULL

Binding	NULL
of	NULL
'*°I-PMI-1	NULL
was	NULL
measured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
EDTA	NULL
to	NULL
maximize	NULL
epitope	NULL
expression	NULL
,	NULL
while	NULL
binding	NULL
of	NULL
'*I-AP-5	NULL
was	NULL
measured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
divalent	NULL
cations	NULL
.	NULL

Panel	NULL
A	NULL
depicts	NULL
the	NULL
time-dependent	NULL
disappearance	NULL
of	NULL
the	NULL
PMI-1	NULL
epitope	NULL
and	NULL
panel	NULL
B	NULL
represents	NULL
the	NULL
same	NULL
data	NULL
plotted	NULL
versus	NULL
the	NULL
exposure	NULL
of	NULL
the	NULL
AP-5	NULL
epitope	NULL
.	NULL

Results	NULL
are	NULL
means	NULL
+	NULL
S.E	NULL
.	NULL

of	NULL
three	NULL
experiments	NULL
conducted	NULL
with	NULL
cells	NULL
from	NULL
different	NULL
donors	NULL
.	NULL

that	NULL
the	NULL
maximal	NULL
number	NULL
of	NULL
binding	NULL
sites	NULL
for	NULL
*°°I-PMI-1	NULL
on	NULL
control	NULL
nontreated	NULL
platelets	NULL
(	NULL
27,270	NULL
+	NULL
5,360	NULL
molecules/platelet	NULL
,	NULL
n	NULL
=	NULL
3	NULL
)	NULL
progressively	NULL
decreased	NULL
upon	NULL
exposure	NULL
of	NULL
cells	NULL
to	NULL
NE	NULL
,	NULL
to	NULL
be	NULL
reduced	NULL
at	NULL
3	NULL
min	NULL
by	NULL
96	NULL
+	NULL
3	NULL
%	NULL
.	NULL

Panel	NULL
B	NULL
demonstrates	NULL
that	NULL
,	NULL
on	NULL
a	NULL
time	NULL
course	NULL
basis	NULL
,	NULL
the	NULL
proteolysis	NULL
of	NULL
the	NULL
carboxyl-terminal	NULL
domain	NULL
of	NULL
amy	NULL
correlates	NULL
linearly	NULL
with	NULL
the	NULL
increased	NULL
capacity	NULL
of	NULL
ar	NULL
,	NULL
;	NULL
to	NULL
bind	NULL
exogenous	NULL
fibrinogen	NULL
(	NULL
r	NULL
'	NULL
=	NULL
0.902	NULL
,	NULL
p	NULL
=	NULL
0.005	NULL
)	NULL
.	NULL

In	NULL
this	NULL
series	NULL
of	NULL
experiments	NULL
,	NULL
the	NULL
maximal	NULL
binding	NULL
of	NULL
'*	NULL
``	NULL
I-AP-5	NULL
(	NULL
measured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
EDTA	NULL
)	NULL
on	NULL
nontreated	NULL
as	NULL
well	NULL
as	NULL
NE-treated	NULL
platelets	NULL
amounted	NULL
to	NULL
18,250	NULL
+	NULL
770	NULL
molecules/	NULL
platelet	NULL
(	NULL
n	NULL
=	NULL
3	NULL
)	NULL
,	NULL
whereas	NULL
the	NULL
specific	NULL
binding	NULL
measured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
divalent	NULL
cations	NULL
and	NULL
fibrinogen	NULL
on	NULL
platelets	NULL
treated	NULL
with	NULL
NE	NULL
for	NULL
3	NULL
min	NULL
amounted	NULL
to	NULL
4,270	NULL
+	NULL
760	NULL
molecules/platelet	NULL
,	NULL
i.e	NULL
.	NULL

23	NULL
+	NULL
3.6	NULL
%	NULL
of	NULL
the	NULL
maximal	NULL
AP-5	NULL
binding	NULL
capacity	NULL
of	NULL
platelets	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
not	NULL
all	NULL
proteolyzed	NULL
af	NULL
,	NULL
,	NULL
molecules	NULL
acquire	NULL
the	NULL
capacity	NULL
to	NULL
bind	NULL
a	NULL
ligand	NULL
,	NULL
and	NULL
that	NULL
the	NULL
stoichiometry	NULL
is	NULL
about	NULL
one	NULL
active	NULL
integrin	NULL
over	NULL
four	NULL
proteolyzed	NULL
.	NULL

DISCUSSION	NULL
The	NULL
aim	NULL
of	NULL
the	NULL
present	NULL
investigation	NULL
was	NULL
to	NULL
characterize	NULL
the	NULL
molecular	NULL
mechanism	NULL
underlying	NULL
the	NULL
synergistic	NULL
activation	NULL
of	NULL
platelets	NULL
by	NULL
the	NULL
neutrophil-derived	NULL
proteinases	NULL
elastase	NULL
and	NULL
cathepsin	NULL
G.	NULL
The	NULL
major	NULL
findings	NULL
are	NULL
as	NULL
follows	NULL
:	NULL
(	NULL
i	NULL
)	NULL
NE	NULL
does	NULL
not	NULL
activate	NULL
the	NULL
platelet	NULL
intracellular	NULL
signaling	NULL
but	NULL
specifically	NULL
cleaves	NULL
the	NULL
of	NULL
,	NULL
subunit	NULL
heavy	NULL
chain	NULL
of	NULL
the	NULL
am	NULL
,	NULL
fB	NULL
;	NULL
integrin	NULL
,	NULL
likely	NULL
between	NULL
Val	NULL
``	NULL
``	NULL
``	NULL
and	NULL
Asp®*	NULL
;	NULL
(	NULL
ii	NULL
)	NULL
this	NULL
proteolysis	NULL
correlates	NULL
with	NULL
an	NULL
up-regulation	NULL
of	NULL
the	NULL
fibrinogen	NULL
receptor	NULL
function	NULL
of	NULL
this	NULL
integrin	NULL
;	NULL
and	NULL
(	NULL
iii	NULL
)	NULL
this	NULL
particular	NULL
activation	NULL
of	NULL
by	NULL
NE	NULL
is	NULL
relevant	NULL
for	NULL
the	NULL
potentiation	NULL
of	NULL
platelet	NULL
aggregation	NULL
initiated	NULL
by	NULL
low	NULL
concentrations	NULL
of	NULL
cathepsin	NULL
G.	NULL
The	NULL
a	NULL
,	NULL
;	NULL
integrin	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
undergo	NULL
variations	NULL
in	NULL
affinity	NULL
for	NULL
fibrinogen	NULL
that	NULL
reflect	NULL
conformational	NULL
changes	NULL
within	NULL
the	NULL
am	NULL
,	NULL
and	NULL
B	NULL
;	NULL
subunits	NULL
(	NULL
20-22	NULL
)	NULL
.	NULL

Since	NULL
cathepsin	NULL
G	NULL
stimulates	NULL
platelets	NULL
as	NULL
potently	NULL
as	NULL
does	NULL
thrombin	NULL
and	NULL
through	NULL
a	NULL
common	NULL
signaling	NULL
pathway	NULL
(	NULL
14-16	NULL
,	NULL
50	NULL
)	NULL
,	NULL
it	NULL
may	NULL
be	NULL
speculated	NULL
that	NULL
the	NULL
mechanism	NULL
which	NULL
regulates	NULL
the	NULL
fibrinogen-binding	NULL
function	NULL
is	NULL
similar	NULL
for	NULL
both	NULL
proteinases	NULL
.	NULL

In	NULL
thrombin-activated	NULL
platelets	NULL
,	NULL
an	NULL
intracellular	NULL
signal	NULL
transduction	NULL
pathway	NULL
,	NULL
includ-	NULL
ing	NULL
heterotrimeric	NULL
GTP-binding	NULL
proteins	NULL
,	NULL
PLC	NULL
,	NULL
PKC	NULL
,	NULL
PI	NULL
3-ki-nase	NULL
,	NULL
low	NULL
molecular	NULL
weight	NULL
GTP-binding	NULL
proteins	NULL
and	NULL
the	NULL
cy-toskeleton	NULL
,	NULL
affects	NULL
the	NULL
cytoplasmic	NULL
domains	NULL
of	NULL
anf	NULL
;	NULL
and	NULL
influence	NULL
the	NULL
conformation	NULL
of	NULL
the	NULL
extracellular	NULL
domains	NULL
(	NULL
in-side-out	NULL
signaling	NULL
)	NULL
(	NULL
22	NULL
,	NULL
51	NULL
)	NULL
.	NULL

Hence	NULL
,	NULL
cathepsin	NULL
G-induced	NULL
activation	NULL
of	NULL
the	NULL
ar	NULL
,	NULL
;	NULL
integrin	NULL
(	NULL
the	NULL
present	NULL
study	NULL
and	NULL
Ref	NULL
.	NULL

43	NULL
and	NULL
50	NULL
)	NULL
is	NULL
likely	NULL
controlled	NULL
by	NULL
this	NULL
complex	NULL
network	NULL
of	NULL
intracellular	NULL
signaling	NULL
reactions	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
that	NULL
exposed	NULL
on	NULL
the	NULL
cell	NULL
surface	NULL
,	NULL
«	NULL
,	NULL
s	NULL
;	NULL
has	NULL
been	NULL
identified	NULL
in	NULL
an	NULL
internal	NULL
membrane	NULL
compartment	NULL
made	NULL
of	NULL
the	NULL
surface-connected	NULL
canalicular	NULL
system	NULL
and	NULL
the	NULL
a-granules	NULL
(	NULL
24	NULL
)	NULL
.	NULL

Compared	NULL
with	NULL
resting	NULL
platelets	NULL
,	NULL
the	NULL
density	NULL
of	NULL
on	NULL
the	NULL
platelet	NULL
plasma	NULL
membrane	NULL
increases	NULL
after	NULL
strong	NULL
stimulation	NULL
,	NULL
due	NULL
to	NULL
the	NULL
mobilization	NULL
of	NULL
these	NULL
intracellular	NULL
stores	NULL
(	NULL
25	NULL
)	NULL
.	NULL

This	NULL
is	NULL
confirmed	NULL
in	NULL
the	NULL
present	NULL
work	NULL
for	NULL
a	NULL
maximal	NULL
concentration	NULL
of	NULL
cathepsin	NULL
G	NULL
(	NULL
550	NULL
nm	NULL
)	NULL
using	NULL
AP-2	NULL
,	NULL
a	NULL
monoclonal	NULL
antibody	NULL
that	NULL
recognizes	NULL
a	NULL
complex-de-pendent	NULL
determinant	NULL
on	NULL
whose	NULL
binding	NULL
doubles	NULL
under	NULL
these	NULL
conditions	NULL
,	NULL
in	NULL
agreement	NULL
with	NULL
previous	NULL
findings	NULL
(	NULL
50	NULL
)	NULL
.	NULL

Other	NULL
serine	NULL
proteinases	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
induce	NULL
the	NULL
activation	NULL
of	NULL
an	NULL
,	NULL
fs	NULL
,	NULL
but	NULL
through	NULL
a	NULL
nonmetabolic	NULL
pathway	NULL
.	NULL

Thus	NULL
,	NULL
treatment	NULL
of	NULL
platelets	NULL
with	NULL
chymotrypsin	NULL
(	NULL
28-80	NULL
)	NULL
or	NULL
elastases	NULL
(	NULL
26	NULL
,	NULL
27	NULL
)	NULL
results	NULL
in	NULL
a	NULL
proteolytic-dependent	NULL
exposure	NULL
of	NULL
fibrinogen-binding	NULL
sites	NULL
at	NULL
the	NULL
platelet	NULL
surface	NULL
.	NULL

In	NULL
accordance	NULL
with	NULL
these	NULL
studies	NULL
,	NULL
measurements	NULL
of	NULL
the	NULL
binding	NULL
of	NULL
PAC-1	NULL
and	NULL
AP-5	NULL
antibodies	NULL
allowed	NULL
us	NULL
to	NULL
demonstrate	NULL
that	NULL
NE	NULL
rapidly	NULL
induces	NULL
the	NULL
high	NULL
affinity	NULL
and	NULL
ligand-occupied	NULL
conformers	NULL
of	NULL
native	NULL
Unlike	NULL
cathepsin	NULL
G	NULL
or	NULL
thrombin	NULL
,	NULL
this	NULL
was	NULL
not	NULL
accompanied	NULL
by	NULL
an	NULL
increase	NULL
of	NULL
the	NULL
number	NULL
of	NULL
ap	NULL
,	NULL
expressed	NULL
on	NULL
the	NULL
platelet	NULL
surface	NULL
.	NULL

Another	NULL
difference	NULL
with	NULL
cathepsin	NULL
G	NULL
or	NULL
thrombin	NULL
is	NULL
that	NULL
the	NULL
up-regulation	NULL
of	NULL
a	NULL
,	NULL
,	NULL
;	NULL
by	NULL
NE	NULL
occurs	NULL
even	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
potent	NULL
inhibitor	NULL
of	NULL
platelet	NULL
activation	NULL
PGI	NULL
;	NULL
or	NULL
after	NULL
the	NULL
metabolic	NULL
pool	NULL
of	NULL
ATP	NULL
has	NULL
been	NULL
depleted	NULL
.	NULL

A	NULL
similar	NULL
stimulation	NULL
of	NULL
fibrinogen	NULL
binding	NULL
at	NULL
the	NULL
platelet	NULL
surface	NULL
,	NULL
independent	NULL
of	NULL
PGI	NULL
,	NULL
-inhibitable	NULL
pathways	NULL
,	NULL
has	NULL
been	NULL
observed	NULL
following	NULL
incubation	NULL
of	NULL
platelets	NULL
with	NULL
Fab	NULL
fragments	NULL
of	NULL
certain	NULL
anti-LIBS	NULL
antibodies	NULL
(	NULL
52	NULL
)	NULL
.	NULL

It	NULL
was	NULL
hypothesized	NULL
that	NULL
these	NULL
activating	NULL
antibodies	NULL
shift	NULL
a	NULL
conformational	NULL
balance	NULL
to	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
/810-0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wo	NULL
;	NULL
popeoumog	NULL
11646	NULL
Fic	NULL
.	NULL

9	NULL
.	NULL

Schematic	NULL
model	NULL
of	NULL
the	NULL
activation	NULL
by	NULL
NE	NULL
of	NULL
the	NULL
a	NULL
;	NULL
p	NULL
,	NULL
B	NULL
,	NULL
integrin	NULL
through	NULL
proteolysis	NULL
of	NULL
the	NULL
a	NULL
,	NULL
,	NULL
,	NULL
subunit	NULL
.	NULL

In	NULL
the	NULL
resting	NULL
conformer	NULL
,	NULL
the	NULL
li-gand-binding	NULL
pocket	NULL
of	NULL
«	NULL
;	NULL
,	NULL
,	NULL
B	NULL
,	NULL
is	NULL
not	NULL
accessible	NULL
to	NULL
ligands	NULL
such	NULL
as	NULL
fibrinogen	NULL
or	NULL
the	NULL
PAC-1	NULL
antibody	NULL
(	NULL
represented	NULL
by	NULL
a	NULL
hatched	NULL
box	NULL
)	NULL
.	NULL

Based	NULL
on	NULL
previous	NULL
structural	NULL
models	NULL
(	NULL
83	NULL
,	NULL
54	NULL
)	NULL
,	NULL
the	NULL
carboxyl	NULL
termi-	NULL
B3	NULL
nus	NULL
domain	NULL
of	NULL
the	NULL
@	NULL
,	NULL
subunit	NULL
heavy	NULL
chain	NULL
proteolyzed	NULL
by	NULL
NE	NULL
could	NULL
be	NULL
located	NULL
in	NULL
a	NULL
cluster	NULL
of	NULL
cryptic	NULL
LIBS	NULL
epitopes	NULL
(	NULL
indicated	NULL
by	NULL
bold	NULL
lines	NULL
)	NULL
including	NULL
PMI-1	NULL
below	NULL
the	NULL
cleavage	NULL
site	NULL
.	NULL

The	NULL
cleavage	NULL
induced	NULL
by	NULL
NE	NULL
would	NULL
remove	NULL
a	NULL
constraint	NULL
in	NULL
this	NULL
region	NULL
,	NULL
converting	NULL
the	NULL
integrin	NULL
from	NULL
a	NULL
resting	NULL
to	NULL
an	NULL
active	NULL
conformer	NULL
and	NULL
856	NULL
releasing	NULL
the	NULL
19-mer	NULL
glycopeptide	NULL
Asp***-	NULL
Arg	NULL
``	NULL
``	NULL
®	NULL
.	NULL

Following	NULL
occupancy	NULL
of	NULL
the	NULL
acti-	NULL
OUTSIDE	NULL
am	NULL
,	NULL
pBs	NULL
and	NULL
Platelet	NULL
Activation	NULL
by	NULL
Elastase	NULL
and	NULL
Cathepsin	NULL
G	NULL
ilbH	NULL
IIDHf	NULL
ELASTASE	NULL
vated	NULL
@	NULL
p	NULL
,	NULL
B3	NULL
,	NULL
further	NULL
conformational	NULL
change	NULL
(	NULL
s	NULL
)	NULL
on	NULL
the	NULL
integrin	NULL
would	NULL
expose	NULL
“	NULL
mm	NULL
“	NULL
Mimi	NULL
”	NULL
;	NULL
m	NULL
the	NULL
LIBS	NULL
epitopes	NULL
.	NULL

WM	NULL
388	NULL
W	NULL
W	NULL
INSIDE	NULL
RESTING	NULL
CONFORMER	NULL
ACTIVE	NULL
CONFORMER	NULL
favor	NULL
or	NULL
stabililize	NULL
the	NULL
high	NULL
affinity	NULL
of	NULL
anf	NULL
,	NULL
for	NULL
fibrinogen	NULL
.	NULL

With	NULL
regard	NULL
to	NULL
NE	NULL
,	NULL
its	NULL
potential	NULL
binding	NULL
to	NULL
the	NULL
integrin	NULL
might	NULL
also	NULL
displace	NULL
a	NULL
structural	NULL
equilibrium	NULL
as	NULL
do	NULL
anti-LIBS	NULL
antibodies	NULL
.	NULL

However	NULL
,	NULL
our	NULL
data	NULL
rather	NULL
indicate	NULL
that	NULL
the	NULL
conformational	NULL
shift	NULL
which	NULL
uncovers	NULL
binding	NULL
site	NULL
(	NULL
s	NULL
)	NULL
for	NULL
fibrinogen	NULL
is	NULL
associated	NULL
with	NULL
a	NULL
proteolytic	NULL
processing	NULL
.	NULL

Indeed	NULL
,	NULL
the	NULL
blockade	NULL
of	NULL
NE	NULL
catalytic	NULL
site	NULL
by	NULL
PMSF	NULL
suppressed	NULL
the	NULL
activation	NULL
of	NULL
e	NULL
,	NULL
B3	NULL
.	NULL

Actu-ally	NULL
,	NULL
immunoblot	NULL
analysis	NULL
as	NULL
well	NULL
as	NULL
the	NULL
measurement	NULL
of	NULL
the	NULL
binding	NULL
capacity	NULL
of	NULL
platelets	NULL
for	NULL
PMI-1	NULL
antibody	NULL
,	NULL
revealed	NULL
a	NULL
limited	NULL
proteolysis	NULL
by	NULL
NE	NULL
of	NULL
the	NULL
ay	NULL
,	NULL
subunit	NULL
heavy	NULL
chain	NULL
carboxyl	NULL
terminus	NULL
.	NULL

Furthermore	NULL
,	NULL
kinetics	NULL
of	NULL
this	NULL
cleavage	NULL
closely	NULL
correlated	NULL
with	NULL
that	NULL
of	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
ligand	NULL
binding	NULL
activity	NULL
.	NULL

It	NULL
is	NULL
of	NULL
note	NULL
,	NULL
however	NULL
,	NULL
that	NULL
these	NULL
two	NULL
events	NULL
occur	NULL
in	NULL
a	NULL
stoichiometry	NULL
of	NULL
about	NULL
four	NULL
a	NULL
;	NULL
,	NULL
3	NULL
;	NULL
molecules	NULL
proteolyzed	NULL
for	NULL
one	NULL
molecule	NULL
activated	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
data	NULL
mean	NULL
that	NULL
NE	NULL
cleaves	NULL
almost	NULL
all	NULL
the	NULL
a	NULL
;	NULL
p	NULL
,	NULL
B	NULL
;	NULL
complexes	NULL
expressed	NULL
at	NULL
the	NULL
platelet	NULL
plasma	NULL
membrane	NULL
,	NULL
but	NULL
only	NULL
a	NULL
fraction	NULL
(	NULL
~25	NULL
%	NULL
)	NULL
of	NULL
them	NULL
shift	NULL
from	NULL
an	NULL
inactive	NULL
to	NULL
an	NULL
active	NULL
conformer	NULL
.	NULL

This	NULL
observation	NULL
is	NULL
actually	NULL
consistent	NULL
with	NULL
studies	NULL
which	NULL
have	NULL
brought	NULL
evidence	NULL
for	NULL
the	NULL
existence	NULL
of	NULL
distinct	NULL
subpopulations	NULL
of	NULL
off	NULL
;	NULL
at	NULL
the	NULL
platelet	NULL
surface	NULL
,	NULL
showing	NULL
distinct	NULL
conformations	NULL
and/or	NULL
susceptibility	NULL
to	NULL
acquire	NULL
an	NULL
activated	NULL
state	NULL
(	NULL
52-54	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
this	NULL
functional	NULL
heterogeneity	NULL
appears	NULL
intrinsic	NULL
to	NULL
the	NULL
mole-cules	NULL
.	NULL

Thus	NULL
,	NULL
after	NULL
purification	NULL
of	NULL
the	NULL
total	NULL
platelet	NULL
integrin	NULL
,	NULL
at	NULL
least	NULL
two	NULL
conformers	NULL
can	NULL
be	NULL
identified	NULL
,	NULL
one	NULL
inactive	NULL
but	NULL
still	NULL
activable	NULL
,	NULL
and	NULL
one	NULL
``	NULL
naturally	NULL
``	NULL
active	NULL
following	NULL
solubilization	NULL
(	NULL
~20	NULL
%	NULL
of	NULL
the	NULL
total	NULL
,	NULL
based	NULL
on	NULL
data	NULL
reported	NULL
in	NULL
Ref	NULL
.	NULL

54	NULL
)	NULL
.	NULL

The	NULL
mechanism	NULL
through	NULL
which	NULL
a	NULL
fraction	NULL
of	NULL
the	NULL
platelet	NULL
om	NULL
,	NULL
fB3	NULL
molecules	NULL
resists	NULL
the	NULL
activation	NULL
shift	NULL
remains	NULL
to	NULL
be	NULL
determined	NULL
.	NULL

Finally	NULL
,	NULL
that	NULL
NE	NULL
activates	NULL
an	NULL
,	NULL
;	NULL
directly	NULL
through	NULL
proteolysis	NULL
was	NULL
confirmed	NULL
using	NULL
CHO	NULL
cells	NULL
transfected	NULL
with	NULL
human	NULL
o	NULL
,	NULL
f	NULL
;	NULL
3	NULL
,	NULL
knowing	NULL
that	NULL
the	NULL
integrin	NULL
expressed	NULL
in	NULL
these	NULL
cells	NULL
is	NULL
unable	NULL
to	NULL
respond	NULL
to	NULL
metabolic	NULL
activation	NULL
(	NULL
49	NULL
)	NULL
.	NULL

All	NULL
these	NULL
data	NULL
concur	NULL
to	NULL
exlude	NULL
that	NULL
NE	NULL
acts	NULL
on	NULL
another	NULL
membrane	NULL
protein	NULL
which	NULL
may	NULL
secondary	NULL
stimulate	NULL
MALDI-TOF	NULL
mass	NULL
spectrometry	NULL
performed	NULL
on	NULL
the	NULL
synthetic	NULL
peptide	NULL
corresponding	NULL
to	NULL
the	NULL
sequence	NULL
Phe®*	NULL
``	NULL
``	NULL
-Leu**	NULL
of	NULL
@	NULL
my	NULL
gave	NULL
an	NULL
insight	NULL
into	NULL
the	NULL
site	NULL
of	NULL
NE-induced	NULL
proteolysis	NULL
by	NULL
indicating	NULL
a	NULL
cleavage	NULL
located	NULL
between	NULL
Val	NULL
``	NULL
and	NULL
Asp***	NULL
.	NULL

This	NULL
finding	NULL
is	NULL
in	NULL
agreement	NULL
with	NULL
the	NULL
primary	NULL
specificity	NULL
of	NULL
NE	NULL
for	NULL
valine	NULL
residues	NULL
(	NULL
55	NULL
)	NULL
.	NULL

As	NULL
a	NULL
result	NULL
of	NULL
this	NULL
cleavage	NULL
by	NULL
NE	NULL
within	NULL
the	NULL
amp	NULL
carboxyl	NULL
terminus	NULL
,	NULL
a	NULL
peptide	NULL
of	NULL
19	NULL
amino	NULL
acids	NULL
,	NULL
i.e	NULL
.	NULL

Asp*®-Arg*	NULL
``	NULL
°	NULL
,	NULL
including	NULL
an	NULL
O-glycosylated	NULL
serine	NULL
residue	NULL
at	NULL
position	NULL
847	NULL
(	NULL
20	NULL
)	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
,	NULL
is	NULL
expected	NULL
to	NULL
be	NULL
released	NULL
.	NULL

The	NULL
difference	NULL
in	NULL
M	NULL
,	NULL
found	NULL
in	NULL
SDS-PAGE	NULL
between	NULL
omy	NULL
and	NULL
its	NULL
membrane-bound	NULL
proteolytic	NULL
derivative	NULL
(	NULL
~6,500	NULL
)	NULL
is	NULL
in	NULL
fair	NULL
agreement	NULL
with	NULL
the	NULL
presumed	NULL
mass	NULL
of	NULL
such	NULL
a	NULL
glycopeptide	NULL
.	NULL

A	NULL
mechanism	NULL
by	NULL
which	NULL
this	NULL
restricted	NULL
cleavage	NULL
can	NULL
modulate	NULL
global	NULL
conformational	NULL
changes	NULL
within	NULL
the	NULL
whole	NULL
ary	NULL
,	NULL
}	NULL
;	NULL
integrin	NULL
can	NULL
be	NULL
hypothesized	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
different	NULL
structural	NULL
models	NULL
of	NULL
this	NULL
integrin	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

9	NULL
)	NULL
.	NULL

From	NULL
the	NULL
model	NULL
proposed	NULL
by	NULL
Honda	NULL
et	NULL
al	NULL
.	NULL

(	NULL
33	NULL
)	NULL
,	NULL
it	NULL
can	NULL
be	NULL
suggested	NULL
that	NULL
the	NULL
an	NULL
,	NULL
,	NULL
domain	NULL
proteolyzed	NULL
by	NULL
NE	NULL
is	NULL
located	NULL
in	NULL
a	NULL
structurally	NULL
constrained	NULL
cluster	NULL
of	NULL
cryptic	NULL
LIBS	NULL
epitopes	NULL
including	NULL
PMI-1	NULL
(	NULL
apy	NULL
842-856	NULL
)	NULL
,	NULL
AP-5	NULL
(	NULL
B	NULL
;	NULL
1-6	NULL
)	NULL
,	NULL
LIBS-2	NULL
(	NULL
B	NULL
;	NULL
602-690	NULL
)	NULL
,	NULL
and	NULL
an	NULL
undefined	NULL
region	NULL
in	NULL
B	NULL
;	NULL
interacting	NULL
with	NULL
the	NULL
PMI-2	NULL
antibody	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
studies	NULL
aimed	NULL
to	NULL
localize	NULL
the	NULL
arp	NULL
,	NULL
sequences	NULL
involved	NULL
in	NULL
the	NULL
intrasubunit	NULL
contacts	NULL
have	NULL
suggested	NULL
that	NULL
ar	NULL
,	NULL
;	NULL
would	NULL
be	NULL
folded	NULL
on	NULL
itself	NULL
,	NULL
notably	NULL
through	NULL
interactions	NULL
between	NULL
its	NULL
amino-terminal	NULL
and	NULL
carboxyl-terminal	NULL
domains	NULL
(	NULL
56	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
it	NULL
may	NULL
be	NULL
speculated	NULL
that	NULL
through	NULL
limited	NULL
proteolysis	NULL
of	NULL
the	NULL
carboxy-terminal	NULL
end	NULL
of	NULL
the	NULL
ayy	NULL
;	NULL
subunit	NULL
,	NULL
NE	NULL
removes	NULL
a	NULL
constraint	NULL
in	NULL
a	NULL
confined	NULL
but	NULL
particularly	NULL
sensitive	NULL
region	NULL
.	NULL

The	NULL
generated	NULL
conformational	NULL
change	NULL
may	NULL
then	NULL
propagate	NULL
over	NULL
the	NULL
whole	NULL
«	NULL
;	NULL
,	NULL
,	NULL
B	NULL
;	NULL
complex	NULL
(	NULL
57	NULL
)	NULL
,	NULL
converting	NULL
a	NULL
subpopulation	NULL
of	NULL
the	NULL
integrin	NULL
molecules	NULL
from	NULL
a	NULL
resting	NULL
to	NULL
an	NULL
active	NULL
fibrinogen	NULL
receptor	NULL
.	NULL

While	NULL
the	NULL
PLC/PKC	NULL
pathway	NULL
controls	NULL
the	NULL
synergism	NULL
resulting	NULL
from	NULL
combination	NULL
of	NULL
low	NULL
concentrations	NULL
of	NULL
platelet	NULL
agonists	NULL
such	NULL
as	NULL
thrombin	NULL
and	NULL
epinephrine	NULL
(	NULL
58	NULL
)	NULL
,	NULL
it	NULL
does	NULL
not	NULL
account	NULL
for	NULL
the	NULL
enhanced	NULL
activation	NULL
of	NULL
of	NULL
,	NULL
;	NULL
and	NULL
platelet	NULL
aggregation	NULL
induced	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
NE	NULL
and	NULL
cathepsin	NULL
G	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

As	NULL
one	NULL
consequence	NULL
,	NULL
it	NULL
can	NULL
be	NULL
ruled	NULL
out	NULL
that	NULL
this	NULL
process	NULL
occurs	NULL
through	NULL
an	NULL
increase	NULL
by	NULL
NE	NULL
of	NULL
the	NULL
catalytic	NULL
activity	NULL
of	NULL
cathepsin	NULL
G	NULL
,	NULL
or	NULL
an	NULL
increase	NULL
of	NULL
cathepsin	NULL
G	NULL
receptor	NULL
expression	NULL
and/or	NULL
affinity	NULL
,	NULL
which	NULL
would	NULL
have	NULL
resulted	NULL
in	NULL
an	NULL
increase	NULL
of	NULL
intracellular	NULL
signaling	NULL
messengers	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
the	NULL
foregoing	NULL
data	NULL
,	NULL
and	NULL
notably	NULL
those	NULL
showing	NULL
the	NULL
activation	NULL
by	NULL
NE	NULL
of	NULL
sur-face-expressed	NULL
ofp	NULL
,	NULL
{	NULL
3	NULL
,	NULL
a	NULL
hypothetical	NULL
mechanism	NULL
may	NULL
be	NULL
pro	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
/810-0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wo	NULL
;	NULL
popeoumog	NULL
am	NULL
,	NULL
pBs	NULL
and	NULL
Platelet	NULL
Activation	NULL
by	NULL
Elastase	NULL
and	NULL
Cathepsin	NULL
G	NULL
posed	NULL
to	NULL
construe	NULL
how	NULL
NE	NULL
enhances	NULL
the	NULL
platelet	NULL
aggregation	NULL
initiated	NULL
by	NULL
low	NULL
concentrations	NULL
of	NULL
cathepsin	NULL
G.	NULL
During	NULL
this	NULL
process	NULL
,	NULL
cathepsin	NULL
G	NULL
would	NULL
initiate	NULL
different	NULL
intracellular	NULL
transduction	NULL
signals	NULL
,	NULL
including	NULL
the	NULL
PLC-Ca	NULL
``	NULL
*-PKC	NULL
pathway	NULL
,	NULL
with	NULL
as	NULL
one	NULL
result	NULL
,	NULL
a	NULL
basal	NULL
metabolic	NULL
activation	NULL
of	NULL
off	NULL
;	NULL
,	NULL
however	NULL
,	NULL
insufficient	NULL
to	NULL
promote	NULL
stable	NULL
aggregate	NULL
formation	NULL
.	NULL

In	NULL
parallel	NULL
,	NULL
NE	NULL
would	NULL
trigger	NULL
a	NULL
proteolysis	NULL
of	NULL
the	NULL
carboxyl	NULL
terminus	NULL
of	NULL
the	NULL
ofp	NULL
,	NULL
subunit	NULL
heavy	NULL
chain	NULL
with	NULL
the	NULL
subsequent	NULL
spatial	NULL
reorientation	NULL
of	NULL
the	NULL
extracellular	NULL
domains	NULL
within	NULL
the	NULL
ap	NULL
,	NULL
,	NULL
and	NULL
B	NULL
;	NULL
,	NULL
subunits	NULL
allowing	NULL
increased	NULL
binding	NULL
of	NULL
fibrinogen	NULL
.	NULL

As	NULL
more	NULL
fibrinogen	NULL
binds	NULL
and	NULL
cross-links	NULL
adjacent	NULL
platelets	NULL
,	NULL
post-occu-pancy	NULL
outside-in	NULL
signaling	NULL
events	NULL
through	NULL
«	NULL
,	NULL
,	NULL
;	NULL
may	NULL
amplify	NULL
cell	NULL
activation	NULL
(	NULL
51	NULL
)	NULL
,	NULL
and	NULL
finally	NULL
maximize	NULL
the	NULL
recruitment	NULL
of	NULL
platelets	NULL
into	NULL
aggregates	NULL
similar	NULL
to	NULL
those	NULL
produced	NULL
by	NULL
high	NULL
concentrations	NULL
of	NULL
strong	NULL
platelet	NULL
agonists	NULL
acting	NULL
through	NULL
a	NULL
solely	NULL
intracellular	NULL
signaling	NULL
pathway	NULL
.	NULL

Consistent	NULL
with	NULL
this	NULL
proposal	NULL
,	NULL
it	NULL
is	NULL
of	NULL
interest	NULL
to	NULL
note	NULL
that	NULL
the	NULL
potentiating	NULL
effect	NULL
of	NULL
NE	NULL
is	NULL
not	NULL
restricted	NULL
to	NULL
cathepsin	NULL
G	NULL
,	NULL
as	NULL
NE	NULL
can	NULL
also	NULL
enhance	NULL
platelet	NULL
aggregation	NULL
initiated	NULL
by	NULL
low	NULL
concentrations	NULL
of	NULL
collagen	NULL
or	NULL
the	NULL
thromboxane	NULL
A	NULL
;	NULL
stable	NULL
analog	NULL
U46619	NULL
(	NULL
not	NULL
shown	NULL
and	NULL
Ref	NULL
.	NULL

19	NULL
)	NULL
.	NULL

Numerous	NULL
studies	NULL
suggest	NULL
that	NULL
platelet	NULL
activation	NULL
in	NULL
vivo	NULL
could	NULL
be	NULL
attributed	NULL
to	NULL
the	NULL
combined	NULL
action	NULL
of	NULL
pairs	NULL
(	NULL
or	NULL
more	NULL
)	NULL
of	NULL
agonists	NULL
(	NULL
58	NULL
,	NULL
59	NULL
)	NULL
.	NULL

The	NULL
potentiation	NULL
by	NULL
NE	NULL
of	NULL
cathepsin	NULL
G-induced	NULL
platelet	NULL
activation	NULL
reported	NULL
in	NULL
the	NULL
present	NULL
work	NULL
might	NULL
be	NULL
relevant	NULL
in	NULL
physiopathological	NULL
situations	NULL
in	NULL
which	NULL
both	NULL
platelets	NULL
and	NULL
neutrophils	NULL
can	NULL
locally	NULL
accumulate	NULL
and	NULL
physically	NULL
interact	NULL
such	NULL
at	NULL
sites	NULL
of	NULL
inflammatory	NULL
or	NULL
thrombotic	NULL
lesions	NULL
(	NULL
4-6	NULL
)	NULL
.	NULL

In	NULL
connection	NULL
with	NULL
these	NULL
studies	NULL
,	NULL
it	NULL
is	NULL
tempting	NULL
to	NULL
speculate	NULL
that	NULL
proteinase-induced	NULL
enhancement	NULL
of	NULL
adhesive	NULL
receptor	NULL
function	NULL
could	NULL
be	NULL
a	NULL
wide	NULL
and	NULL
physiologically	NULL
relevant	NULL
process	NULL
.	NULL

Indeed	NULL
,	NULL
like	NULL
the	NULL
proteolysis-dependent	NULL
activation	NULL
of	NULL
o	NULL
,	NULL
fB3	NULL
by	NULL
NE	NULL
described	NULL
here	NULL
,	NULL
a	NULL
recent	NULL
study	NULL
provided	NULL
evidence	NULL
that	NULL
serine	NULL
proteinases	NULL
proteolytically	NULL
enhance	NULL
cell	NULL
adhesion	NULL
mediated	NULL
by	NULL
the	NULL
integrin	NULL
ayf	NULL
;	NULL
(	NULL
60	NULL
)	NULL
.	NULL

Acknowledgments-We	NULL
thank	NULL
Dr.	NULL
Mark	NULL
H.	NULL
Ginsberg	NULL
,	NULL
Dr.	NULL
Thomas	NULL
J.	NULL
Kunicki	NULL
,	NULL
and	NULL
Dr.	NULL
Stanley	NULL
E.	NULL
D'Souza	NULL
,	NULL
from	NULL
the	NULL
Scripps	NULL
Research	NULL
Institute	NULL
(	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
for	NULL
kindly	NULL
providing	NULL
antibodies	NULL
essential	NULL
for	NULL
this	NULL
project	NULL
.	NULL

We	NULL
are	NULL
indebted	NULL
to	NULL
Jean-Charles	NULL
Théodet	NULL
for	NULL
his	NULL
participation	NULL
in	NULL
the	NULL
early	NULL
steps	NULL
of	NULL
this	NULL
study	NULL
.	NULL

We	NULL
also	NULL
thank	NULL
Dr.	NULL
Juan	NULL
J.	NULL
Calvete	NULL
(	NULL
Institut	NULL
fiir	NULL
Reproduktionsmedizin	NULL
,	NULL
Hannover	NULL
,	NULL
Germany	NULL
)	NULL
for	NULL
helpful	NULL
comments	NULL
during	NULL
these	NULL
investigations	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Cerletti	NULL
,	NULL
C.	NULL
,	NULL
Evangelista	NULL
,	NULL
V.	NULL
,	NULL
Molino	NULL
M.	NULL
,	NULL
and	NULL
de	NULL
Gaetano	NULL
,	NULL
G.	NULL
(	NULL
1995	NULL
)	NULL
Thromb	NULL
.	NULL

Haemostasis	NULL
44	NULL
,	NULL
218-223	NULL
2	NULL
.	NULL

Marcus	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
Safier	NULL
,	NULL
L.	NULL
B.	NULL
,	NULL
Brockman	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Islam	NULL
,	NULL
N.	NULL
,	NULL
Fliessbach	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
Hajjar	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Kaminski	NULL
,	NULL
W.	NULL
E.	NULL
,	NULL
Jendraschak	NULL
,	NULL
E.	NULL
,	NULL
Silverstein	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
and	NULL
von	NULL
Schacky	NULL
,	NULL
C.	NULL
(	NULL
1995	NULL
)	NULL
Thromb	NULL
.	NULL

Haemostasis	NULL
74	NULL
,	NULL
218-217	NULL
3	NULL
.	NULL

Del	NULL
Maschio	NULL
,	NULL
A.	NULL
,	NULL
Dejana	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Bazzoni	NULL
,	NULL
G.	NULL
(	NULL
19938	NULL
)	NULL
Ann	NULL
.	NULL

Hematol	NULL
.	NULL

67	NULL
,	NULL
28-31	NULL
4	NULL
.	NULL

Issekutz	NULL
,	NULL
A.	NULL
C.	NULL
,	NULL
Ripley	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Jackson	NULL
,	NULL
J.	NULL
R.	NULL
(	NULL
1983	NULL
)	NULL
Lab	NULL
.	NULL

Invest	NULL
.	NULL

49	NULL
,	NULL
716-724	NULL
5	NULL
.	NULL

Bednar	NULL
,	NULL
M.	NULL
,	NULL
Smith	NULL
,	NULL
B.	NULL
,	NULL
Pinto	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Mullane	NULL
,	NULL
K.	NULL
M.	NULL
(	NULL
1985	NULL
)	NULL
J.	NULL
Cardiovasc	NULL
.	NULL

Pharmacol	NULL
.	NULL

5	NULL
,	NULL
906-912	NULL
6	NULL
.	NULL

Mehri	NULL
,	NULL
Y.	NULL
,	NULL
Lacoste	NULL
,	NULL
L.-L.	NULL
,	NULL
and	NULL
Lam	NULL
,	NULL
Y.	NULL
T.	NULL
(	NULL
1994	NULL
)	NULL
Circulation	NULL
90	NULL
,	NULL
997-1002	NULL
7	NULL
.	NULL

Chignard	NULL
,	NULL
M.	NULL
,	NULL
Selak	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
and	NULL
Smith	NULL
,	NULL
J	NULL
.	NULL

B	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

88	NULL
,	NULL
8609-8613	NULL
8	NULL
.	NULL

Del	NULL
Maschio	NULL
,	NULL
A.	NULL
,	NULL
Evangelista	NULL
,	NULL
V.	NULL
,	NULL
Rajtar	NULL
,	NULL
G.	NULL
,	NULL
Min	NULL
Chen	NULL
,	NULL
Z.	NULL
,	NULL
Cerletti	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
de	NULL
Gaetano	NULL
,	NULL
G.	NULL
(	NULL
1990	NULL
)	NULL
Am	NULL
.	NULL

J.	NULL
Physiol	NULL
.	NULL

258	NULL
,	NULL
H870-H879	NULL
9	NULL
.	NULL

Renesto	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Chignard	NULL
,	NULL
M.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

7	NULL
,	NULL
2305-2309	NULL
10	NULL
.	NULL

Si-Tahar	NULL
,	NULL
M.	NULL
,	NULL
Renesto	NULL
,	NULL
P.	NULL
,	NULL
Balloy	NULL
,	NULL
V.	NULL
,	NULL
and	NULL
Chignard	NULL
,	NULL
M.	NULL
(	NULL
1994	NULL
)	NULL
Eur	NULL
.	NULL

Cytokine	NULL
Netw	NULL
.	NULL

5	NULL
,	NULL
455-460	NULL
11	NULL
.	NULL

Selak	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Chignard	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Smith	NULL
,	NULL
J	NULL
.	NULL

B	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Biochem	NULL
.	NULL

J	NULL
.	NULL

251	NULL
,	NULL
298-299	NULL
12	NULL
.	NULL

Ferrer-Lopez	NULL
,	NULL
P.	NULL
,	NULL
Renesto	NULL
,	NULL
P.	NULL
,	NULL
Shattner	NULL
,	NULL
M.	NULL
,	NULL
Bassot	NULL
,	NULL
S.	NULL
,	NULL
Laurent	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Chignard	NULL
,	NULL
M.	NULL
(	NULL
1990	NULL
)	NULL
Am	NULL
.	NULL

J.	NULL
Physiol	NULL
.	NULL

258	NULL
,	NULL
€1100-C1107	NULL
13	NULL
.	NULL

Evangelista	NULL
,	NULL
V.	NULL
,	NULL
Piccardoni	NULL
,	NULL
P.	NULL
,	NULL
White	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
de	NULL
Gaetano	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Cerletti	NULL
,	NULL
C.	NULL
(	NULL
1993	NULL
)	NULL
Blood	NULL
81	NULL
,	NULL
2947-2957	NULL
14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

28	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

60	NULL
.	NULL

11647	NULL
Molino	NULL
,	NULL
M.	NULL
,	NULL
Di	NULL
Lallo	NULL
,	NULL
M.	NULL
,	NULL
de	NULL
Gaetano	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Cerletti	NULL
,	NULL
C.	NULL
(	NULL
1992	NULL
)	NULL
Biochem	NULL
.	NULL

J	NULL
.	NULL

288	NULL
,	NULL
741-745	NULL
Selak	NULL
,	NULL
M.	NULL
A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Platelets	NULL
4	NULL
,	NULL
85-89	NULL
Si-Tahar	NULL
,	NULL
M.	NULL
,	NULL
Renesto	NULL
,	NULL
P.	NULL
,	NULL
Falet	NULL
,	NULL
H.	NULL
,	NULL
Rendu	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Chignard	NULL
,	NULL
M.	NULL
(	NULL
1996	NULL
)	NULL
Biochem	NULL
.	NULL

J	NULL
.	NULL

818	NULL
,	NULL
401-408	NULL
Bykowska	NULL
,	NULL
K.	NULL
,	NULL
Kaczanowska	NULL
,	NULL
J.	NULL
,	NULL
Karpowicz	NULL
,	NULL
M.	NULL
,	NULL
Stachurska	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Kopec	NULL
,	NULL
M.	NULL
(	NULL
1983	NULL
)	NULL
Thromb	NULL
.	NULL

Haemostasis	NULL
50	NULL
,	NULL
768-772	NULL
Selak	NULL
,	NULL
M.	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Thromb	NULL
.	NULL

Haemostasis	NULL
68	NULL
,	NULL
570-576	NULL
Renesto	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Chignard	NULL
,	NULL
M.	NULL
(	NULL
1993	NULL
)	NULL
Blood	NULL
82	NULL
,	NULL
139-144	NULL
Calvete	NULL
,	NULL
J.	NULL
J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Thromb	NULL
.	NULL

Haemostasis	NULL
72	NULL
,	NULL
1-15	NULL
Ginsberg	NULL
,	NULL
M.	NULL
H.	NULL
,	NULL
Du	NULL
,	NULL
X.	NULL
,	NULL
O'Toole	NULL
,	NULL
T.	NULL
E.	NULL
,	NULL
and	NULL
Loftus	NULL
,	NULL
J.	NULL
C.	NULL
(	NULL
1995	NULL
)	NULL
Thromb	NULL
.	NULL

Haemostasis	NULL
74	NULL
,	NULL
352-359	NULL
Stuiver	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
O'Toole	NULL
,	NULL
T.	NULL
E.	NULL
(	NULL
1995	NULL
)	NULL
Stem	NULL
Cells	NULL
18	NULL
,	NULL
250-262	NULL
Hynes	NULL
,	NULL
R.	NULL
O	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Cell	NULL
69	NULL
,	NULL
11-25	NULL
Wencel-Drake	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Plow	NULL
E.	NULL
F.	NULL
,	NULL
Kunicki	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
Woods	NULL
,	NULL
V.	NULL
L.	NULL
,	NULL
Keller	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
and	NULL
Ginsberg	NULL
,	NULL
M.	NULL
H.	NULL
(	NULL
1986	NULL
)	NULL
Am	NULL
.	NULL

J.	NULL
Pathol	NULL
.	NULL

124	NULL
,	NULL
824-334	NULL
Niiya	NULL
,	NULL
K.	NULL
,	NULL
Hodson	NULL
,	NULL
E.	NULL
,	NULL
Bader	NULL
,	NULL
R.	NULL
,	NULL
Byers-Ward	NULL
,	NULL
V.	NULL
,	NULL
Koziol	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Plow	NULL
,	NULL
E.	NULL
F.	NULL
,	NULL
and	NULL
Ruggeri	NULL
,	NULL
Z.	NULL
M.	NULL
(	NULL
1987	NULL
)	NULL
Blood	NULL
70	NULL
,	NULL
475-483	NULL
Kornecki	NULL
,	NULL
E.	NULL
,	NULL
Ehrlich	NULL
,	NULL
Y.	NULL
H.	NULL
,	NULL
De	NULL
Mars	NULL
,	NULL
D.	NULL
D.	NULL
,	NULL
and	NULL
Lenox	NULL
,	NULL
R.	NULL
H.	NULL
(	NULL
1986	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

77	NULL
,	NULL
150-756	NULL
Kornecki	NULL
,	NULL
E.	NULL
,	NULL
Ehrlich	NULL
,	NULL
Y.	NULL
H.	NULL
,	NULL
Egbring	NULL
,	NULL
R.	NULL
,	NULL
Gramse	NULL
,	NULL
M.	NULL
,	NULL
Seitz	NULL
,	NULL
R.	NULL
,	NULL
Eckardt	NULL
,	NULL
A.	NULL
,	NULL
Lukasiewicz	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Niewiarowski	NULL
,	NULL
S.	NULL
(	NULL
1988	NULL
)	NULL
Am	NULL
.	NULL

J.	NULL
Physiol	NULL
.	NULL

255	NULL
,	NULL
H651-H658	NULL
Kornecki	NULL
,	NULL
E.	NULL
,	NULL
Tuszynski	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
and	NULL
Niewiarowski	NULL
,	NULL
S.	NULL
(	NULL
1983	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

258	NULL
,	NULL
9349-9356	NULL
Peerschke	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Coller	NULL
,	NULL
B.	NULL
S.	NULL
(	NULL
1984	NULL
)	NULL
Blood	NULL
64	NULL
,	NULL
59-63	NULL
Pidard	NULL
,	NULL
D.	NULL
,	NULL
Frelinger	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
Bouillot	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Nurden	NULL
,	NULL
A.	NULL
T.	NULL
(	NULL
1991	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Biochem	NULL
.	NULL

200	NULL
,	NULL
487-447	NULL
Taub	NULL
,	NULL
R.	NULL
,	NULL
Gould	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Garsky	NULL
,	NULL
V.	NULL
M.	NULL
,	NULL
Ciccarone	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
Hoxie	NULL
,	NULL
J.	NULL
,	NULL
Friedman	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
and	NULL
Shattil	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

264	NULL
,	NULL
259-265	NULL
Pidard	NULL
,	NULL
D.	NULL
,	NULL
Montgomery	NULL
,	NULL
R.	NULL
R.	NULL
,	NULL
Bennett	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
and	NULL
Kunicki	NULL
,	NULL
T.	NULL
J	NULL
.	NULL

(	NULL
1983	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

258	NULL
,	NULL
12582-12586	NULL
Honda	NULL
,	NULL
S.	NULL
,	NULL
Tomiyama	NULL
,	NULL
Y.	NULL
,	NULL
Pelletier	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
Annis	NULL
,	NULL
D.	NULL
,	NULL
Honda	NULL
,	NULL
Y.	NULL
,	NULL
Orchelowski	NULL
,	NULL
R.	NULL
,	NULL
Ruggeri	NULL
,	NULL
Z.	NULL
,	NULL
and	NULL
Kunicki	NULL
,	NULL
T.	NULL
J	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270	NULL
,	NULL
11947-11954	NULL
Loftus	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Plow	NULL
,	NULL
E.	NULL
F.	NULL
,	NULL
Frelinger	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
III	NULL
,	NULL
D'Souza	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
Dixon	NULL
,	NULL
D.	NULL
,	NULL
Lacy	NULL
,	NULL
J.	NULL
,	NULL
Sorge	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Ginsberg	NULL
,	NULL
M.	NULL
H.	NULL
(	NULL
1987	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

840	NULL
,	NULL
7114-7118	NULL
Poncz	NULL
,	NULL
M.	NULL
,	NULL
Eisman	NULL
,	NULL
R.	NULL
,	NULL
Heidenreich	NULL
,	NULL
R.	NULL
,	NULL
Silver	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Vilaire	NULL
,	NULL
G.	NULL
,	NULL
Surrey	NULL
,	NULL
S.	NULL
,	NULL
Schwartz	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Bennett	NULL
,	NULL
J.	NULL
S.	NULL
(	NULL
1987	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

262	NULL
,	NULL
8476-8482	NULL
Fitzgerald	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
Steiner	NULL
,	NULL
B.	NULL
,	NULL
Rall	NULL
,	NULL
S.	NULL
C.	NULL
,	NULL
Jr.	NULL
,	NULL
Lo	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Phillips	NULL
,	NULL
D.	NULL
R.	NULL
(	NULL
1987	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

262	NULL
,	NULL
8986-3939	NULL
Kieffer	NULL
,	NULL
N.	NULL
,	NULL
Melchior	NULL
,	NULL
C.	NULL
,	NULL
Guinet	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Michels	NULL
,	NULL
S.	NULL
,	NULL
Gouon	NULL
,	NULL
V.	NULL
,	NULL
and	NULL
Bron	NULL
,	NULL
N.	NULL
(	NULL
1996	NULL
)	NULL
Cell	NULL
Adhes	NULL
.	NULL

Comm	NULL
.	NULL

4	NULL
,	NULL
25-89	NULL
Laemmli	NULL
,	NULL
U.	NULL
K.	NULL
(	NULL
1970	NULL
)	NULL
Nature	NULL
227	NULL
,	NULL
680-685	NULL
Jolles	NULL
,	NULL
J.	NULL
,	NULL
Zwiers	NULL
,	NULL
H.	NULL
,	NULL
Dekker	NULL
,	NULL
A.	NULL
,	NULL
Wirtz	NULL
,	NULL
K.	NULL
W.	NULL
A.	NULL
,	NULL
and	NULL
Gispen	NULL
,	NULL
W.	NULL
H.	NULL
(	NULL
1981	NULL
)	NULL
Biochem	NULL
.	NULL

J	NULL
.	NULL

194	NULL
,	NULL
283-291	NULL
Renesto	NULL
,	NULL
P.	NULL
,	NULL
Ferrer-Lopez	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Chignard	NULL
,	NULL
M.	NULL
(	NULL
1990	NULL
)	NULL
Lab	NULL
.	NULL

Invest	NULL
.	NULL

62	NULL
,	NULL
409-416	NULL
Frelinger	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
III	NULL
,	NULL
Lam	NULL
,	NULL
S.	NULL
C.-T.	NULL
,	NULL
Plow	NULL
,	NULL
E.	NULL
F.	NULL
,	NULL
Smith	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Loftus	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
and	NULL
Ginsberg	NULL
,	NULL
M.	NULL
H.	NULL
(	NULL
1988	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268	NULL
,	NULL
12397-12402	NULL
Vorm	NULL
,	NULL
O.	NULL
,	NULL
and	NULL
Roepstorff	NULL
,	NULL
P.	NULL
(	NULL
1994	NULL
)	NULL
Biol	NULL
.	NULL

Mass	NULL
Spectrom	NULL
.	NULL

28	NULL
,	NULL
734-740	NULL
LaRosa	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
Rohrer	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Benoit	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
Rodino	NULL
,	NULL
L.	NULL
J.	NULL
,	NULL
Barnard	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
and	NULL
Michelson	NULL
,	NULL
A.	NULL
D.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Vasc	NULL
.	NULL

Surg	NULL
.	NULL

19	NULL
,	NULL
306-319	NULL
Nishizuka	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1984	NULL
)	NULL
Nature	NULL
308	NULL
,	NULL
693-698	NULL
Toullec	NULL
,	NULL
D.	NULL
,	NULL
Pianetti	NULL
,	NULL
P.	NULL
,	NULL
Coste	NULL
,	NULL
H.	NULL
,	NULL
Bellevergue	NULL
,	NULL
P.	NULL
,	NULL
Grand-Perret	NULL
,	NULL
T.	NULL
,	NULL
Ajakane	NULL
,	NULL
M.	NULL
,	NULL
Baudet	NULL
,	NULL
V.	NULL
,	NULL
Boissin	NULL
,	NULL
P.	NULL
,	NULL
Boursier	NULL
,	NULL
E.	NULL
,	NULL
Loriolle	NULL
,	NULL
F.	NULL
,	NULL
Duhamel	NULL
,	NULL
L.	NULL
,	NULL
Charon	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Kirilovsky	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266	NULL
,	NULL
15771-15781	NULL
Graber	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
and	NULL
Hawiger	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1982	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

257	NULL
,	NULL
14606-14609	NULL
Pidard	NULL
,	NULL
D.	NULL
,	NULL
Renesto	NULL
,	NULL
P.	NULL
,	NULL
Berndt	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
Rabhi	NULL
,	NULL
S.	NULL
,	NULL
Clemetson	NULL
,	NULL
K.	NULL
J.	NULL
,	NULL
and	NULL
Chignard	NULL
,	NULL
M.	NULL
(	NULL
1994	NULL
)	NULL
Biochem	NULL
.	NULL

J	NULL
.	NULL

808	NULL
,	NULL
489-498	NULL
Verhoeven	NULL
,	NULL
A.	NULL
J.	NULL
M.	NULL
,	NULL
Mommersteeg	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
and	NULL
Akkerman	NULL
,	NULL
J.	NULL
W.	NULL
N.	NULL
(	NULL
1985	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

260	NULL
,	NULL
2621-2624	NULL
O'Toole	NULL
T.	NULL
E.	NULL
,	NULL
Loftus	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Du	NULL
,	NULL
X.	NULL
,	NULL
Glass	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
,	NULL
Ruggeri	NULL
,	NULL
Z.	NULL
M.	NULL
,	NULL
Shattil	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
Plow	NULL
,	NULL
E.	NULL
F.	NULL
,	NULL
and	NULL
Ginsberg	NULL
,	NULL
M.	NULL
H.	NULL
(	NULL
1990	NULL
)	NULL
Cell	NULL
Regul	NULL
.	NULL

1	NULL
,	NULL
883-893	NULL
Molino	NULL
,	NULL
M.	NULL
,	NULL
Di	NULL
Lallo	NULL
,	NULL
M.	NULL
,	NULL
Martelli	NULL
,	NULL
N.	NULL
,	NULL
de	NULL
Gaetano	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Cerletti	NULL
,	NULL
C.	NULL
(	NULL
19983	NULL
)	NULL
Blood	NULL
82	NULL
,	NULL
2442-2451	NULL
Shattil	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Thromb	NULL
.	NULL

Haemostasis	NULL
74	NULL
,	NULL
149-155	NULL
Frelinger	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
III	NULL
,	NULL
Du	NULL
,	NULL
X.	NULL
,	NULL
Plow	NULL
,	NULL
E.	NULL
F.	NULL
,	NULL
and	NULL
Ginsberg	NULL
,	NULL
M.	NULL
H.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Bio	NULL
.	NULL

Chem	NULL
.	NULL

266	NULL
,	NULL
17106-17111	NULL
Kouns	NULL
,	NULL
W.	NULL
C.	NULL
,	NULL
Hadvary	NULL
,	NULL
P.	NULL
,	NULL
Haering	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Steiner	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267	NULL
,	NULL
18844-18851	NULL
Kunicki	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
Annis	NULL
,	NULL
D.	NULL
S.	NULL
,	NULL
Deng	NULL
,	NULL
Y.-J	NULL
.	NULL

,	NULL
Loftus	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
and	NULL
Shattil	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271	NULL
,	NULL
20815-20821	NULL
Nakajima	NULL
,	NULL
K.	NULL
,	NULL
Powers	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Ashe	NULL
,	NULL
B.	NULL
M.	NULL
,	NULL
and	NULL
Zimmerman	NULL
,	NULL
M.	NULL
(	NULL
1979	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

254	NULL
,	NULL
4027-4082	NULL
Calvete	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
Mann	NULL
,	NULL
K.	NULL
,	NULL
Alvarez	NULL
,	NULL
M.	NULL
V.	NULL
,	NULL
Lopez	NULL
,	NULL
M.	NULL
M.	NULL
,	NULL
and	NULL
Gonzalez-Rodriguez	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Biochem	NULL
.	NULL

J	NULL
.	NULL

282	NULL
,	NULL
528-582	NULL
Du	NULL
,	NULL
X.	NULL
,	NULL
Gu	NULL
,	NULL
M.	NULL
,	NULL
Nagaswami	NULL
,	NULL
C.	NULL
,	NULL
Bennett	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
and	NULL
Ginsberg	NULL
,	NULL
M.	NULL
H.	NULL
(	NULL
1993	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268	NULL
,	NULL
28087-23092	NULL
Siess	NULL
,	NULL
W.	NULL
(	NULL
1991	NULL
)	NULL
News	NULL
Physiol	NULL
.	NULL

Sci	NULL
.	NULL

6	NULL
,	NULL
51-56	NULL
Huang	NULL
,	NULL
E.	NULL
M.	NULL
,	NULL
and	NULL
Detwiler	NULL
,	NULL
T.	NULL
C.	NULL
(	NULL
1981	NULL
)	NULL
Blood	NULL
57	NULL
,	NULL
685-691	NULL
Fujii	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Imamura	NULL
,	NULL
S.	NULL
(	NULL
1995	NULL
)	NULL
Exp	NULL
.	NULL

Cell	NULL
Res	NULL
.	NULL

220	NULL
,	NULL
201-211	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
/810-0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wo	NULL
;	NULL
popeoumog	NULL
Human	NULL
Neutrophil	NULL
Elastase	NULL
Proteolytically	NULL
Activates	NULL
the	NULL
Platelet	NULL
Integrin	NULL
op	NULL
B3	NULL
through	NULL
Cleavage	NULL
of	NULL
the	NULL
Carboxyl	NULL
Terminus	NULL
of	NULL
the	NULL
Subunit	NULL
Heavy	NULL
Chaln	NULL
INVOLVEMENT	NULL
IN	NULL
THE	NULL
POTENTIATION	NULL
OF	NULL
PLATELET	NULL
AGGREGATION	NULL
Mustapha	NULL
Si-Tahar	NULL
,	NULL
Dominique	NULL
Pidard	NULL
,	NULL
Viviane	NULL
Balloy	NULL
,	NULL
Marc	NULL
Moniatte	NULL
,	NULL
Nelly	NULL
Kieffer	NULL
,	NULL
Alain	NULL
Van	NULL
Dorsselaer	NULL
and	NULL
Michel	NULL
Chignard	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

1997	NULL
,	NULL
272:11636-11647.	NULL
doi	NULL
:	NULL
10.1074/jb0.272.17.11636	NULL
Access	NULL
the	NULL
most	NULL
updated	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
http	NULL
:	NULL
/www.jbe.org/content/272/17/11636	NULL
Alerts	NULL
:	NULL
«	NULL
When	NULL
this	NULL
article	NULL
is	NULL
cited	NULL
«	NULL
When	NULL
a	NULL
correction	NULL
for	NULL
this	NULL
article	NULL
is	NULL
posted	NULL
Click	NULL
here	NULL
to	NULL
choose	NULL
from	NULL
all	NULL
of	NULL
JBC	NULL
's	NULL
e-mail	NULL
alerts	NULL
This	NULL
article	NULL
cites	NULL
60	NULL
references	NULL
,	NULL
29	NULL
of	NULL
which	NULL
can	NULL
be	NULL
accessed	NULL
free	NULL
at	NULL
http	NULL
:	NULL
//www	NULL
7/1	NULL
1636	NULL
.full.html	NULL
#	NULL
ref-list-1	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL

